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1. RESUMEN
1.1. Introducción y objetivos  
La química biológica nació hace dos décadas con objeto de estudiar la interfase 
entre la química y la biología, utilizando para ello herramientas capaces de interrogar los 
distintos sistemas biológicos, facilitando así la comprensión de los mismos.1-3 Sin 
embargo, existen sistemas biológicos de gran relevancia cuyo estudio no ha sido 
abordado hasta ahora. Uno de ellos es el sistema cannabinoide endógeno ( endogenous 
cannabinoid system, ECS), que durante los últimos años ha sido relacionado con diversas 
funciones fisiológicas a nivel tanto central como periférico.4-7 Sin embargo, no existe 
ningún fármaco en el mercado a día de hoy dirigido a la modulación de este sistema. En 
este contexto, una mayor comprensión de algunos de los aspectos de la biología del ECS, 
tales como la localización de los receptores de cannabinoides (cannabinoid receptors, 
CBRs) a nivel celular, su localización a nivel subcelular, la existencia de otras dianas 
distintas de los receptores conocidos y molecularmente caracterizados CB1R y CB2R, y el 
estudio de otros ligandos de los CBRs, podrían permitir una aplicación terapéutica real 
de este sistema. Así, los objetivos generales del presente trabajo de investigación son: i) 
el desarrollo de sondas para el estudio de la expresión de los CBRs en el sistema inmune, 
ii) el diseño y síntesis de herramientas para explorar las diferencias entre el CB1R de la 
membrana plasmática y el mitocondrial, iii) el descubrimiento de las dianas adicionales 
de los agonistas sintéticos HU210 y HU308, y iv) la identificación de las dianas 
terapéuticas del producto de origen natural honokiol. 
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1.2. Resultados y discusión 
1.2.1. Desarrollo de sondas para el estudio de la expresión de los CBRs en el sistema 
inmune 
La amplia distribución de los CBRs en los diferentes órganos y teji dos, así como su 
implicación en la regulación de muchas funciones (fisio)patológicas, abre una ventana de 
oportunidades para el tratamiento de diversas enfermedades. En este sentido, el 
sistema inmune además de ofrecer un gran potencial terapéutico, representa una 
excelente oportunidad para la búsqueda de biomarcadores que reflejen la existencia de 
tales desórdenes y su gravedad. Así, es bien conocido que las células del sistema inmune 
expresan los CBRs, que dicha expresión cambia en función de diferentes condiciones, y 
que el ECS regula muchos aspectos relacionados con el correcto funcionamiento del 
sistema inmune.8-10 Por lo tanto, el desarrollo de herramientas que nos permitan 
estudiar el papel de los CBRs en condiciones fisiológicas, así como poder establecer si 
estos pueden ser usados como biomarcadores de enfermedades o de su prognosis, sería 
muy interesante. Con este objetivo, se llevó a cabo el diseño de sondas moleculares 
formadas por: i) un grupo de unión basado en un esqueleto de alta afinidad por los 
CBRs, ii) una subunidad de marcaje (S.M.) que permita su detección y visualización, y iii) 
un espaciador apropiado con objeto de evitar un posible impedimento estérico por 
parte de la subunidad de marcaje, que podría traducirse en una pérdida de la afi nidad 
(Figura 1). Con respecto al grupo de unión, se eligió el esqueleto del ligando sintético 
HU210, con alta afinidad por los CBRs. En lo que se refiere a la subunidad de marcaje, se 
seleccionaron la biotina y el fluoróforo Alexa Fluor 488 para la detección de los CBRs por 
microscopía confocal y citometría de flujo, respectivamente. 
De este modo, se sintetizaron los derivados 1, 2, y 20 en los que se ha considerado la 
utilización de un grupo amida en los compuestos 1 y 2, o un éter en el derivado 20, 
como espaciador entre el grupo de unión y la subunidad de marcaje.  Por otro lado, para 
la preparación del derivado fluorescente se seleccionó el espaciador tipo amida de la 
sonda 1 y se sustituyó la subunidad de biotina por el fluoróforo Alexa Fluor 488 en el 
compuesto 22 (Figura 1). Todos los compuestos sintetizados mostraron una elevada 
afinidad por los CBRs, con valores de la constante en el rango nanomolar. En concreto, el 
compuesto 1 presentó los mejores valores de afinidad [Ki (CB1)=1.6±0.5 nM; Ki 
(CB2)=0.36±0.02 nM], y el derivado 22 mostró una elevada selectividad por el CB1R [Ki 
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(CB1)=28±4 nM; Ki (CB2)=0.7±0.2 M], y por lo tanto fueron seleccionados para el 
estudio de los CBRs en sistemas celulares. 
 
Figura 1. Diseño de las sondas derivadas de HU210 1, 2, 20, y 22. 
De entre las diferentes posibilidades con potencial terapéutico dentro del sistema 
inmune, inicialmente seleccionamos las enfermedades alérgicas, ya que se ha descrito 
que el ECS juega un papel protector en este tipo de desórdenes.11,12 En este contexto, 
nos propusimos explorar la presencia de los CBRs en pacientes de distintas alergias 
frente a individuos sanos. Para ello se seleccionaron células mononucleares de sangre 
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periférica (peripheral blood mononuclear cells, PBMCs) y de órganos linfoides como las 
amígdalas (tonsil mononuclear cells, TMCs).  
Así, la sonda 1 fue utilizada en diferentes células del sistema inmune para el estudio 
del CB1R, demostrando la presencia de este receptor en pacientes alérgicos.
13 Por otro 
lado, la sonda fluorescente 22 permitió la visualización directa del CB1R en PBMCs 
mediante citometría de flujo, destacando así como una valiosa herramienta para 
estudiar posibles modificaciones en la expression de este receptor en muestras con 
relevancia clínica, y también para estudiar su potencial como biomarcador. 
1.2.2. Diseño y síntesis de herramientas para explorar las diferencias entre el CB1R de la 
membrana plasmática y el mitocondrial 
La complejidad de la señalización mediada por el CB1R se ha visto incrementada 
como consecuencia de la identificación de un nuevo receptor localizado en la 
mitocondria, mtCB1R,
14,15 existiendo hipótesis que sugieren que ambos receptores están 
involucrados en la regulación de distintos efectos.16,17 Para poder diferenciar entre 
ambos receptores sería necesario el desarrollo de compuestos que, mantenie ndo una 
elevada afinidad por el CB1R localizado en la membrana plasmática, fueran incapaces de 
atravesar dicha membrana, no pudiendo activar el mtCB1R. Así, llevamos a cabo el 
diseño, síntesis, y evaluación biológica de los compuestos derivados de HU210 26-28, 
con subunidades de elevada polaridad como pueden ser una urea o una acilurea en los 
compuestos 26 y 27, respectivamente, o un anillo de tetrazol en el derivado 28, unidos 
al esqueleto a través de un grupo amida y el espaciador con la longitud óptima 
determinado con anterioridad (Figura 2). Los compuestos 26-28 mostraron buena 
afinidad por el CB1R (Ki=4-12.1 nM), y por tanto destacan como prometedores 
candidatos para estudiar los efectos mediados por el CB1R de la membrana plasmática, 
ya que estos derivados serán en principio incapaces de cruzar la membrana celular 
debido a su elevada polaridad, y por lo tanto, no podrán activar el mtCB1R. Este trabajo 
se está llevando a cabo en colaboración con el profesor Giovanni Marsicano en la 
Universidad de Bordeaux (Francia). 
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Figura 2. Derivados polares de HU210 26-28. 
1.2.3. Descubrimiento de las dianas adicionales de los agonistas sintéticos HU210 y 
HU308 
La identificación de dianas adicionales a los receptores CB1 y CB2 es posiblemente 
uno de los retos más importantes para el entendimiento del ECS. En este contexto, el 
cáncer y los desórdenes del sistema inmune son dos áreas que están recibi endo cada 
vez mayor atención debido al aumento en el número de efectos descritos que no están 
mediados por CB1/2Rs.
18-24 Por tanto, el desarrollo de herramientas diseñadas 
específicamente para identificar las dianas de los cannabinoides reviste una gran 
importancia. Para lograr este objetivo se requieren sondas químicas que, además de 
presentar en su estructura el grupo de unión y la subunidad de marcaje, incorporen 
también un grupo de fotoentrecruzamiento como una subunidad de benzofenona, que 
tras irradiación con luz ultravioleta a la longitud de onda apropiada forme un enlace 
covalente con dichas proteínas, y éstas puedan ser posteriormente capturadas e 
identificadas. 
Por tanto, se llevó a cabo el diseño y síntesis de las nuevas sondas 39-41 por 
incorporación directa de una subunidad de marcaje, que contenía tanto biotina como 
benzofenona, en los esqueletos de HU210 y HU308 (Figura 3). Puesto que la sonda 39 
mostró los mejores valores de afinidad por ambos receptores [Ki (CB1)=25.7±0.4 nM; Ki 
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(CB2)=12.1±0.2 nM], se seleccionó para llevar a cabo experimentos de proteómica en 
membranas de células HEK-293-EBNA que sobreexpresan el CB2R humano. 
 
Figura 3. Estructura de las sondas 39-41. 
El empleo de 39 permitió la identificación de 15 proteínas de diferentes tipos, que 
participan en diversos procesos biológicos de interés. En concreto, la presencia del CB2R 
entre ellas es especialmente importante, ya que pone de manifiesto la validez tanto de 
la plataforma como de la metodología. 
1.2.4. Identificación de las dianas terapéuticas del producto de origen natural honokiol  
El producto natural honokiol (Figura 4) muestra interesantes propiedades 
terapéuticas25,26 entre las que destaca su capacidad antitumoral.25,27 Sin embargo, se 
desconocen las dianas concretas en las que actúan tanto el honokiol como sus 
derivados, por lo que su identificación permitiría establecer nuevas estrategias 
farmacológicas para el tratamiento de esta enfermedad. 
 
Figura 4. Estructura química del honokiol y 2-O-etilhonokiol . 
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Con el objetivo de identificar las dianas de estos compuestos,  hemos llevado a cabo 
el diseño y síntesis de los derivados 56-59. Estas sondas están basadas en el esqueleto 
de 2-O-etilhonokiol (Figura 4), un derivado sintético más activo que el honokiol, 28 e 
incorporan además las subunidades de benzofenona y biotina en su estructura. 
Adicionalmente, se han planteado también las sondas 64 y 65, en las que se ha 
reemplazado la benzofenona por el grupo de menor tamaño diazirina, y la subunidad de 
biotina por un alquino terminal (Figura 5). 
 
Figura 5. Estructura de las sondas 56-59, 64 y 65. 
Entre los compuestos sintetizados, las sondas 64 y 65 mostraron la mayor capacidad 
para inhibir la proliferación celular en distintas líneas de cáncer de mama (MDA -MB-
231) y ovario (SKOV3 y OVCAR3), por lo que se seleccionaron para experimentos 
posteriores. Así, se evaluó su potencial para marcar proteínas de forma específica. 
Puesto que la sonda 65 exhibió un mejor perfil de marcaje, se seleccionó ésta para 
identificar las proteínas capturadas con dicha sonda mediante espectrometría de masas 
cuantitativa SILAC (stable isotope labelling by amino acids in cell culture).29,30 Los 
Resumen 
 
10 
 
resultados obtenidos han permitido identificar alrededor de 42 proteínas como dianas 
del honokiol, entre las que destaca la proteína LYRIC,31 involucrada en mecanismos 
relacionados con la viabilidad de las células de cáncer tales como la apoptosis. 
1.3. Conclusiones 
En el presente trabajo de investigación se han desarrollado diferentes sondas para el 
estudio del ECS. 
Así, se ha llevado a cabo la síntesis de la sonda biotinilada 1 y la sonda fluorescente 
22 (Figura 1) que han permitido la detección del CB1R en células humanas del sistema 
inmune. 
Con respecto al estudio del mtCB1R, se han sintetizado los ligandos de alta afinidad 
por el CB1R 26-28 (Figura 2, Ki=4-12.1 nM). Dada la elevada polaridad de los mismos, 
estos compuestos constituyen un conjunto de herramientas prometedoras para el 
estudio de los diferentes efectos mediados por el CB1R de membrana y el mitocondrial. 
Por último, se han desarrollado una serie de sondas que están posibilitando 
descubrir las dianas de diferentes compuestos. Así, la sonda 39 (Figura 3) se está 
empleando para identificar las dianas adicionales del compuesto HU210, y la sonda 65 
(Figura 5) está permitiendo revelar algunas de las dianas del honokiol en células de 
cáncer de mama MDA-MB-231, proporcionando por primera vez información directa 
sobre los mecanismos de acción de este producto natural.  
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2. SUMMARY 
2.1. Introduction and objectives
Chemical biology emerged two decades ago aimed at the study of the interface 
between chemistry and biology, producing a great improvement in our understandi ng of 
complex biological systems by means of the development of chemical tools able to 
interrogate them.1-3 In spite of these advances, there are relevant systems that hold 
great therapeutic promise but which have not been studied up to date. One of these 
cases is the endogenous cannabinoid system (ECS), which has been involved in almost 
every central and peripheral function.4-7 However, there is no drug in the market 
targeting this system so far. In this context, it seems clear that there is a crucial need to 
understand some aspects of the biology of the ECS in a deeper manner. Among them, 
the cellular location of cannabinoid receptors (CBRs), as well as their localization within 
the cell, the existence of other cannabinoid targets different from the molecu larly 
characterized CB1R and CB2R, and the study of interesting cannabinoid-related ligands, 
might help to exploit the therapeutic potential of the ECS. Thus, the overall objectives 
for the present work are: i) the development of probes to study the expression of CBRs 
in the immune system, ii) the design and synthesis of tools to explore the differences 
between plasma and mitochondrial CB1Rs, iii) the discovery of the off-targets of the 
synthetic CBR agonists HU210 and HU308, and iv) the identification of the binding 
proteins of the natural product honokiol. 
 
 
Summary 
 
16 
 
2.2. Results and discussion 
2.2.1. Development of probes to study the expression of CBRs in the immune system 
The widespread distribution of CBRs and their involvement in the regulation of 
different functions could offer a way of therapeutic intervention for many disorders. In 
this context, the immune system is of particular relevance because of its involvement in 
many diseases, and also for finding biomarkers that can reflect the presence or severity 
of different disorders. In this sense, it is known that immune cells express CBRs, that this 
expression changes under different conditions, and that the ECS regulates many aspects 
of the immune system.8-10 Hence, there is an interest in studying the role of CBRs in the  
control of the immune function as well as in determining whether they can be 
biomarkers of diseases or prognosis. Therefore, we focused our attention on the 
development of small-molecule probes that could be used to detect CBRs in a direct 
manner. Such probes should have three features: i) a binding group based on a scaffold 
with high affinity for the CBR under study, ii) an appropriate tag that enables target 
detection and visualization, and iii) a suitable spacer in order to avoid potential steric 
interferences which could produce a loss of affinity (Figure 1). With regard to the 
binding group, we selected the scaffold of the synthetic high affinity ligand HU210 for 
the design of the new probes. As for the tag, we considered the biotin subunit and the 
fluorophore Alexa Fluor 488 for the detection of CBRs by confocal microscopy and flow 
cytometry, respectively. 
Therefore, we synthesized compounds 1, 2, and 20 in which we have considered an 
amide in derivatives 1 and 2, or an ether group in compound 20 as the linker between 
the binding group and the tag. With regard to the preparation of the fluorescent 
derivative, we selected the amide linker of probe 1 and replaced the biotin subunit by 
the fluorophore Alexa Fluor 488 in probe 22 (Figure 1). Interestingly, all compounds 
exhibited affinity values in the nanomolar range. In particular, compound 1 presented 
the best Ki values [Ki (CB1)=1.6±0.5 nM; Ki (CB2)=0.36±0.02 nM], and derivative 22 was 
selective for CB1R [Ki (CB1)=28±4 nM; Ki (CB2)=0.7±0.2 M]. Hence, these compounds 
were selected for the analysis of CBRs in cellular systems. 
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Figure 1. Design of new HU210-based probes 1, 2, 20, and 22. 
Among the different possibilities with therapeutic relevance in the immune system, 
we initially focused on allergy, where the ECS has been suggested to play a protective 
role.11,12 In this context, we aimed to explore the presence of CBRs in human allergic 
diseases of atopic patients and healthy subjects. To this end, mononuclear cells from 
peripheral blood (PBMCs) and from lymphoid organs such as tonsils (TMCs) were 
selected. 
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Thus, probe 1 was used in several cell subsets of immune cells to detect the CB1R by 
confocal microscopy, proving for the first time that the CB1R is highly expressed in 
tonsils of patients with different types of allergic diseases.13 Alternatively, fluorescent 
probe 22 enabled the direct visualization of this receptor in human PBMCs by flow 
cytometry. Hence, this probe stands out as a valuable tool to study the modifications in 
the expression of this receptor in clinically relevant samples, and to establish its 
potential as a biomarker. 
2.2.2. Design and synthesis of tools to explore the differences between plasma and 
mitochondrial CB1Rs 
The complexity of the CB1R-mediated signalling has been recently increased by the 
identification of a new CB1R located in the mitochondria, mtCB1,
14,15 which has been 
hypothesized to be involved in the regulation of effects different from those mediated 
by the membrane CB1R.
16,17 To differentiate between these two receptors, it would be 
necessary to develop compounds that keep the affinity towards the plasma membrane 
CB1R but are unable to cross the cell membrane. Thus, we synthesized HU210-based 
compounds 26-28 with highly polar subunits such as an urea or an acylurea in 
compounds 26 and 27 respectively, and a tetrazole-containing chain in derivative 28, 
attached through an amide linker and the optimal length of the spacer as determined 
before (Figure 2). Compounds 26-28 displayed good affinities towards CB1R with Ki 
values in the nanomolar range (Ki=4-12.1 nM), and therefore they represent a promising 
tool to study the effects mediated by the plasma membrane CB1R, as these derivatives 
are, in principle, unable to cross the cell membrane and activate the mtCB1R. This work 
is currently ongoing in collaboration with Prof. Giovanni Marsicano at Université de 
Bordeaux (France). 
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Figure 2. Polar derivatives 26-28. 
2.2.3. Discovery of the off-targets of the synthetic CBR agonists HU210 and HU308 
The identification of cannabinoid binding sites different from the known CBRs is 
possibly one of the foremost challenges to fully understand the ECS physiology. In this 
context, cancer and immune modulation are receiving increasing attention as non 
CB1/2R-mediated effects have been described.
18-24 Hence, the development of analytical 
tools specifically tailored to enable the identification of cannabinoid targets would be of 
great value. To achieve this objective, we need to prepare chemical probes that besides 
bearing the binding group and the tag, present also a photocrosslinking group such as 
benzophenone, which after ultraviolet (UV) irradiation at the appropriate wavelength 
will form a covalent bond with the probe-target proteins, which in turn will be analyzed 
by multidimensional liquid chromatography altogether with mass spectrometry 
detection (LC-MS). 
Therefore, probes 39-41 were designed and synthesized by direct incorporation of a 
tag bearing the biotin subunit and the benzophenone group into the HU210 and HU308 
scaffolds, in order to study the differences between the two ligands (Figure 3). Since 
probe 39 presented the highest affinity towards both receptors [Ki (CB1)=25.7±0.4 nM; Ki 
(CB2)=12.1±0.2 nM], it was selected to carry out proteomic experiments. The use of this 
probe enabled the identification of 15 proteins of different functional classes which 
participate in diverse biological processes. Among them, the identification of the CB2R 
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deserves special attention since it supports the solidness of the platform and therefore, 
validates the methodology. 
 
Figure 3. Structure of probes 39-41. 
2.2.4. Identification of the binding proteins of the natural product honokiol  
Honokiol (Figure 4) is known due to its anxiolytic, analgesic, anti-depressant, anti-
tumorigenic, and neuroprotective properties among others.25,26 Among the different 
indications reported for honokiol and its derivatives, cancer has received increasing 
attention because of the significant activities shown by these compounds in several 
cancer models of different origins.25,27 However, their actual targets are not known, and 
their identification could lead to the discovery of new therapeutic strategies. Hence, we 
have focused our efforts on the development of chemical probes based on the synthetic 
derivative 2-O-ethylhonokiol (Figure 4), which is more potent than honokiol in some 
assays.28 
 
Figure 4. Chemical structure of honokiol and its synthetic derivative, 2-O-ethylhonokiol . 
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Thus, we designed and synthesized probes 56-59, with a biotin and benzophenone 
containing tag, and probes 64 and 65, where we have replaced the benzophenone by 
the less bulky diazirine group as the photocrosslinking moiety, and the biotin subunit by 
a terminal alkyne (Figure 5). 
 
Figure 5. Structure of honokiol -based probes 56-59, 64, and 65. 
Among the synthesized compounds, probes 64 and 65 displayed the best 
cytotoxicity values in breast (MDA-MB-231) and ovarian (SKOV3 and OVCAR3) cancer 
cell lines, and hence were selected for further experiments.  Then, we confirmed that 
these probes were able to label proteins in a specific way. Considering that probe 65 
showed a slightly better labelling profile, it was se lected to identify the targets of 
honokiol in MDA-MB-231 cells by SILAC quantitative MS.29,30 This experiment enabled 
the identification of about 40 proteins that were significantly competed by honokiol. 
Among them, LYRIC protein31 deserves particular attention since it is involved in 
mechanisms related to cell viability. 
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2.3. Conclusions 
In the present work we have developed a set of chemical probes for the study of the 
ECS. 
Biotinylated probe 1 (Figure 1), with high affinity toward both CBRs [Ki (CB1)=1.6 nM; 
Ki (CB2)=0.36 nM], enabled the visualization of the CB1R in several subsets of human 
immune cells proving the expression of this receptor in patients with different types of 
allergic diseases. In addition, the fluorescent CB1R-selective probe 22 has been 
successfully used to detect and semi-quantify the levels of expression of CB1R in PBMCs. 
This result highlights the suitability of 22 to study possible modifications in such levels in 
clinically relevant systems, and to establish the potential of CB1R as a biomarker. 
Concerning the study of the mtCB1R, highly polar compounds 26-28 (Figure 2), with 
high affinity values for the CB1R (Ki=4-12.1 nM) represent promising tools to study the 
different effects mediated by the plasma membrane CB1R and the mtCB1R. 
Finally, we have developed a series of chemical probes to enable the identification of 
the targets of different compounds. Thus, probe 39 (Figure 3) is being used to discover 
additional targets of the HU210 ligand, while probe 65 (Figure 5) is allowing the 
characterization of some of the direct targets of honokiol in MDA-MB-231 breast cancer 
cells, providing for the first time direct insights into the mechanisms of action of this 
natural product. 
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3. INTRODUCTION AND OBJECTIVES
During the last decades a vast amount of research has been devoted to the 
development of novel synthetic approaches, which altogether with undeniable advances 
in technology have made possible a constant increase in the number of new chemical 
entities designed for therapeutic applications.1 However, despite the increasing 
investment in the drug discovery process, the rate of success continues to fall , fact only 
justifiable by the extraordinary complexity of the biological world implicated in the 
different pathological states. 
In this regard, chemical biology emerged two decades ago aimed at the study of the 
interface between chemistry and biology, producing a great improvement in our 
understanding of complex biological systems by means of the development of chemical 
tools able to interrogate them.2-4 In spite of these advances, there are relevant systems 
that hold great therapeutic promise but which have not been studied up to date. One of 
these cases is the endogenous cannabinoid system (ECS) , which has been involved, 
during the last years, in almost every central and peripheral function.5-8 However, no 
drug targeting this system remains in the market after the withdrawal of Rimonabant 
(Acomplia®), the only agent acting at the ECS ever approved. This compound, prescribed 
as an anti-obesity drug, was retired from the European market in 2008 due to safety 
concerns related with a high risk of serious psychiatric problems, including suicide.9,10 
This fact, rather than discourage researchers and pharmaceutical companies working on 
the cannabinoid field, inspired them to search for new alternatives in order to avoid the 
undesired side effects. As a result, different approaches based on the constituents of the 
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ECS have emerged.6 The current view of the ECS includes, as the main elements, two 
cannabinoid receptors (CBRs), CB1R
11,12 and CB2R,
13  being the former mainly located in 
the central nervous system (CNS) and the later mostly expressed in tissues and cells of 
the immune system (Figure 1).14,15 Nonetheless, other proteins have been related to the 
ECS such as the orphan G protein-coupled receptors (GPCRs) GPR18 and GPR55,16,17 the 
transient receptor potential (TRP) of the type 1 vanilloid channel, or the nuclear 
peroxisome proliferator-activated receptors (PPARs).18 
 
Figure 1. Schematic representation of the ECS (adapted from Alhouayek et al.
19
). 
In addition, two molecules, N-arachidonoylethanolamine (AEA, anandamide)20 and 
2-arachidonoylglycerol (2-AG)21,22 have been identified as the main endocannabinoids 
(eCBs), i.e., the endogenous ligands for these receptors (Figure 2). These derivatives of 
the arachidonic acid (AA) are biosynthesized and degraded by specific enzymes. The 
main responsible for their synthesis are N-arachidonoylphosphatidylethanolamine 
phospholipase D (NAPE-PLD) for AEA, and diacylglycerol lipase (DAGL) in the case of 2-
AG.18 Eventually, both eCBs are metabolized by different hydrolases, being fatty acid 
amide hydrolase (FAAH),23,24 and monoacyl glycerol lipase (MAGL)25 the ones 
accountable for the majority of AEA and 2-AG degradation, respectively. Nevertheless, 
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the enzymes N-acylethanolamine-hydrolysing acid amidase (NAAA)18 and /-hydrolase 
domain 6 (ABHD6)26 partially contribute to the degradation of these eCBs (Figure 1). 
 
Figure 2. Structure of the main endocannabinoid l igands. 
Since the discovery of the main psychoactive constituent of the plant Cannabis 
sativa, (-)-9-tetrahydrocannabinol (THC, Figure 3),27 a great amount of research has 
been devoted to the synthesis and biological evaluation of cannabinoid ligands able to 
reproduce its effects. Among all the synthesized compounds, a few derivatives deserve 
special attention28 due to their widespread use for the study of the functions of the ECS: 
i) the non-selective agonists HU210, CP55940, and the aminoalkylindol R-(+)-
WIN552122, and ii) the selective agonists R-(+)-methanandamide and HU308. In 
particular, HU210 is a classical cannabinoid agonist with high affinity and potency for 
both CBRs widely used for the study of the ECS physiology,29,30 while the tritiated 
derivative of CP55940,28 which led to the discovery of the CB1R, is the most widely used 
radiolabelled cannabinoid ligand. With respect to HU308,31 it is one of the most selective 
ligands for the CB2R,
28 whereas R-(+)-methanandamide,32 the AEA-based ligand, 
represents the first generation of CB1R selective compounds. 
 
Figure 3. Representative CB1R and/or CB2R agonists. 
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Moreover, the study of the ECS would not have been possible without the 
development of selective antagonists/inverse agonists for each CBR, altogether with the 
use of CB1R and/or CB2R knock-out mice. In this sense, the most representative 
antagonists/inverse agonists of CBRs are the CB1R-selective ligand SR141716A, and the 
CB2R-selective one SR144528, both of them sharing a diarylpyrazole scaffold in their 
structure (Figure 4).28  
 
Figure 4. Representative CB1R and CB2R antagonists/inverse agonists. 
According to the elements that form the ECS, potential approaches to exploit its 
therapeutic potential while keeping away the undesirable side effects have emerged. 
One of them has been the inhibition of the eCB metabolism in order to increase the eCB 
tone to achieve the benefits of cannabinoid agonists while avoiding psychotropic 
effects.33-37 Also, a lot of research has pursued the identification of either peripherally 
restricted CB1R inverse agonists/antagonists,
38 or CB2R selective agonists,
39-41 since both 
would lack the side effects mainly mediated by the CB1Rs present in the brain. Finally, a 
more recent approach has been the development of allosteric modulators for the 
CB1R.
42-44 These are ligands that engage the CB1R in a different binding site than that of 
the orthosteric ligand, modulating its binding and/or affinity. The major advantage of 
these ligands is that, as a consequence of a less conserved binding site in comparison 
with the orthosteric binding pocket, they present a better selectivity profile with respect 
to other proteins of the same family, with a consequent reduction of side effects .45 
In spite of all the efforts made with regard to the development of new CBR ligands 
and new inhibitors for the metabolic enzymes of the eCBs, it is a fact that the 
therapeutic potential of the ECS can not be, still today, separated from the undesirable 
side effects. This is because there are some fundamental gaps in the understanding of 
the ECS that have not been resolved yet. Some of these aspects are: 
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 Cellular location 
This has arisen as a critical aspect in CBR-induced effects. In this regard, CB1Rs are 
mainly present in the presynaptic terminals of GABAergic interneurons, but also in other 
neuronal types such as glutamatergic, serotonergic, or cholinergic, among others. 
Besides, they are present in glial cells including microglia46 and astrocytes.47 Genetic 
mouse models are helping to determine which cell types are involved in which CB1R-
mediated effects. For example, CB1R can both inhibit and stimulate food intake in 
fasting/refeeding conditions, depending on the specific neuronal population involved. 
CB1Rs located in the ventral striatal neurons exerted a hypophagic action (that is, a 
reduction in food intake) through inhibition of GABAergic transmission. Conversely, 
brain CB1Rs modulating excitatory transmission mediated the well -known effects of 
cannabinoids on appetite stimulation.48,49 To further complicate the situation, recent 
studies suggest that the CB1Rs localized in the peripheral nervous system are responsible 
not only for the appetite reduction induced by the CB1R antagonist Rimonabant, but also 
for the behavioural negative effects associated to its administration. 50  
Different cellular localization of CB1R has also been suggested as a potential way of 
dissociating therapeutic from undesirable side effects. In this regard, it has been 
described that peripheral CB1R is involved in spasticity reduction whereas central CB1R is 
responsible for the typical cannabinoid-induced hypothermia.51 Similarly, CB1Rs in 
GABAergic neurons are involved in the amnesic- and anxiogenic-like effects of THC,52,53 
whereas CB1Rs in principal forebrain glutamatergic neurons are necessary for the 
anxiolytic properties of low doses of cannabinoids.53 
Importantly, although CB1R expression levels can vary between different 
populations, differential expression of CB1Rs is not directly linked with equivalent 
functional relevance. The intracellular consequences of CB1R signalling, and hence the 
resulting phenotypic effects, appear to emerge from its cellular localization, rather than 
being an intrinsic property of the protein. In fact, some of the signalling pathways 
appear to be specific of certain cell types.  
In this context, it is evident that there is a clear need to establish where and when 
CBRs are expressed. As differences between in vitro and in vivo experiments have been 
detected,47,54 it is important to develop sensitive methods that enable the study of CBR 
expression in native systems. In addition, most of the studies have been carried out in 
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the CNS, so it is essential to extend this knowledge to the periphery, 8 where the 
important role of the ECS is just starting to be established.  
 Subcellular location 
Another important aspect to consider in the search of new therapeutic opportunities 
for targeting CBRs is their localization within the cell. As G protein coupled receptors 
(GPCRs), CBRs are located in the plasma membrane of the cells, but their presence in 
other cell compartments has been proposed. In particular, the CB1R has been found in 
the mitochondria (mtCB1R),
55-57 adding a degree of complexity to the ECS physiology. 
The involvement of this new mtCB1R in the beneficial and/or psycotropic effects shown 
by cannabinoid ligands is currently under evaluation. Accordingly, the development of 
appropiate pharmacological tools that facilitate these studies could be of great interest.  
 Other cannabinoid targets 
There is evidence to suggest that binding to the molecularly characterized CB1 and 
CB2 receptors is not the only mechanism by which cannabinoid ligands exert some of 
their actions. In this regard, genetic deletion of CB1R and CB2R and/or administration of 
receptor antagonists do not eliminate some of the effects induced by eCBs, plant active 
principles (such as THC), or synthetic ligands such as HU210.16,28,58-60 In this sense, the 
identification of these cannabinoid off-targets would undoubtedly contribute to a better 
understanding of the biology of the ECS, and hence, their uncovering is essential in order 
to be able to draw upon the therapeutic potential of this system. 
 Other cannabinoid ligands 
Besides the traditionally accepted cannabinoid ligands (summarized in Figures 3 and 
4) other compounds have been suggested to induce cannabinoid-like effects.39,61-63 
Among them, the natural product honokiol (Figure 5) and its derivatives deserve special 
attention since they have been reported to have therapeutic relevance in important 
processes such as bone remodeling, and disorders such as neurodegenerative diseases 
or different types of cancer.64-66 However, although honokiol and related compounds 
have a potential role in the treatment of several pathologies, a thorough unde rsanding 
of their mechanisms of action is imperative in order to use them for the treatment of 
human diseases.66 
Introduction and objectives 
 
33 
 
Figure 5. Natural product honokiol . 
Considering that chemical probes could help to get deeper insights in all the above 
mentioned aspects, the overall objectives for the present work are: 
1. Development of probes to study the expression of CBRs in the immune system 
2. Design and synthesis of tools to explore the differences between membrane and 
mitochondrial CB1Rs 
3. Discovery of the off-targets of the synthetic CBR agonists HU210 and HU308 
4. Identification of the target proteins of the natural product honokiol 
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4. RESULTS AND DISCUSSION 
4.1. Development of probes to study the expression of CBRs in the immune system 
The widespread distribution of CBRs and their involvement in the regulation of 
different functions could offer a way of therapeutic intervention for many disorders. In 
this regard, many efforts have been devoted to establish the role of the ECS in the 
CNS,5,67-69 although its therapeutic applications seem to be limited by the existence of 
undesirable side effects. However, the relevance of the peripheral ECS for human health 
and disease pathogenesis still remains to be completely elucidated.8 
In this context, the immune system is of particular relevance because of its 
fundamental role in the body. The immune system’s main function is to protect against 
disease by recognizing pathogens and distinguishing them from the organism's own 
healthy tissue. Accordingly, disorders of the immune system can result in 
immunodeficiency (when the immune system is less active than normal) or in 
autoimmune diseases, which result from a hyperactive immune system attacking normal 
tissues as if they were foreign organisms. In addition, malfunctioning of the immune 
system has also been linked to inflammatory diseases and cancer.70,71 These facts 
convert the immune system not only in a system with therapeutic potential for many 
diseases but also for finding biomarkers that can reflect the presence or severity of 
different disorders. In this regard, the number of immune biomarkers is rapidly 
increasing specially in the fields of cancer, autoimmune disorders and 
neurodegenerative diseases.72,73 However, the identification of immune biomarkers 
which can be analyzed in a straightforward manner from a simple blood test and in a 
multiplexed manner (i.e., more than one biomarker at the same time) by routine 
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techniques such as flow cytometry, remains a challenge.72 In this context, it is known 
that immune cells express CBRs, that this expression changes under different conditions, 
and that the ECS regulates many aspects of the immune system.74-76 Hence, there is an 
interest in studying the role of CBRs in controlling the immune function as well as in 
determining whether they can be biomarkers of diseases or prognosis. Towards this 
objective, it is necessary the development of tools that enable the visualization of CBRs 
in the immune system in a direct manner. Their availability would enable: (i) to detect 
up- or down-regulation of CBRs as biomarkers of diseases; (ii) to cluster patients and 
hence propose tailored therapeutic strategies; and (iii) to carry out multiplexed analysis 
with other clinically validated biomarkers. 
However, the lack of appropriate tools has hampered these studies. In this regard, 
antibodies that recognize CBRs have been used, but they have important limitations due 
to their insufficient sensitivity and specificity.77,78 In addition, the batch-to-batch 
variations inherent to the way in which antibodies are produced has been recognised as 
an important problem of reliability.79,80 
Hence, our objective was to develop small molecule probes that could be used for 
detecting CBRs in blood cells. Towards this aim, we envisioned that the adequate probes 
should have three features: i) a binding group based on a scaffold with high affinity for 
the CBR under study, ii) an appropriate tag that enables target detection and 
visualization, and iii) a suitable spacer in order to avoid potential steric interferences 
which could produce a loss of affinity (Figure 6). 
With regard to the tag, we have considered biotin and the green-fluorescent Alexa 
Fluor 488 dye (Figure 6). Biotin has been chosen because of its versatility, since it can be 
recognized by many different conjugates. In addition, it has been successfully used in 
other probes developed in our research group where it has enabled the visualization of 
different GPCRs by confocal microscopy in a variety of cells. 81-83 Alternatively, and in 
order to avoid the two-step labelling required by biotin, we have also conceived the 
bright dye Alexa Fluor 488 for flow cytometry experiments,  as it can be directly 
visualized under the routinely used instruments, including microscopes and flow 
cytometers. 
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Figure 6. CBR probe design and selected tags. 
With respect to the binding group, a variety of cannabinoid ligands could be initially 
considered. However, previous studies in our research group revealed that structural 
modification of the main eCBs involved decreases in affinity, although they could be 
used in transfected cell systems.82 On the contrary, HU210 and HU308 scaffolds can be 
converted into probes that keep high affinity towards CBRs. In particular, probes 
UCM143 and UCM168 (Figure 7) have been successfully used for the visualization of CB1 
and CB2 receptors in neurons and microglial cells, respectively.
83 However, preliminary 
studies aimed at the in vivo detection of CBRs with UCM143, evidenced the degradation 
of the probe. Interestingly, UCM143 produced typical HU210-induced behavioral effects 
such as catalepsy, antinociception or hypothermia, suggesting the hydrolysis of the ester 
group present in UCM143. This finding led us to consider other linkers with higher 
expected metabolic stability in the design of the new probes.  
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Figure 7. Structure of HU210 and HU308 and their previously designed probes. 
Taking into account the above-mentioned results, the new series of probes were 
designed considering the scaffold of HU210 as binding moiety, amide and ether groups 
as linkers, and both the biotin subunit and the fluorophore Alexa Fluor 488 as tags 
(Figure 8). 
 
Figure 8. Design of new HU210-based probes. 
Therefore, we designed compounds 1-3 in which we have replaced the ester linker 
of UCM143 by an amide in derivatives 1 and 2, or by an ether group in compound 3 
(Figure 9), keeping the same tag and length of the spacer as in UCM143. 
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Figure 9. Design of HU210-based probes 1-3. 
The preparation of the desired probes 1-3 involved the synthesis of the HU210 
scaffold, carried out as previously reported by Mechoulam et al.84 Esterification of 
commercially available (1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-methanol [(-)-
myrtenol] with pivaloyl chloride provided ester (-)-4, which gave 4-oxo-myrtenyl pivalate 
[(-)-5] upon oxidation with chromium(VI) oxide (Scheme 1). Reduction of ketone (-)-5 
with lithium tri-tert-butoxyaluminium hydride led to alcohol (-)-6. With regard to 
resorcinol 7, it was prepared by deprotection of the methoxy groups in the commercially 
available 1-(1,1-dimethylheptyl)-3,5-dimethoxybenzene by boron tribromide. 
Subsequent condensation of alcohol (-)-6 with resorcinol 7 in the presence of boron 
trifluoride diethyl etherate afforded chromene 8. Once the scaffold was prepared, 
phenol 8 was protected before carrying out any further of the allylic alcohol. Among the 
different protecting groups available for phenols, we selected the bulky triisopropylsilyl 
(TIPS) ether trying to avoid the high tendency of smaller analogs such as tert-
butyldimethylsilyl (TBS) to be cleavaged under mild conditions. Thus, 8 was transformed 
into the corresponding silyl-ether 9 by treatment with TIPS chloride and imidazole under 
microwave (MW) irradiation, followed by removal of the pivaloyl group with lithium 
aluminium hydride. 
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Scheme 1. Reagents and conditions: (a) (CH3)3CCOCl, pyridine, DCM, 0 ºC, 92%; (b) CrO3, 3,5-
dimethylpyrazole, DCM, -20 ºC to 0 ºC, 46%; (c) LiAlH(t-BuO)3, THF, 0 ºC to rt, 63%; (d) BBr3, DCM, 
0 ºC to rt, 100%; (e) BF3·Et2O, DCM, -20 ºC to rt, 50%; (f) TIPS-Cl, imidazole, DMF, MW, 200 ºC, 
95%; (g) LiAlH4, THF, 0 ºC, 72%. 
The preparation of amides 1, 2 required the transformation of alcohol 9 into the 
corresponding amine or carboxylic acid, as well as the synthesis of the proper biotin 
derivatives functionalized as a carboxylic acid or an amine, respectively.  
Hence, amine 11 was obtained through the Mitsunobu reaction of alcohol 9 with 
phthalimide in the presence of diethyl azodicarboxylate (DEAD) and triphenylphosphine 
and subsequent deprotection of the resulting phthalimide 10, using hydrazine as the 
cleaving reagent and ethanol as solvent (Scheme 2). As for carboxylic acid 13, it was 
prepared through the corresponding aldehyde 12 by consecutive oxidations of alcohol 9 
with pyridinium chlorochromate (PCC) and sodium chlorite. 
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Scheme 2. Reagents and conditions: (a) phthalimide, PPh3, DEAD, THF, rt, 93%; (b) i) N2H4·H2O, 
EtOH, reflux; i i) HCl/H2O 1:1 reflux to rt, 96%; (c) PCC, DCM, rt, 85%; (d) NaClO2, 2-methyl-2-
butene, KH2PO4, t-BuOH, rt, 74%. 
As for the corresponding biotinylated tags, amine 15 was prepared by condensation 
between tert-butyl (6-aminohexyl)carbamate with biotin in the presence of 
tributylamine and isobutyl chloroformate, followed by removal of the tert-
butoxycarbonyl (Boc) protecting group of intermediate 14 with trifluoroacetic acid (TFA) 
(Scheme 3). 
 
Scheme 3. Reagents and conditions: (a) Bu3N, isobutyl chloroformate, DMF, 0 ºC, 80%; (b) TFA, 
DCM, rt, 81%. 
Once the fragments were synthesized, amide 16 was prepared through 
condensation between amine 11 and commercially available N-(+)-biotinyl-6-
aminohexanoic acid using N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) and 1-
hydroxybenzotriazole (HOBt) as coupling reagents in the presence of catalytic amounts 
of 4-dimethylaminopyridine (DMAP), and the same conditions were employed in the 
synthesis of amide 17 from carboxylic acid 13 and amine 15 (Scheme 4). Then, final 
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compounds 1 and 2 were obtained by removal of the TIPS protecting group with 
tetrabutylammonium fluoride (TBAF). 
 
Scheme 4. Reagents and conditions: (a) EDC, HOBt, DMAP, DCM, DMF, 77 ºC to rt, 62%; (b) TBAF, 
THF, 0 ºC, 80-84%; (c) EDC, HOBt, DMAP, DCM, DMF, rt, 48%. 
The synthesis of ether 3 was firstly envisioned as a Williamson alkylation of alcohol 9 
with the corresponding biotinylated bromoderivative. This compound was synthesized 
following a previously described procedure,85 through condensation between 6-
aminohexanol and biotin followed by the Appel reaction of the obtained alcohol 18 
(Scheme 5). Unfortunately, Williamson alkylation of alcohol 9 with bromoderivative 19 
in the presence of sodium hydride and tetrabutylammonium iodide (TBAI) did not 
provide the desired allylic ether 3, but instead phenolic ether 20 was isolated in all the 
assayed conditions. The obtention of 20 can be explained by in situ cleavage of the TIPS 
group followed by the alkylation of the resulting phenol (Scheme 5). 
Results and discussion 
 
45 
 
Scheme 5. Reagents and conditions: (a) Bu3N, isobutyl chloroformate, DMF, 0 ºC, 97%; (b) CBr4, 
PPh3, DMF, rt, 74%; (c) NaH, TBAI, THF, 0 ºC to reflux, 75%. 
Next, we approached the synthesis of 3 through the Mitsunobu reaction between 
alcohols 9 and 18 using tributylphosphine and 1,1'-(azodicarbonyl)dipiperidine (ADDP) 
as coupling reagents, conditions that have been commonly used with weakly acidic 
nucleophiles (Scheme 6). However, the formation of the byproduct of the addition of 
alcohol 9 to ADDP was always observed as previously reported for alcohols with 
pKa>11,
86 which indicates the low acidity of allylic alcohol 9 for undergoing this reaction. 
Finally, we tried to carry out the nucleophylic substitution of bromoderivative 21, 
previously prepared through the Appel reaction of alcohol 9, with alcohol 18 although 
we only observed a complex reaction mixture, which did not contain the desired product 
(Scheme 6). 
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Scheme 6. Reagents and conditions: (a) PBu3, ADDP, toluene, 60 ºC; (b) CBr4, PPh3, DCM, rt, 65%; 
(c) NaH, TBAI, DMF, rt.  
Since ether 3 could not be prepared but ether 20 was obtained instead, we 
proceeded with its biological evaluation, together with amides 1 and 2. 
Affinity of compounds 1, 2, and 20 for CB1 and CB2 receptors was evaluated by 
radioligand competitive binding assays using membranes of HEK-293-EBNA cells 
transfected with human CB1R and CB2R (hCB1R and hCB2R), respectively, and [
3H]-
CP55940 as radioligand. The competitive inhibition assays were first performed at a 
fixed dose of 1 μM. Then, the complete dose-response curve, at six different 
concentrations of the ligand, was determined for those compounds that displaced more 
than the 50% of the radioligand. The affinity constant Ki was calculated from the 
inhibitory concentration 50 (IC50) value using the Cheng-Prusoff equation
87 and is 
expressed as the average and standard error (SEM) obtained from two to four 
independent experiments carried out in triplicate. Table 1 shows the affinity values of 
probes 1, 2, and 20 for both CBRs. 
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Table 1. Binding affinities of probes 1, 2, and 20 for CBRs. 
 
Compound X Y 
Receptor affinity
a
 
Ki±SEM (nM) 
CB1 CB2 
UCM143 
 
OH 2.4±0.4 1.6±0.4 
1 
 
OH 1.6±0.5 0.36±0.02 
2 
 
OH 36±12 25±11 
20 CH2OH 
 
40±5 13±3 
a
The values are the mean±SEM obtained from two to four independent experiments performed 
in triplicate. 
As shown in Table 1, probes 1, 2, and 20 displayed high affinity for both CBRs with Ki 
values in the nanomolar range. In particular, compound 1, the amide analog of UCM143, 
presented the best Ki values and was selected for the analysis of CBRs in cellular 
systems.  
With regard to the preparation of the fluorescent derivative, and considering the 
affinity values represented in Table 1, we selected the amide linker of probe 1 and 
replaced the biotin subunit by the fluorophore Alexa Fluor 488 in probe 22. 
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The preparation of 22 was carried out by condensation between the commercially 
available tetrafluorophenyl (TFP) ester of Alexa Fluor 488, and the HU210 scaffold 
properly functionalized with the desired spacer. Thus, coupling of amine 11 with 
commercially available 6-(N-Boc-amino)hexanoic acid in the presence of N,N’-
dicyclohexylcarbodiimide (DCC) provided amide 23 (Scheme 7). Cleavage of the TIPS 
protecting group of 23 by TBAF and subsequent deprotection of Boc with TFA led to 
amine 25. Condensation of amine 25 with Alexa Fluor 488 TFP ester afforded fluorescent 
derivative 22. 
 
Scheme 7. Reagents and conditions: (a) DCC, DCM, rt, 74%; (b) TBAF, THF, 0 ºC, 81%; (c) TFA, 
DCM, rt, 84%; (d) Alexa Fluor 488 TFP ester, DCM, DMF, rt, 66%. 
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Once synthesized, the affinity of 22 for CBRs was evaluated. Interestingly, probe 22 
exhibited affinity values in the nanomolar range toward CB1R while showing almost no 
affinity for CB2R (submicromolar range) [Ki (CB1)=28±4 nM; Ki (CB2)=0.7±0.2 M]. 
Among the different possibilities with therapeutic relevance in the immune system, 
we have initially focused on allergy. Allergic diseases encompass a number of 
inflammatory conditions caused by the hypersensitivity of the immune system against 
innocuous antigens for non-allergic patients, so called human allergenes. It has been 
suggested that the ECS can play a protective role in some types of allergy,88,89 including 
contact allergy in the skin,90 or allergic asthma.74 However, studies reporting human data 
are still scarce. 
In this context we aimed to explore the presence of CBRs in human allergic diseases 
of atopic patients (suffering from food anaphylaxis or allergic rhinitis, atopic dermatitis, 
and/or asthma) and healthy subjects. Mononuclear cells from peripheral blood (PBMCs) 
and from lymphoid organs such as tonsils (TMCs), which have also been involved in 
allergic responses,91 were selected. The obtained results showed that messenger 
ribonucleic acid (mRNA) levels of CB1R were significantly increased in both TMCs and 
PBMCs of allergic patients when compared to healthy subjects.92 In order to check 
whether this expression could be directly observed at the protein level, compound 1 was 
used in different subsets of TMCs. Thus, purification of B and T lymphocytes, and 
plasmacytoid and myeloid dendritic cells (pDCs and mDCs, respectively) was carried out 
and the different cell types were stained with their corresponding marker in red (CD20 
for B cells, CD3 for T cells, CD123 for pDCs, and HLA-DR for mDCs) and, simultaneously, 
with compound 1 in green (Figure 10). The obtained images clearly show that probe 1 
can be used to detect the CB1R in purified subsets of mononuclear cells isolated from 
human tissues such as tonsils. 
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Figure 10. CB1R expression in tonsil  B and T cells  (A), and purified pDCs and mDCs (B) from atopic 
donors. All  cell  subtypes were stained with probe 1 (0.5 M, green), the nuclear marker DAPI 
(blue), and CD20, CD3, CD123 or HLA-DR (red) for B cells, T cel ls, pDCs and mDCs, respectively. 
Merged images show the combination of the three types of staining. All  preparations were 
analyzed by confocal microscopy. Data are from 1 of at least 2 different atopic donors with 
similar results. White bars, 5 m. DAPI, 4’-6-diamidino-2-phenylindole dihydrochloride. 
Taken together, these data demonstrate for the first time that mRNA expression 
levels of CB1R are upregulated in tonsils and peripheral blood of patients with different 
types of allergic diseases (allergic rhinitis, atopic dermatitis, and food allergy). 
Furthermore, B cells, T cells, pDCs, and mDCs from allergic patients express high protein 
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levels of CB1R, indicating that these cell subsets could also contribute to the regulation 
of the pathogenesis of allergic diseases mediated by the ECS.92 
Once confirmed that biotinylated probe 1 could be used in human cells to detect the 
CB1R using confocal microscopy, we aimed to confirm whether fluorescent probe 22 
could allow the direct visualization of this receptor in human PBMCs using flow 
cytometry. Our results show that probe 22 is able to detect CB1R in human lymphocytes 
from PBMCs (54.2% positive cells) and that this signal significantly decreases, as 
expected, in the presence of HU210 (32.3% positive cells) (Figure  11). In addition, no 
fluorescent signal was obtained when control experiments using the fluorophore Alexa 
Fluor 488 alone were carried out. 
 
Figure 11. Flow cytometry analysis of PBMCs using probe 22. Representative dot plots of PBMCs 
labelled with (A) vehicle, (B) probe 22 (1 M), or (C) probe 22 (1 M) plus an excess of HU210 (50 
M). (D) Bar chart displays the percentage of fluorescent PBMCs obtained in dot plots  from three 
different experiments carried out separatedly. Forward scatter (FS) indicates the size of the gated 
cells. ***, P<0.001 (vs probe-treated cells, Student’s t test). 
These results indicate that probe 22 can be successfully used to detect and semi-
quantify the levels of expression of CB1R in PBMCs. Hence, this probe stands out as a 
valuable tool to study the modifications in the expression of this receptor in clinically 
relevant samples under different physio- or pathological conditions, and to establish its 
potential as a biomarker. 
In summary, we have developed chemical probes 1 and 22 suitable for the detection 
of CB1R in complex and clinically relevant systems such as immune cells.  
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4.2. Design and synthesis of tools to explore the differences between membrane and 
mitochondrial CB1Rs 
The complexity of the CB1R-mediated signalling has been recently increased by the 
identification of a new CB1R located in the mitochondria, mtCB1R,
55,57 instead of the 
plasma membrane, which is the usual cellular location for GPCRs (Figure 12). 
 
Figure 12. Subcellular locations of the CB1R. 
It has been hypothesized that this receptor could be involved in the regulation of 
different effects from those mediated by the membrane CB1R. In particular, recent 
results suggest that the mtCB1R mediates important cannabinoid-induced adverse 
effects such as catalepsy or memory impairment whereas therapeutic properties such as 
antinociception are associated to the plasma membrane CB1R.
93,94 However, the 
described cannabinoid ligands are highly lipophilic (Figures 3 and 4)28 and therefore, 
they bind to the membrane CB1R but they are also able to cross the cell membrane and 
target the mtCB1R. This fact makes them unsuitable to study whether these two types of 
receptors mediate different effects and if this fact is therapeutically relevant. To be able 
to distinguish between the two receptors, it would be necessary to develop compounds 
that keep the affinity towards the plasma membrane CB1R but are unable to cross the 
cell membrane. In this regard, the topological polar surface area (tPSA) has been 
recognized as a reliable physicochemical parameter for the prediction of membrane 
permeability,95 being generally accepted that the higher the tPSA, the less the cell 
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membrane penetration. In particular for the intestinal barrier, it has been described that 
while molecules with tPSA lower than 60 Å2 are completely permeable,96 the absortion 
degree decreases with the rise in the tPSA up to a maximal value of 140 Å2, when the 
absortion has been shown to be less than 10%.97 
Based on these considerations, and taking into account our previous results, we 
considered the possibility of introducing highly polar groups to the HU210 scaffold in an 
attempt to keep the CB1R affinity, but with high tPSA values to impair plasma membrane 
crossing. Thus, we designed HU210-based compounds 26-28 with highly polar subunits 
such as an urea or an acylurea in compounds 26 and 27 respectively, and a tetrazole 
containing chain in derivative 28, attached through an amide linker and the optimal 
length of the spacer as determined before (Figure 13). The polarity of compounds 26-28 
(tPSA: 113.7-171.2 Å2) is highly increased with regard to the lipophilic cannabinoid ligand 
HU210 (tPSA: 49.7 Å2). 
 
Figure 13. Design of polar derivatives 26-28. 
The synthesis of compounds 26-28 involved the condensation between amine 11 
and the carboxylic acids of the corresponding derivatives 29-31, followed by cleavage of 
the TIPS protecting group of amides 32-34 by TBAF (Scheme 8). 
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Scheme 8. Reagents and conditions: (a) EDC, HOBt, DMAP, DMF, DCM, rt, 49-75%; (b) TBAF, THF, 
0 ºC, 32-93%. 
Preparation of polar chains 29-31 started in all cases from commercially available 6-
aminohexanoic acid (Scheme 9). Thus, its treatment with potassium cyanate in water 
provided urea 29 in quantitative yield. Further acylation of urea 29 with potassium 
acetate in acetic anhydride afforded polar chain 30. Alternatively, esterification of 6-
aminohexanoic acid, followed by condensation of amine 35 with N-Boc--alanine using 
EDC and HOBt as coupling reagents led to amide 36, whose deprotection with TFA 
yielded amine 37. Final condensation of 37 with 1H-tetrazol-5-ylacetic acid in the 
presence of bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) at low temperature 
and further hydrolysis of the resulting ester 38, gave the desired carboxylic acid 31. 
Then, the affinity of compounds 26-28 for CB1 and CB2 receptors was evaluated by 
radioligand competitive binding assays (Table 2). 
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Scheme 9. Reagents and conditions: (a) KCN, H2O, 60 ºC, 100%; (b) KOAc, Ac2O, reflux, 28%; (c) 
SOCl2, MeOH, 0 ºC, 100%; (d) N-Boc--alanine, EDC, HOBt, Et3N, DCM, 0 ºC to rt, 100%; (e) TFA, 
DCM, rt, 94%; (f) 1H-tetrazol-5-ylacetic acid, Et3N, BOP-Cl, DCM, 10 ºC to rt, 57%; (g) NaOH, 
MeOH, rt, 100%. 
Table 2. Binding affinities of probes 26-28 for CBRs. 
 
Compound Polar group 
Receptor affinity
a
 (nM) 
Ki±SEM 
CB1 CB2 
26 
 
4±1 4±1 
27 
 
8±3 7±2 
28 
 
12.1±0.5 16±4 
a
The values are the mean±SEM obtained from two to four independent 
experiments performed in triplicate. 
These results show that the three compounds displayed good affinities towards both 
CBRs with Ki values in the nanomolar range. Therefore, compounds 26-28 stand out as 
promising candidates to study the effects mediated by the plasma membrane CB1R, as 
these derivatives are uncapable of crossing the cell membrane and activate the mtCB1R. 
This work is currently ongoing in collaboration with Professor Giovanni Marsicano at 
NeuroCentre Magendie at Université de Bordeaux (France). 
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4.3. Discovery of the off-targets of the synthetic CBR agonists HU210 and HU308 
Among the issues regarding the understanding of the ECS, the identification of 
cannabinoid binding sites different from the known CBRs is possibly one of the foremost 
challenges to fully understand the ECS physiology. Although most of the THC-induced 
effects are mediated through the activation of CB1R or, albeit with less efficacy, CB2R, 
evidence has emerged suggesting that some of its effects are independent of these 
receptors.60,98,99 For example, THC has been shown to potentiate glycine receptors,100 
and to activate the deorphanized GPCRs GPR18101 and GPR55,28,102 the TRPs of the type 
1 ankyrin and type 2 vanilloid channels,103 and the gamma member of the PPAR family of 
receptors.28 Conversely, it has been found that THC blocks the activation of both the 
serotonin 5-HT3 receptor and the TRP of the type 8 melastatin channel.
103,104 In addition, 
there has also been reported that submicromolar concentrations of THC can regulate 
the activity of some enzymes such as lysophosphaditylcholine acyl transferase or 
phospholipase C.105 In a similar manner, some of the effects induced by the 
endocannabinoids AEA and 2-AG have been described to be CBR-independent.8,28 
Collectively, these findings open new pharmacological strategies regarding (i) the 
possibility of dissociating therapeutic benefits from adverse effects ,106 or (ii) the 
existence of alternative targets that may increase the efficacy for treating a particular 
disorder.6 
In this context, cancer and immune modulation are two areas that have received a 
growing attention as non CB1/2R-mediated effects have been described.
107-113 Hence, the 
development of analytical tools specifically tailored to enable the identification of 
cannabinoid targets would be of great value. 
To achieve this objective, we need to develop chemical probes that besides bearing 
the binding group and the tag, present also an additional element able to “freeze” the 
possible reversible union between the probe and the protein, as we have previously 
described for other GPCRs.114 This additional element is a photocrosslinking group such 
as benzophenone, which after ultraviolet (UV) irradiation at the appropriate wavelength 
will form a covalent bond with the probe-target proteins (Figure 14). 
Results and discussion 
 
57 
 
Figure 14. Probe for the isolation and identification of cannabinoid targets. 
Thus, after incubation of the probes in the proteome of interest, UV irradiation and 
enrichment with streptavidin beads, the captured proteins will be digested with trypsin, 
and the resulting peptides analyzed by multidimensional liquid chromatography 
altogether with mass espectrometry (LC-MS) detection (Figure 15). 
 
Figure 15. Proteomic platform scheme. 
Therefore, design of the new probes was addressed by direct incorporation of a tag 
bearing the biotin subunit and the benzophenone group into the HU210 scaffold. We 
also considered the structure of HU308, which is one of the most selective ligands for 
the CB2 receptor [Ki (CB1)>10 μM; Ki (CB2)=22.7 nM],
115 to study the differences between 
the two compounds. 
Hence, we designed probes 39-41 in which we have incorporated the tag in the 
allylic alcohol of HU210 and HU308 through an ester in compound 39 or an amide linker 
in derivatives 40 and 41 (Figure 16).  
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Figure 16. Structure of probes 39-41. 
The preparation of compounds 39-41 was achieved by condensation of the HU210 or 
HU308 scaffolds conveniently functionalized with the carboxylic acid of the tag. Thus, 
HU210 (42) was synthesized from phenol 8, by cleavage of the pivaloyl group with 
lithium aluminium hydride (Scheme 10). 
 
Scheme 10. Reagents and conditions: (a) LiAlH4, THF, 0 ºC to rt, 100%. 
The synthesis of the HU308 amine 43, necessary for the preparation of probe 41, 
started from commercially available (1R,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-2-ene (α-
pinene) (Scheme 11).31,84 Thus, oxidation of α-pinene with selenium dioxide  and tert-
butyl hydroperoxide led to the corresponding aldehyde which, without further 
purification, was reduced with lithium aluminium hydride to obtain 44. Conversion of 
alcohol 44 into 4-hydroxymyrtenyl pivalate [(+)-6] was achieved through the same 
sequence of reactions previously described for its (-)-enantiomer (Scheme 1, p. 42). 
Condensation of alcohol (+)-6 with resorcinol 7 in the presence of p-toluenesulfonic acid 
(p-TSA) gave intermediate 45,116 whose dimethylation reaction followed by subsequent 
cleavage of the pivaloyl ester in intermediate 46 with lithium aluminium hydride led to 
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HU308 (47). Mitsunobu reaction of alcohol 47, followed by deprotection of the resulting 
phthalimide 48, gave the desired amine 43. 
 
Scheme 11. Reagents and conditions: (a) (i) SeO2, t-BuOOH, DCM, rt; (i i) LiAlH4, Et2O, 0 ºC, 54%; 
(b) (CH3)3CCOCl, pyridine, DCM, 0 ºC, 100%; (c) CrO3, 3,5-dimethylpyrazole, DCM, -20 ºC, 40%; (d) 
LiAlH(t-BuO)3, THF, 0 ºC to rt, 63%; (e) 7, p-TSA, DCM, 0 ºC to rt, 82%; (f) CH3I, NaH, DMF, rt, 81%; 
(g) LiAlH4, Et2O, reflux, 45%; (h) phthalimide, PPh3, DEAD, THF, rt, 47%; (i) i) N2H4·H2O, EtOH, 
reflux; i i) HCl/H2O 1:1 reflux to rt, 80%. 
Once the scaffolds were synthesized, we proceeded with the preparation of tag 49 
from 4-benzoyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanine (Scheme 12). Its 
esterification with iodomethane and potassium carbonate yielded methyl ester 50, 
whose 9-fluorenylmethoxycarbonyl (Fmoc) deprotection with piperidine afforded free 
amine 51.117 Then, biotin was introduced in the presence of EDC and HOBt as coupling 
reagents and DMAP as catalyst, leading to methyl ester 52, which was hydrolyzed with 
lithium hydroxide and further treated with mineral acid (HCl) to provide carboxylic acid 
49. 
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Scheme 12. Reagents and conditions: (a) K2CO3, CH3I, DMF, 0 ºC to rt, 91%; (b) piperidine, DCM, 0 
ºC to rt, 88%; (c) biotin, EDC, HOBt, DMAP, DMF, DCM, 77 ºC to rt, 59%; (d) (i) LiOH·H2O, H2O, 
THF, rt; (i i) 1 M HCl, 100%. 
Finally, condensation of alcohol 42 (HU210) or amines 11 and 43 with carboxylic acid 
49 in the presence of EDC and HOBt as coupling reagents, followed by TIPS deprotection 
with TBAF in the case of amide 53, afforded the desired probes 39-41 (Scheme 13). 
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Scheme 13. Reagents and conditions: (a) EDC, HOBt, DMF, DCM, 36 ºC to rt, 31-35%; (b) TBAF, 
THF, 0 ºC, 36%. 
Affinity of compounds 39-41 for CB1 and CB2 receptors was evaluated. As shown in 
Table 3, probe 39 presented high affinity towards both receptors, while amide 40 
displayed a considerable loss of affinity towards CB1R. Notably, probe 41 exhibited high 
Ki value for CB2R, maintaining the selectivity profile of its parent ligand (HU308).   
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Table 3. Binding affini ties  of probes  39-41. 
 
Compound Scaffold Linker 
Receptor affinity
a
 (nM) 
Ki±SEM 
CB1 CB2 
39 HU210 OCO 25.7±0.4 12.1±0.2 
40 HU210 NHCO 268±28 55±17 
41 HU308 NHCO >1000 28±6 
a
The values are the mean±SEM obtained from two to four independent 
experiments performed in triplicate. 
Before carrying out the proteomic experiments, it is necessary to confirm that the 
designed compounds are able to label proteins in a specific way, which is in a 
concentration- and UV-dependent manners. In order to do so, we chose probe 39 
because of its affinity for CBRs, and replaced the biotin subunit by the fluorophore 
lissamine (probe 54, Figure 17A) to enable, after separation by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), the visualization of the labelled proteins 
by fluorescence scanning (Figure 17B). 
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Figure 17. (A) Structure of probe 54. (B) Proteomic platform for the visualization of probe-
labelled proteins by in-gel fluorescence scanning. 
Synthesis of probe 54 started with the preparation of fluorescent tag 55 by 
condensation between commercially available 4-benzoyl-L-phenylalanine and 
rhodamine B sulfonyl chloride in the presence of N,N’-diisopropylethylamine (DIPEA) 
and sodium hydroxide, followed by its condensation with HU210 (42) (Scheme 14). 
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Scheme 14. Reagents and conditions: (a) rhodamine B sulfonyl chloride, DIPEA, NaOH, acetone,  
0 ºC to rt, 22%; (b) EDC, HOBt, DMF, DCM, rt, 20%. 
In order to test the suitability of probe 54 for labelling proteins, membranes of HEK-
293-EBNA cells overexpressing the hCB2R were treated with different concentrations (5-
50 μM) of the probe and subjected to UV irradiation to promote covalent binding 
between the probe and the target proteins. After that, proteins were separated by SDS-
PAGE and the obtained fluorescent bands (corresponding to probe-protein complexes) 
revealed a concentration- and UV- dependent labelling (data not shown), which 
highlighted the ability of HU210-based probes to detect the targets of this cannabinoid 
ligand. 
Hence, and as proof of concept, we carried out proteomic experiments (see Figure 
15) incubating membranes of HEK-293-EBNA cells overexpressing the hCB2R with probe 
39, which presented the best affinity values [Ki (CB1)=25.7 nM; Ki (CB2)=12.1 nM, Table 
3], at 25 M concentration. Samples were then exposed to UV irradiation at 0 ºC for 1 h 
in order to induce covalent binding between the probe and the target proteins. After 
that, the labelled proteome was subjected to streptavidin enrichment and on-bead 
trypsin digestion, and the resulting peptides were analyzed using an Orbitrap. To 
minimize false positives, only those hits identified in two independent runs and absent 
from control experiments, carried out in duplicate with DMSO as vehicle instead of the 
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probe, were considered as significant. Hence, 15 proteins were identified using probe 39 
(Table 4). It is important to note that probe 39 was able to engage the CB2R, thus 
validating the methodology. 
Table 4. Proteins identified with probe 39. 
Accession Symbol Description 
P34972 CNR2 Cannabinoid receptor 2 
P78527 PRKDC DNA-dependent protein kinase catalytic subunit 
P40939 HADHA Trifunctional enzyme subunit alpha, mitochondrial  
P63261 ACTG1 Heat shock 70 kDa protein 1A/1B 
P42704 LRPPRC Leucine-rich PPR motif-containing protein, mitochondrial  
P05023 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 
P53396 ACLY ATP-citrate synthase 
Q08211 DHX9 ATP-dependent RNA helicase A 
P61978 HNRNPK Heterogeneous nuclear ribonucleoprotein K 
P23396 RPS3 40S ribosomal  protein S3 
Q99623 PHB2 Prohibitin-2 
Q12931 TRAP1 Heat shock protein 75 kDa, mitochondrial  
P33778 HIST1H2BB Histone H2B type 1-B 
P05141 SLC25A5 ADP/ATP translocase 2 
Q9NR30 DDX21 Nucleolar RNA helicase 2 
The obtained results were analyzed based on gene ontology (GO) annotations 
(protein class, cellular localization and biological processes) using the protein analysis 
through the evolutionary relationships (PANTHER) classification system, 118,119 which 
includes both experimental data and bioinformatics algorithms. This analysis revealed 
that the proteins targeted by probe 39 belong to a variety of functional classes (Figure 
18A), and participate in different biological processes (Figure 18B). Regarding the 
cellular component, a great enrichment of membrane proteins (13 out of 15, p<0.001) 
was detected, which deserves special attention considering that the platform was 
initially designed for the identification of GPCRs. 
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Figure 18. Analysis of gene ontology (GO) terms. (A) Protein classes identified with probe 39. (B) 
Involvement of identified proteins in specific biological processes. 
Based on these results, and taking into account the reported non CB1/2R-mediated 
effects in immune modulation and cancer,107-113 we are currently using this probe in the 
Jurkat T cell line and the breast cancer cell line MDA-MB-231 in order to identify the 
targets of cannabinoids in these systems. 
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4.4. Identification of the target proteins of the natural product honokiol 
Magnolia plant extracts have been widely used in Asiatic traditional medicine for the 
treatment of different disorders. The different species of the Magnolia family contain 
several biologically active compounds, being the main ones honokiol, magnolol, and 4’-
O-methylhonokiol (Figure 19), with therapeutic implications in neuronal, inflammatory 
and cardiovascular diseases, as well as in different types of cancer.120 
 
Figure 19. Main constituents of the Magnolia family. 
In particular, honokiol is known due to its anxiolytic, analgesic, anti -depressant, anti-
tumorigenic, and neuroprotective properties among others.65,66 Interestingly, all these 
properties are extraordinarily related to those shown by ligands acting at the ECS.6 
Actually, honokiol and its derivatives have been related not only to CB1 and CB2 
receptors, but also to GPR55, and to the PPAR family of receptors. 63,64,121-123  
Among the different indications reported for honokiol and its derivatives, cancer has 
received an increasing attention because of the significant activities shown by these 
compounds in several cancer models of different origins such as lung, breast, ovarian, 
prostate and gastrointestinal cancers.65,124 In particular, this family of natural products 
significantly inhibit the growth of highly aggressive malignancies characterized by a lack 
of specific treatments and, hence, a poor prognosis, such as some types of breast, 
pancreas, or brain tumors.65,125 In order to obtain information about the mechanisms 
affected by these compounds and to develop more potent derivatives, some structure-
activity relationship (SAR) studies have been carried out,64,126,127 indicating that at least 
one hydroxyl group and one allyl chain are needed for activity. All these compounds 
have contributed to elucidate, at least in part, some of the signalling pathways affected 
by these derivatives. However, the actual targets of honokiol and related compounds 
are not known, and their identification could lead to the discovery of new therapeutic 
strategies for highly aggressive type of cancers, an urgent unmet medical need. Hence, 
we have started a project aimed at the study of the targets of honokiol and its 
derivatives in order to shed some light on their mechanisms of action. In particular, we 
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have focused our efforts on the design, synthesis and development of chemical probes 
based on the synthetic derivative 2-O-ethylhonokiol (Figure 20), which is a more potent 
derivative than honokiol in some assays.64 
 
Figure 20. Chemical structure of 2-O-ethylhonokiol . 
4.4.1. Design and synthesis of probes for the study of the targets of honokiol and its 
derivatives 
In order to be able to identify the targets of these compounds, we introduced in the 
honokiol scaffold a photocrosslinking group to form the covalent bond with the target 
proteins, and a biotin subunit to allow their enrichment and identification. Taking into 
account the previous SAR studies, we kept in all the probes one free phenol and at least 
one allyl group. Therefore, we designed probes 56-59 (Figure 21, left panel) where the 
scaffold and the tag are linked by a triazol ring formed through a copper catalyzed 
cycloaddition of honokiol-based azides (60-62, Figure 21, right panel) and the alkyne of 
the tag, or viceversa (honokiol-based alkyne 63 and the azide of the tag, Figure 21, right 
panel). 
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Figure 21. Design of probes 56-59 and the corresponding honokiol -based fragments 60-63. 
In addition, we designed the smaller clickable probes 64 and 65 (Figure 22), where 
we have replaced the benzophenone by the less bulky diazirine group as the 
photocrosslinking moiety. Moreover, we have removed the biotin subunit, and 
introduced instead a terminal alkyne to allow, after incubation with the desired 
proteome, visualization, enrichment and identification of probe-labelled proteins 
through a click chemistry reaction with the proper reporter groups (biotin or 
fluorophore) bearing an azide within their structure. 
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Figure 22. Design of probes 64 and 65. 
The preparation of probes 56-59 required the synthesis of the honokiol-based 
fragments 60-63. Starting with azide 60, the different possibilities of its retrosynthetic 
analyisis are indicated in Figure 23. Thus, the most convergent synthetic route would 
entail the preparation of the bromoderivative of one of the phenyl rings and the boronic 
fragment of the other, which would be attached through a Suzuki coupling in the last 
step of the synthesis (Figure 23A and B). In addition, a linear approach could be also 
possible in order to introduce the al lyl chain after the Suzuki coupling of both phenyl 
rings (Figure 23C). 
 
Figure 23. Retrosynthetic analysis of azide 60. 
Starting with the first possibility (A), the preparation of the boronic acid derivative 
started from commercially available 4-allylanisole (Scheme 15). Its deprotection with 
boron tribromide, followed by Williamson alkylation of phenol 66 with bromoethane 
under MW irradiation provided ethyl ether 67. However, organolithiation of 67 followed 
by treatment with trimethylborate and mineral acid as previously described for 4-
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allylanisole128 was unsuccessful probably due to the higher steric hindrance of the 
ethoxy group with respect to the methoxy substituent. 
 
Scheme 15. Reagents and conditions: (a) BBr3, DCM, -78 ºC to rt, 93%; (b) EtBr, K2CO3, acetone, 
MW, 140 ºC, 98%; (c) (i) s-BuLi, TMEDA, -78 ºC, (i i) B(OMe)3, HCl, -78 ºC to rt. 
To overcome this obstacle, we decided to perform the Suzuki coupling exchangi ng 
the functionality of each partner as depicted in Figure 23B. Hence, bromoderivative 
69127 was synthesized by bromination of phenol 66 with 1,3-dibromo-5,5-
dimethylhydantoin (DBDMH) in the presence of isopropyl magnesium chloride, and 
further O-alkylation of intermediate 68 with bromoethane (Scheme 16). 
 
Scheme 16. Reagents and conditions: (a) DBDMH, i-PrMgCl, Et2O, -78 ºC to rt, 33%; (b) EtBr, 
K2CO3, acetone, MW, 140 ºC, 87%. 
Boronate 77 was prepared from commercially available 4-bromophenol (Scheme 
17). Its Williamson alkylation with allyl bromide, followed by Claisen rearrangement of 
allyl ether 70 under MW irradiation, and further protection of the resulting phenol 71 
with TBS, provided silyl ether 72 in excellent yields. Then, hydroboration-oxidation of 72 
afforded alcohol 73, which was transformed into azide 75 through the nucleophilic 
substitution of the corresponding mesylate 74 with sodium azide. Finally, cleavage of 
the TBS group, followed by Suzuki coupling of 76 with bis(pinacolato)diboron in the 
presence of palladium led to the desired boronate 77. 
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Scheme 17. Reagents and conditions: (a) allyl bromide, K2CO3, acetone, MW, 140 ºC, 97%; (b) 1,2-
dichlorobenzene, MW, 250 ºC, 73%; (c) TBS-Cl, imidazole, DMF, MW, 100 ºC, 97%; (d) BH3, H2O2, 
THF, 0 ºC to rt, 77%; (e) MsCl, Et3N, DCM, -20 ºC to rt, 100%; (f) NaN3, DMF, 90 ºC, 93%; (g) TBAF, 
THF, 0 ºC, 93%; (h) B2pin2, Pd(dppf)Cl2, KOAc, 1,4-dioxane, 80 ºC, 78%. 
The Suzuki coupling of bromoderivative 69 and boronate 77 was carried out in the 
presence of Pd2dba3, 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl (S-PHOS) and 
potassium fluoride (Scheme 18). These conditions were selected since Denton et al.128 
had previously described the use of these coupling reagents in the presence of aryl 
halides bearing allyl substituents without observing the isomerization of the allyl chain. 
However, in our hands the coupling took place with the undesired isomerization and we 
obtained an inseparable mixture of the expected coupling product together with the 
conjugated alkene. 
 
Scheme 18. Reagents and conditions: (a) Pd2dba3, S-PHOS, KF, 1,4-dioxane, H2O, 110 ºC. 
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This result prompted us to follow the linear synthetic route showed in Figure 23C 
where the Suzuki coupling between both phenyl rings would take place before the 
introduction of the allyl chain in order to avoid its isomerization. This route could start 
with the coupling between 2-bromo-4-chloro-1-ethoxybenzene and 4-
hydroxyphenylboronic acid, followed by alkylation of the free phenol with allyl bromide, 
Claisen rearrangement, hydroboration-oxidation of the double bond, introduction of the 
allyl group through the chloro substituent, and transformation of the corresponding 
alcohol into the desired azide 60 (Figure 24).  
 
Figure 24. Linear retrosynthetic analysis of azide 60. 
Accordingly, 2-bromo-4-chlorophenol was alkylated with bromoethane to provide 2-
bromo-4-chloro-1-ethoxybenzene (78) (Scheme 19). MW-assisted Suzuki coupling of 78 
with 4-hydroxyphenylboronic acid led to phenol 79, whose O-allylation followed by 
Claisen rearrangement of intermediate 80 at low temperature afforded phenol 81. Then, 
hydroboration-oxidation of 81 gave alcohol 82. The introduction of the allyl chain 
through the chlorine substituent of 82 was approached as a Stille coupling using 
allyltributylstannane in the presence of a palladium source. However, all the assayed 
conditions provided the desired product 83 with a conversion lower than 60% and 
always impurified with the starting material 82 (Table 5). Unfortunately, both 
compounds presented the same retention factor (Rf) and therefore, they could not be 
separated by column chromatography. 
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Scheme 19. Reagents and conditions: (a) EtBr, K2CO3, acetone, MW, 140 ºC, 96%; (b) 4-
hydroxyphenylboronic acid, Pd(PPh3)4, Na2CO3, toluene, EtOH, MW, 110 ºC, 92%; (c) allyl 
bromide, K2CO3, acetone, MW, 140 ºC, 98%; (d) AlMe3, H2O, DCM, -20 ºC, 90%; (e) BH3, H2O2, THF, 
0 ºC to rt, 84%; (f) allylSnBu3, catalyst system, base, 1,4-dioxane, MW (Table 5). 
Table 5. Experimental conditions for the synthesis of 83. 
AllylSnBu3 
(equiv) 
Catalyst system (equiv) Base (equiv) T (ºC), t Conversion
a
 (%) 
1.1 Pd2dba3/P(t-Bu)3 (0.06:0.24) CsCO3 (2.2) 180, 10’ 0 
1.1 Pd[P(t-Bu)3]2 (0.03) CsF (2.5) 180, 10’ 17 
1.1 Pd[P(t-Bu)3]2 (0.03) CsF (4) 180, 30’ 36 
1.1 Pd[P(t-Bu)3]2 (0.05) CsF (4) 200, 1 h 56 
1.5 Pd[P(t-Bu)3]2 (0.05) CsF (4) 200, 1.5 h 56 
1.5 Pd[P(t-Bu)3]2 (0.05) CsF (4) 110, 48 h
b
 32 
a
Determined by 
1
H-NMR of the reaction crude. 
b
Carried out under reflux instead of under MW irradiation. 
Therefore, we envisioned the synthesis of 83 as a MW-assisted Suzuki coupling 
between allyl bromide and the corresponding pinacol borane ester of the biphenyl 
scaffold in the presence of potassium carbonate and Pd2dba3 as catalyst. To this end, 
and taking into account that we are using potassium carbonate and allyl bromide in the 
presence of a free phenol at high temperature, we optimized the conditions in order to 
avoid the O-alkylation side reaction, using commercially available 4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenol (Table 6). 
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Table 6. Optimization of the Suzuki coupling. 
 
Pd2dba3 (equiv) Allyl bromide (equiv) Ratio
a
 A:B:C 
0.1 2.5 1:0.26:0.26 
0.1 1.2 1:0.18:0.51 
0.2 1.2 1:0.12:0.20 
a
Determined by 
1
H-NMR of the reaction crude. 
As shown in Table 6, the best results were obtained with 0.2 equiv of catalyst and 
1.2 equiv of allyl bromide, since the O-alkylation byproducts B and C were obtained in 
low proportion. Therefore, we decided to use these conditions for the synthesis of 83. 
Thus, chloroderivative 82 was transformed into boronate 84 in the presence of 
bis(pinacolato)diboron, Pd2dba3, and S-PHOS under MW irradiation (Scheme 20). Suzuki 
coupling of boronate 84 with allyl bromide under the selected conditions provided pure 
83 in 60% yield. Finally, transformation of alcohol 83 into mesylate 85 followed by 
nucleophilic substitution with sodium azide, provided the desired honokiol -based azide 
60. 
 
Scheme 20. Reagents and conditions: (a) B2pin2, Pd2dba3, S-PHOS, KOAc, 1,4-dioxane, MW, 140 
ºC, 89%; (b) allyl bromide, Pd2dba3, K2CO3, toluene, MW, 150 ºC, 60%; (c) MsCl, pyridine, DCM,      
-20 ºC to rt, 42%; (d) NaN3, DMF, 60 ºC, 70%. 
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Following a similar approach (Scheme 21), transformation of chloroderivative 79 into 
the corresponding boronate 86, and further Suzuki coupling of 86 with allyl bromide 
followed by hydroboration-oxidation of the resulting phenol 87, provided alcohol 88. O-
allylation of phenol 88 and Claisen rearrangement of the obtained allyl ether 89 
afforded alcohol 90, which was transformed into the desired azide 61 through the 
corresponding mesylate 91 (Scheme 21). 
 
Scheme 21. Reagents and conditions: (a) B2pin2, Pd2dba3, S-PHOS, KOAc, 1,4-dioxane, MW, 140 
ºC, 75%; (b) allyl bromide, Pd2dba3, K2CO3, toluene, MW, 150 ºC, 75%; (c) BH3, H2O2, THF, 0 ºC to 
rt, 53%; (d) allyl bromide, K2CO3, acetone, MW, 140 ºC, 92%; (e) Et2AlCl, DCM, -20 ºC to 0 ºC, 97%; 
(f) MsCl, pyridine, DCM, -20 ºC to rt, 77%; (g) NaN3, DMF, 60 ºC, 67%. 
Azide 62 was obtained by etherification of 2-bromo-4-chlorophenol with 3-
bromopropan-1-ol, followed by subsequent Suzuki couplings,  O-allylation, Claisen 
rearrangement and activation of the primary alcohol through the corre sponding 
mesylate (Scheme 22). 
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Scheme 22. Reagents and conditions: (a) 3-bromopropan-1-ol, K2CO3, acetone, MW, 140 ºC, 85%; 
(b) 4-hydroxyphenylboronic acid, Pd(PPh3)4, Na2CO3, toluene, EtOH, MW, 110 ºC, 82%; (c) B2pin2, 
Pd2dba3, S-PHOS, KOAc, 1,4-dioxane, MW, 140 ºC, 78%; (d) allyl bromide, Pd2dba3, K2CO3, 
toluene, MW, 150 ºC, 47%; (e) Et2AlCl, DCM, -20 ºC to 0 ºC, 70%; (f) MsCl, pyridine, DCM, -20 ºC to 
rt, 53%; (g) NaN3, DMF, 60 ºC, 77%. 
Finally, synthesis of alkyne 63 was performed as depicted in Scheme 23. Williamson 
alkylation of 3-bromo-4-hydroxybenzaldehyde with bromoethane, followed by Suzuki 
coupling of bromoderivative 98 with 4-hydroxyphenylboronic acid yielded biphenyl 
derivative 99. O-Allylation of phenol 99, followed by treatment of the resulting aldehyde 
100 with ethynylmagnesium bromide, and subsequent reduction of the propargylic 
alcohol 101 provided allyl ether 102, whose Claisen rearrangement led to the desired 
alkyne 63. 
 
Scheme 23. Reagents and conditions: (a) EtBr, K2CO3, acetone, MW, 140 ºC, 89%; (b) 4-
hydroxyphenylboronic acid, Pd(PPh3)4, Na2CO3, toluene, EtOH, MW, 110 ºC, 68%; (c) K2CO3, allyl 
bromide, acetone, MW, 140 ºC, 96%; (d) ethynylmagnesium bromide, THF, 0 ºC to rt, 97%; (e) 
TES, TFA, DCM, 0 ºC, 33%; (f) Et2AlCl, DCM, -20 ºC to 0 ºC, 51%. 
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Once honokiol-based fragments 60-63 were prepared, we addressed the synthesis of 
the corresponding tags 105 and 106 by condensation of 4,4'-diaminobenzophenone with 
biotin using DCC and HOBt in the presence of DMAP, and further coupling of the 
resulting aniline 103 either with 5-hexynoic acid or 6-azidohexanoic acid (104)129 in the 
presence of EDC and HOBt (Scheme 24). Acid 104 was prepared as previously 
described129 by nucleophilic substitution of 6-bromohexanoic acid with sodium azide. 
 
Scheme 24. Reagents and conditions: (a) biotin, DCC, HOBt, DMAP, DCM, DMF, 77 ºC to rt, 97%; 
(b) EDC, HOBt, DCM, DMF, rt, 14-36%; (c) NaN3, DMF, 50 ºC, 76%. 
Honokiol derivatives 60-63 and tags 105 and 106 were then assembled via copper-
catalyzed cycloadditions as outlined in Scheme 25. 
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Scheme 25. Reagents and conditions: (a) 105 or 106, CuSO4·5H2O, sodium ascorbate, DMF, H2O, 
rt, 25-64%. 
With respect to probes 64 and 65, their preparation required the synthesis of the 
corresponding carboxylic acid 110 by oxidation of 4-pentyn-1-ol to aldehyde 107, 
followed by treatment with ethyl acrylate, further hydrolysis of the resulting ester 108, 
and final transformation of ketone 109 into the diazirine 110 (Scheme 26). 
 
Scheme 26. Reagents and conditions: (a) (i) (COCl)2, DMSO, DCM, -78 ºC, (i i) Et3N, DCM, -78 ºC to 
rt, 85%; (b) ethyl acrylate, 3-benzyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazolium chloride, Et3N, 
1,4-dioxane, 80 ºC, 28%; (c) LiOH, MeOH, rt, 95%; (d) (i) NH3, MeOH, 0 ºC, (i i) NH2NHSO3H, MeOH, 
0 ºC to rt, (i i i) I2, DIPEA, MeOH, 0 ºC, 28%. 
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Finally, the Staudinger reaction of azides 60 and 61 using triphenylphosphine in the 
presence of water, followed by condensation of the obtained amines 111 and 112 with 
carboxylic acid 110 yielded the desired probes 64 and 65 (Scheme 27). 
 
Scheme 27. Reagents and conditions: (a) PPh3, THF, H2O, reflux, 49-76%; (b) 110, EDC, HOBt, 
DIPEA, DCM, rt, 45-62%. 
For comparative purposes in the biological experiments, we also synthesized 2-O-
ethylhonokiol (Scheme 28). 
 
Scheme 28. Reagents and conditions: (a) allyl bromide, K2CO3, acetone, MW, 140 ºC, 92%; (b) 
Et2AlCl, DCM, -20 ºC to 0 ºC, 97%. 
4.4.2. Phenotypic screening of honokiol-based probes 
In order to identify the targets of honokiol and its derivatives, responsible for their 
antitumor effects, we first determined whether the synthesized probes kept the ir 
biological activity. Among the different malignancies in which honokiol and related 
compounds have been shown to be antitumorigenic,65,124 we focused our efforts on the 
study of their targets in breast and ovarian cancer cell lines since these types of cancer 
still show dramatically high incidence and mortality rates.130,131 
Ovarian cancer represents the leading mortality malignancy within gynaecological 
cancers.132 Regarding breast cancer, among the different subtypes of malignancies 
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based on the expression of estrogen, progesterone, and human epidermal growth factor 
2 receptors (ER, PR and HER2, respectively), triple-negative breast cancer (TNBC) -
characterized by the absence of the three receptors-133 deserves special attention. 
Although TNBC accounts for a low percentage of all breast tumors, it represents a 
disproportionate number of deaths.134 For this reason, this group of patients has a very 
poor prognosis,135,136 and therefore the discovery of new targets and drugs for the 
treatment of this disease is an urgent clinical challenge. Hence, the highly aggressive 
TNBC cell line MDA-MB-231, together with two ovarian cancer cell lines with different 
invasive potentials, SKOV3 and OVCAR3 (the former one being significantly more 
invasive than the latter one),137 were chosen to evaluate the ability of honokiol, 2-O-
ethylhonokiol and probes 56-59, 64, and 65 to inhibit cell proliferation (Table 7). 
Table 7. Citotoxicity of honokiol, 2-O-ethylhonokiol, and honokiol-
based probes 56-59, 64, and 65 in MDA-MB-231, SKOV3 and 
OVCAR3 cancer cells. 
Compound 
Cell viability (%)
a
 
MDA-MB-231 SKOV3 OVCAR3 
Honokiol  49±3 67±10 74±4 
2-O-Ethylhonokiol 12±4 41±14 25±5 
56 87±11 95±5 90±8 
57 96±3 84±11 83±21 
58 92±7 79±13 63±2 
59 86±19 56±15 72±9 
64 7±2 38±15 53±5 
65 6±1 26±8 13±3 
a
Cell viability was determined at 50 M and it is expressed as the 
average±SEM obtained from two to four independent experiments 
carried out in triplicate. 
The obtained results (Table 7) showed that the introduction of the biotin and 
benzophenone-containing tags (probes 56-59) significantly reduced their activity when 
compared with honokiol and 2-O-ethylhonokiol. However, the diazirine-containing 
probes 64 and 65 showed good cytotoxicity values, specially in the case of MDA-MB-231 
cells, and hence were selected for further experiments. 
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4.4.3. In gel validation of probes 64 and 65 
Before carrying out proteomic experiments, we confirmed that probes 64 and 65 
were able to label proteins in a specific way, i.e., in a concentration- and UV-dependent 
manners. In addition, if, as expected, some of the targets are the same as those of  
honokiol and 2-O-ethylhonokiol, their labelling must be competed by an excess of these 
compounds. In order to assess all these aspects, we took advantage of the presence of 
the terminal alkyne group in probes 64 and 65 to introduce, after cell labelling, a 
fluorophore suitable for in-gel fluorescence scanning (Figure 25A). Briefly, cells were 
treated with the probes and subjected to UV irradiation to promote covalent binding 
between the probe and the target proteins. After that, cells were homogenized, the 
soluble and membrane proteomes separated by centrifugation, and each of these two 
fractions was reacted with rhodamine-azide (Rh-N3, Figure 25B) under click chemistry 
conditions.138 Finally, proteins were separated by SDS-PAGE and fluorescent bands 
(corresponding to probe-protein complexes) visualized in a fluorescence scanner. 
 
Figure 25. (A) Proteomic platform for the visualization of probe-labelled proteins by in-gel 
fluorescence scanning after click chemistry with rhodamine azide (RhN3, B). 
Thus, we first evaluated the UV- and concentration-dependent labelling of probes 64 
and 65 (0.2-20 μM) in MDA-MB-231 cells. The results shown in Figure 26 confirm that 
the labelling is concentration-dependent for both probes 64 and 65 as the intensity of 
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the bands clearly increases with their concentration, ranging from almost no bands for 
concentrations under 1 μM to intense bands at 10 μM, which seems to reach saturation 
as as no significant increase is perceived at 20 μM. In addition, we observed that the 
labelling was UV-dependent since in the absence of irradiation only some non-specific 
fluorescence was detected (see UV negative lanes in Figure 26). 
 
Figure 26. Concentration- and UV-dependent labelling of MDA-MB-231 breast cancer cells by 
probes 64 and 65. Numbers in the left side indicate the molecular weights (in kDa) of proteins. 
Fluorescence is  shown in grey scale. All  lanes contained 20 g of total protein and equal loading 
was confirmed by coomassie bril l iant blue staining (see Figure S1 in the Supplementary 
Information). 
Then, we performed competition experiments in the presence of an excess of 
honokiol and 2-O-ethylhonokiol (H and EH, respectively, in Figure 27) to ensure that at 
least some of the labelled proteins were targets of these compounds. Remarkably, some 
of the bands disappeared in the presence of an excess of honokiol and 2-O-
ethylhonokiol both in membrane and soluble fractions (see some examples marked with 
an orange arrowhead in Figure 27). This result indicates that probes 64 and 65 are 
indeed labelling some of the targets of the honokiol family in MDA-MB-231 cells. 
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Figure 27. Competition of probes 64 (A, C) and 65 (B, D) at 10 M by honokiol (H) or 2-O-
ethylhonokiol (EH) at 100 M in membrane (A, B) and soluble (C, D) proteomes, respectively, in 
MDA-MB-231 breast cancer cells. Numbers in the left side indicate the molecular weights (in kDa) 
of proteins. Fluorescence is shown in grey scale. Arrowheads show some representative 
competed proteins. All  lanes contained 20 g of total protein and equal loading was confirmed by 
coomassie bril l iant blue staining (see Figure S2 in the Supplementary Information). 
Next we wanted to evaluate the potential of the probes to differenciate between 
SKOV3 and OVCAR3 ovarian cancer cell lines, which have the same origin but different 
invasive capacity. After confirming that the labelling in these cells was concentration- 
and UV- dependent, and that this labelling could be competed by honokiol and 2-O-
ethylhonokiol (data not shown), we used probe 65 to establish the labelling pattern in 
both cell lines (Figure 28). Probe 65 was selected because of its superior ability to label 
proteins compared to probe 64, specially in the soluble proteome (Figure 27). 
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Figure 28. Labelling pattern of probe 65 in the ovarian cancer cell  l ines SKOV3 and OVCAR3. 
Competition of probe 65 at 10 M by honokiol (H) or 2-O-ethylhonokiol (EH) at 100 M in 
membrane (A) and soluble (B) proteomes. Numbers in the left side indicate the molecular 
weights (in kDa) of proteins. Fluorescence is shown in grey scale. Arrowheads show some 
representative bands. All  lanes contained 20 g of total protein and equal loading was confirmed 
by coomassie bril l iant blue staining (see Figure S3 in the Supplementary Information). 
The obtained labelling reveals two important findings. Firstly, both honokiol and 2-
O-ethylhonokiol target specific proteins in these cell lines. These targets are those 
labelled by probe 65 which disappear in the presence of an excess of honokiol and/or 2-
O-ethylhonokiol. Some examples are marked with an orange arrowhead around 35 and 
75 kDa in the membrane fraction of the proteome (Figure 28A), or around 30 and 50 kDa 
in the soluble one (Figure 28B). Secondly, there are differences in the obtained profiling 
between the two cell lines (Figure 28, green arrowheads). For example, in the 
membrane fraction of the proteome we can observe a clear band around 50 kDa that 
shows differences in terms of expression, being almost imperceptible in the SKOV3 cell 
line, while showing an intense fluorescence in the OVCAR3 cells, and which is highly 
competed by 2-O-ethylhonokiol (Figure 28A). Conversely, we observe a band around 37 
kDa that is only labelled in the SKOV3 cells but not in the OVCAR3 ones, and that is 
highly competed by both honokiol and 2-O-ethylhonokiol (Figure 28A). As for the soluble 
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proteome, we observe two bands around 37 kDa, one of them only expressed in the 
SKOV3 cell line, and the other one in the less aggressive partner (OVCAR3), both of them 
being competed by honokiol and 2-O-ethylhonokiol (Figure 28B).  
In summary, the in situ profiling in MDA-MB-231 (Figures 25 and 26) and ovarian 
(Figure 28) cancer cell lines confirms the suitability of probes 64 and 65 for identifying 
the targets of honokiol and 2-O-ethylhonokiol in these systems. 
4.4.4. Proteomic profiling of probe 65 
Proteins targeted by probe 65 were enriched and identified using stable isotope 
labelling by amino acids in cell culture (SILAC) quantitative MS.139,140 In SILAC 
experiments, two groups of cells are grown in parallel using the same culture media but 
with at least one essential amino acid isotopically labelled in one of the groups (termed 
heavy), while the same amino acid is the light version in the other group. Since cells are 
not able to synthesize essential amino acids, they are forced to use only the externally 
supplied one, eventually incorporating 100% of the given ‘‘light’’ or ‘‘heavy’’ amino acid 
in all the proteins. Finally, after lysing the “heavy” and “light” cells, they can be 
combined and the mixture can be treated as a single sample in all subsequent steps. 
Hence, once the final sample has been trypsinized, SILAC peptide pairs have the same 
retention time, but different mass, thus enabling the measurement of the ratio between 
both peptides, referred to as SILAC ratio, providing an accurate method for 
quantification of the labelled proteins.  
In particular, in these experiments cells are grown in the presence of either the 
heavy version of Lys (13C6, 
15N) and Arg (13C6, 
15N4) or their light versions (
12C6, 
14N-Lys; 
12C6, 
14N4-Arg). Hence, the same peptide will differentiate in 7 mass units if it possesses 
only one Lys residue or in 10 mass units if it possesses only one Arg residue. 
Hence, MDA-MB-231 cells were cultured for at least six cell doublings to ensure 
complete incorporation of the light or heavy version of the amino acids in all the 
proteins. Then, “heavy” cells were incubated with 10 μM of probe 65, and “light” cells 
with 10 μM of probe 65 plus 100 μM of honokiol. Both samples were UV-irradiated, 
homogenized and mixed in a 1:1 ratio (Figure 29A). After that, the sample was coupled 
to a biotin-azide reporter tag (biotin-N3, Figure 29B) under click chemistry conditions,141 
and probe-protein complexes were captured by incubation with streptavidin beads. 
Results and discussion 
 
87 
After digestion with trypsin, the obtained peptides were separated by LC and identified 
by MS. The resulting SILAC ratios were normalized in a 1-20 scale, where a ratio of 1 
indicates no difference between the light and heavy labelled samples, and therefore no 
competition by honokiol, and 20 is the maximal difference. 
 
Figure 29. (A) Scheme of the proteomic platform for the preparation of SILAC samples. (B) 
Structure of the biotin-azide reporter tag. 
Figure 30A shows the heavy:light SILAC ratio plot for all the identified proteins using 
probe 65. Proteins that exhibited SILAC ratios ≥3 were designated as preferred targets of 
honokiol (Figure 30B). Therefore, the use of probe 65 enabled the identification of about 
40 proteins that were significantly competed by honokiol (Table 8), highlighting the 
suitability of probe 65 for the study of the targets of this compound in cancer cells. 
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Figure 30. (A) SILAC ratio plots for total proteins or (B) proteins with a SILAC ratio≥3, identified 
comparing cells treated with probe 65 at 10 μM versus probe 65 at 10 μM plus honokiol at 100 
μM. 
Among the identified proteins showed in Table 8, some of them deserve particular 
attention since they are involved in mechanisms related to the viability of cancer cells 
such as apoptosis, cell proliferation or cell growth. For example, LYRIC protein (pdb 
number Q86UE4)142 activates the nuclear factor kappa B (NF-B), transcription factor 
which interestingly has been previously related to honokiol. 65 
Although in-depth validation of these hits is ongoing in our laboratory, the results 
reported herein provide, for the first time, direct insights into the mechanism of action 
of the natural product honokiol and its derivatives, aiding to the identification of new 
targets for addressing currently unmet medical needs. 
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Table 8. Proteins with SILAC ratio≥3 
 
SILAC ratio Identifier Description
20 P52209 PGD 6-phosphogluconate dehydrogenase, decarboxylating 
20 Q86UE4 MTDH Protein LYRIC 
20 P53396 ACLY ATP-citrate synthase 
11.1 P07384 CAPN1 Calpain-1 catalytic subunit 
6.95 Q9BWD1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic 
6.69 P43490 NAMPT Nicotinamide phosphoribosyltransferase 
5.02 P29401 TKT Transketolase 
4.9 P07339 CTSD Cathepsin D 
4.78 P40926 MDH2 Malate dehydrogenase, mitochondrial 
4.53 P00367 GLUD1 Glutamate dehydrogenase 1, mitochondrial 
4.41 P04181 OAT Ornithine aminotransferase, mitochondrial 
4.25 P36776 LONP1 Lon protease homolog, mitochondrial 
4.24 P46821 MAP1B Microtubule-associated protein 1B 
4.14 P07195 LDHB L-lactate dehydrogenase B chain 
4.1 P39687 ANP32A Acidic leucine-rich nuclear phosphoprotein 32 family member A
3.98 P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial 
3.97 P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 
3.92 P11498 PC Pyruvate carboxylase, mitochondrial 
3.84 P10809 HSPD1 60 kDa heat shock protein, mitochondrial 
3.72 P49327 FASN Fatty acid synthase 
3.7 P14618 PKM Pyruvate kinase isozymes M1/M2 
3.56 P26038 MSN Moesin 
3.47 P23526 AHCY Adenosylhomocysteinase 
3.44 P07900 HSP90AA1 Heat shock protein HSP 90-alpha 
3.42 Q01105 SET Protein SET 
3.37 Q9NY33 DPP3 Dipeptidyl peptidase 3 
3.37 P31948 STIP1 Stress-induced-phosphoprotein 1 
3.36 P06733 ENO1 Alpha-enolase 
3.34 P06737 PYGL Glycogen phosphorylase, liver form 
3.25 P08670 VIM Vimentin 
3.24 P47897 QARS Glutamine--tRNA ligase 
3.24 P60174 TPI1 Triosephosphate isomerase 
3.23 P07737 PFN1 Profilin-1 
3.23 Q86VP6 CAND1 Cullin-associated NEDD8-dissociated protein 1 
3.22 P15311 EZR Ezrin 
3.2 O00299 CLIC1 Chloride intracellular channel protein 1 
3.16 P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 
3.15 P22392 NME2 Nucleoside diphosphate kinase B 
3.12 O43707 ACTN4 Alpha-actinin-4 
3.09 P08238 HSP90AB1 Heat shock protein HSP 90-beta 
3.08 P62258 YWHAE 14-3-3 protein epsilon 
3.04 Q96TA1 FAM129B Niban-like protein 1 
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5. CONCLUSIONS 
In the present work we have focused our efforts on the development of chemical 
probes aimed at the study of the ECS. In particular, we were interested in: i) the 
detection of CBRs in the immune system, ii) studying the functions of the mtCB1R, iii) the 
discovery of the off-targets of the cannabinoid agonists HU210 and HU308, and iv) the 
identification of the targets of the natural product honokiol .  
With respect to the first goal, biotinylated probe 1 with high affinity toward both 
CBRs enabled the visualization of the CB1R in several cell subsets of immune cells, thus 
proving the high levels of expression of this receptor in patients with different types of 
allergic diseases. 
 
In addition, the fluorescent CB1R-selective probe 22 has been successfully used to 
detect and semi-quantify the levels of expression of CB1R in PBMCs, standing out as a 
valuable tool to study possible modifications in such levels in clinically relevant systems, 
and to establish its potential as a biomarker. 
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Concerning the study of the mtCB1R, polar synthesized compounds 26-28, with high 
affinity values for the CB1R (Ki=4-12.1 nM), represent promising tools to differenciate 
between the effects mediated by the plasma membrane CB1R and the mtCB1R. 
 
Regarding HU210-based probe 39, featuring a benzophenone group and a biotin 
subunit, it displayed high affinity values for CBRs [Ki (CB1)=25.7±0.4 nM; Ki 
(CB2)=12.1±0.2 nM], and was therefore selected to carry out proteomic experiments. 
The use of 39 enabled the identification of 15 proteins of different functional classes, 
which participate in diverse biological processes. Among them, the identification of the 
CB2R deserves special attention since it supports the solidness of the platform and 
therefore, validates the methodology. 
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Finally, we have developed a series of chemical probes for the identification of the 
targets of honokiol and its derivatives. Among the synthesized compounds, derivative 65 
was used in quantitative SILAC MS experiments to enable the identification of some of 
the direct targets of honokiol in MDA-MB-231 cells, such as the cancer related protein 
LYRIC, providing for the first time direct insights into the mechanism of action of this 
natural product, and aiding to the identification of new targets for addressing currently 
unmet medical needs. 
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6. EXPERIMENTAL SECTION 
6.1. Synthesis 
Unless otherwise stated, the starting materials, reagents, and solvents were 
purchased as high-grade commercial products from Sigma-Aldrich, Acros, ABCR, 
Fluorochem, Bachem, Scharlab, or Panreac. Dry dichloromethane (DCM), 
tetrahydrofuran (THF), and Et2O were obtained by passing the previously degassed 
solvents through activated alumina columns using a Pure Solv™ Micro 100 Liter solvent 
purification system. Acetone was dried under K2CO3. Triethylamine and pyridine were 
dried over KOH and distilled before using. Reactions under MW irradiation were 
performed in a Biotage Initiator 2.5 reactor. 
Analytical thin-layer chromatography (TLC) was run on Merck silica gel plates 
(Kieselgel 60 F-254), with detection by UV light (=254 nm), ninhydrin solution, 10% 
phosphomolybdic acid solution in ethanol, or KMnO4 (aqueous, aq). Unless otherwise 
stated, products were purified by flash chromatography using a VARIAN 971-FP system 
with cartridges of silica gel (Varian, particle size 50 µm). Alternatively, purification on 
glass column with silica gel type 60 (particle size 230-400 mesh from Merck) was 
performed in some indicated cases. For all compounds containing an allyl chain attached 
to a phenyl ring, silica gel was previously neutralized with triethylamine. 
All compounds were obtained as oils, except for those whose melting points (mp) 
are indicated, which were solids. Mp (uncorrected) were determined on a Stuart 
Scientific electrothermal apparatus. Optical rotation [was measured on a Perkin 
Elmer 241 polarimeter or an Anton Paar MCP 100 modular circular polarimeter using a 
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sodium lamp (=589 nm) with a 1 dm path length; concentrations (c) are given as g/100 
mL. Infrared (IR) spectra were measured on a Bruker Tensor 27 instrument equipped 
with a Specac ATR accessory of 5200-650 cm-1 transmission range; frequencies () are 
expressed in cm-1. Nuclear magnetic resonance (NMR) spectra were recorded on a 
Bruker Avance III 700 MHz (1H, 700 MHz; 13C, 175 MHz), Bruker Avance 500 MHz (1H, 500 
MHz; 13C, 125 MHz) or Bruker DPX 300 MHz (1H, 300 MHz; 13C, 75 MHz) instrument at 
room temperature (rt) at the Universidad Complutense de Madrid (UCM) NMR core 
facility, being the last one the routine equipment, always used unless otherwise  stated. 
Chemical shifts () are expressed in parts per million relative to internal 
tetramethylsilane; coupling constants (J) are in hertz (Hz). The following abbreviations 
are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), 
q (quartet), qt (quintet), sept (septet), m (multiplet), app (apparent), and br (broad). 2D 
NMR experiments -homonuclear correlation spectroscopy (H,H-COSY), heteronuclear 
multiple quantum correlation (HMQC) and heteronuclear multiple bond correlation 
(HMBC)- of representative compounds were acquired to assign protons and carbons of 
new structures. High resolution mass spectrometry (HRMS) spectra were recorded on a 
FTMS Bruker APEX Q IV spectrometer in electrospray ionization (ESI) or matrix-assisted 
laser desorption ionization (MALDI) mode at UCM mass spectrometry core facility. 
For all final compounds, purity was determined by high-performance liquid 
chromatography coupled to mass spectrometry (HPLC-MS) using an Agilent 1200LC-MSD 
VL instrument, and satisfactory chromatograms confirmed a purity of at least 95% for all 
tested compounds. LC separation was achieved with a Zorbax SB-C3 column (5 μm, 2.1 
mm x 50 mm), together with a guard column (5 μm, 4.6 mm x 12.5 mm). The gradient 
mobile phase consisted of A (95:5 water/acetonitrile) and B (5:95 water/acetonitrile) 
with 0.1% ammonium hydroxide and 0.1% formic acid as solvent modifiers , and the 
gradients are indicated in Table 9. Spectra were acquired in positive or negative 
ionization mode from 100 to 1000 m/z and in UV-mode at four different wavelengths 
(210, 230, 254, and 280 nm). MS analysis was performed with an ESI source. The 
capillary voltage was set to 3.0 kV and the fragmentor voltage was set at 25 eV. The 
drying gas temperature was 350 ºC, the drying gas flow was 10 L/min, and the nebulizer 
pressure was 20 psi. 
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Table 9. HPLC gradients. 
 Method A  Method B  
 t (min) % B  t (min) % B  
 0 0  0 0  
 2 0  2 0  
 8 80  8 60  
 12 100  20 100  
 25 100  25 100  
 30 0  30 0  
IUPAC rules have been followed for naming all organic compounds, except for the 
radicals {5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl}, 
prop-2-en-1-yl and prop-2-yn-1-yl, whose common names biotinyl, allyl, and propargyl, 
respectively, have been employed for simplicity. 
6.1.1. General procedures 
6.1.1.1.  Cleavage of silyl ethers 
To a solution of the corresponding silyl-protected phenol (1 equiv) in anhydrous THF 
(50 mL/mmol) at 0 ºC and under an argon atmosphere, a 1 M solution of TBAF (1.3 
equiv) in anhydrous THF was added, and the mixture was stirred at this temperature for 
3 h. EtOAc and water were added, and the organic layer was separated, washed with 
brine, dried (Na2SO4), filtered, and evaporated under reduced pressure. The crude was 
purified by chromatography using the appropriate eluent to afford the corresponding 
phenol. 
6.1.1.2.  Williamson alkylation of phenols 
To a solution of the corresponding phenol (1 equiv) in dry acetone (7.5 mL/mmol) 
under an argon atmosphere, K2CO3 (1.2 equiv) was added at rt and the mixture was 
stirred for 10 min. The corresponding bromoalkane (1.2 equiv) was then added and the 
reaction was heated at 140 ºC for 20 min under MW irradiation. Once cooled to rt, water 
was added and the mixture was extracted with EtOAc (2x), washed with brine, dried 
(Na2SO4), filtered, and evaporated under reduced pressure. The crude was purified by 
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chromatography using the appropriate eluent to afford the corresponding aryl alkyl 
ether. 
6.1.1.3.  Suzuki coupling of bromoderivatives and 4-hydroxyphenylboronic acid 
To a solution of the corresponding bromoderivative (1 equiv)  and 4-
hydroxyphenylboronic acid (1.5 equiv) in a mixture of toluene/EtOH 1:1 (12 mL/mmol) a 
solution of 0.5 M Na2CO3 (aq, 3 equiv) was added and the mixture was degassed with 
argon. Then, Pd(PPh3)4 (0.06 equiv) was added and the reaction mixture was heated at 
110 ºC for 15 min under MW irradiation. The organic phase was separated, and the 
aqueous layer was extracted with EtOAc (2x). The combined organic extracts were 
washed with brine, dried (Na2SO4), filtered, and evaporated under reduced pressure. 
The crude was purified by chromatography using the appropriate eluent to afford the 
corresponding biphenyl derivative. 
6.1.1.4.  Hydroboration-oxidation of allyl chains 
To a well-stirred solution of the corresponding allyl derivative (1 equiv) in anhydrous 
THF (2 mL/mmol) at rt, BH3 (2 equiv, 1 M in THF) was added and the mixture was stirred 
for 4 h. Water was added (0.2 mL/mmol) followed by 3 M NaOH (aq, 0.3 mL/mmol). 
Then, 30% H2O2 (aq, 3.3 mL/mmol) was slowly added at 0 ºC and the mixture was stirred 
at rt for 16 h. The reaction was diluted with EtOAc, washed with water and brine, dried 
(Na2SO4), filtered, and evaporated under reduced pressure. The crude was purified by 
chromatography using the appropriate eluent to afford the corresponding primary 
alcohol. 
6.1.1.5.  Transformation of chloroderivatives into boronates 
A suspension of the corresponding chloroderivative (1 equiv) , B2pin2 (1.5 equiv), 
Pd2dba3 (0.05 equiv), S-PHOS (0.2 equiv), and KOAc (3 equiv), in anhydrous 1,4-dioxane 
(2 mL/mmol) was heated under an argon atmosphere at 140 ºC for 45 min under MW 
irradiation. Once at rt, the mixture was filtered through a pad of celite, washed with 
EtOAc and the solvents were evaporated under reduced pressure. The residue was 
purified by chromatography using the appropriate eluent to afford the corresponding 
boronate. 
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6.1.1.6.  Suzuki coupling of boronates with allyl bromide 
A suspension of the corresponding boronate (1 equiv), allyl bromide (1.2 equiv) , 
Pd2dba3 (0.24 equiv), and K2CO3 (6 equiv) in anhydrous toluene (9 mL/mmol of 
boronate) under an argon atmosphere, was heated at 150 ºC for 45 min under MW 
irradiation. The mixture was filtered through a pad of celite, washed with EtOAc, and the 
solvents were evaporated under reduced pressure. The residue was purified by 
chromatography using the appropriate eluent to afford the corresponding allyl arene.  
6.1.1.7.  Activation of primary alcohols as mesylates 
To a well-stirred solution of the corresponding alcohol (1 equiv) in dry DCM (9.5 
mL/mmol) at -20 ºC and under an argon atmosphere, methanesulfonyl chloride (MsCl, 
1.05 equiv) and anhydrous pyridine (4.2 equiv) were added. The reaction mixture was 
allowed to warm to rt and stirred for 16 h. Then, concentrated HCl was carefully added 
and the resulting solution was extracted with EtOAc (2x). The combined organic extracts 
were sequentially washed with saturated CuSO4 (aq) and brine, dried (Na2SO4), filtered, 
and evaporated under reduced pressure. The residue was purified by chromatography 
using the appropriate eluent to afford the corresponding mesylate.  
6.1.1.8.  Nucleophilic substitution of mesylates with NaN3 
To a solution of the corresponding mesylate (1 equiv) in anhydrous DMF (6 
mL/mmol) under an argon atmosphere, NaN3 (2 equiv) was added and the reaction 
mixture was stirred at 60 ºC for 16 h. The resulting solution was diluted with EtOAc, 
washed with water and brine, dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by chromatography using the appropriate eluent to 
afford the corresponding azide. 
6.1.1.9.  Claisen rearrangement 
To a solution of the corresponding allyl phenyl ether (1 equiv) in dry DCM (7 
mL/mmol) at -20 ºC and under an argon armosphere, diethylaluminium chloride (2.5 
equiv, 1 M in hexane) was slowly added and the mixture was allowed to warm to 0 ºC 
and stirred at that temperature for 3 h. The reaction was quenched with 1 M HCl ( aq) at 
0 ºC and the mixture was extracted with EtOAc (2x), washed with brine, dried (Na2SO4), 
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filtered and evaporated under reduced pressure. The residue was purified by 
chromatography using the appropriate eluent to afford the corresponding phenol.  
6.1.2. Synthesis of probes 1, 2, 20, and 22 
 Synthesis of intermediates 11 and 13 
Derivatives 4-6 were obtained following experimental procedures previously 
described by Liddle et al. and their spectroscopic data correspond with those 
reported.143  
(-)-[(1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl pivalate [(-)-4]. To a 
solution of (1R,5S)-myrtenol (5.00 g, 33 mmol) in dry DCM (30 mL) and pyridine (30 mL) 
at 0 ºC and under an argon atmosphere, trimethylacetyl chloride (5.0 mL, 41 mmol) was 
added dropwise and the reaction was stirred at 0 ºC for 2.5 h. Et2O was then added and 
the mixture was washed with 10% HCl (aq, 6x), saturated NaHCO3 (aq), and brine. The 
organic layer was dried (Na2SO4), filtered, and evaporated under reduced pressure to 
yield the title compound (-)-4 (7.12 g, 92%), which was used in the next step without 
further purification. []D
20: -14.0 (c=3.2, EtOH). Rf: 0.25 (hexane/DCM, 7:3). 
 
1H-NMR (CDCl3, ): 0.85 (s, 3H, CH3), 1.20 (s, 9H, C(CH3)3), 1.26-1.29 (m, 4H, ½CH2cyc, 
CH3), 2.10 (dd, J=5.5, 1.2, 2H, 2CH), 2.26-2.29 (m, 2H, CH2CH=), 2.39 (dt, J=8.6, 5.6, 1H, 
½CH2cyc), 4.43 (AB system, J=12.5, 2H, CH2O), 5.50-5.53 (m, 1H, CH=). 
(-)-[(1R,5S)-6,6-Dimethyl-4-oxobicyclo[3.1.1]hept-2-en-2-yl]methyl pivalate [(-)-5]. 
To a suspension of CrO3 (36.20 g, 362 mmol) in dry DCM (270 mL) at -20 ºC, 3,5-
dimethylpyrazole (37.70 g, 362 mmol) was added portionwise. After stirring for 15 min, 
a solution of compound (-)-4 (7.12 g, 30 mmol) in dry DCM (50 mL) was added and the 
mixture was stirred at 0 ºC for 1 h. The organic phase was separated, washed with 10% 
HCl (aq) and brine, dried (Na2SO4), filtered, and evaporated under reduced pressure. The 
residue was purified by chromatography (hexane/EtOAc, 9:1) to afford ketone (-)-5 (3.49 
g, 46%). []D
20: -92.3 (c=2.6, EtOH). Rf: 0.33 (chloroform). 
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1H-NMR (CDCl3, ): 1.02 (s, 3H, CH3), 1.22 (s, 9H, C(CH3)3), 1.51 (s, 3H, CH3), 2.12 (d, 
J=9.3, 1H, ½CH2cyc), 2.43 (td, J=6.6, 1.3, 1H, CH), 2.69 (td, J=6.0, 1.7, 1H, CH), 2.86 (dt, 
J=9.3, 5.5, 1H, ½CH2cyc), 4.70 (AB system, J=16.6, 2H, CH2O), 5.83-5.86 (m, 1H, CH=). 
(-)-[(1R,5S)-4-Hydroxy-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl pivalate   
[(-)-6]. To a solution of ketone (-)-5 (3.49 g, 14 mmol) in anhydrous THF (14 mL) at 0 ºC 
and under an argon atmosphere, lithium tri-tert-butoxyaluminium hydride (5.17 g, 20 
mmol) was added portionwise. The mixture was allowed to warm to rt and stirred for 4 
h. The reaction was quenched with saturated NH4Cl (aq) and extracted with Et2O. The 
combined organic extracts were dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by chromatography (hexane to hexane/EtOAc, 8:2) to 
yield alcohol (-)-6 (2.17 g, 63%). []D
20: -10.3 (c=2.0, EtOH). Rf: 0.25 (hexane/EtOAc, 7:3). 
 
1H-NMR (CDCl3, ): 1.10 (s, 3H, CH3), 1.22 (s, 9H, C(CH3)3), 1.35-1.38 (m, 4H, CH3, 
½CH2cyc), 1.65 (br s, 1H, OH), 2.11 (td, J=5.6, 1.2, 1H, CHC=), 2.32-2.38 (m, 1H, CHCHOH), 
2.51 (dt, J=9.3, 5.5, 1H, ½CH2cyc), 4.45-4.57 (m, 3H, CH2O, CHOH), 5.66-5.68 (m, 1H, CH=). 
5-(1,1-Dimethylheptyl)benzene-1,3-diol (7). To a solution of 1-(1,1-dimethylheptyl)-
3,5-dimethoxybenzene (2.36 g, 8.6 mmol) in dry DCM (9.2 mL) at 0 ºC and under an 
argon atmosphere, BBr3 (23 mL, 1 M in DCM) was added dropwise. The reaction mixture 
was stirred at 0 ºC for 2 h, allowed to warm to rt and stirred for 16 h. The mixture was 
then cooled to 0 ºC, carefully quenched with water, extracted with 10% NaOH (aq), 
acidified with concentrated HCl, and extracted with Et2O (2x). The combined organic 
extracts were dried (Na2SO4), filtered, and evaporated under reduced pressure to yield 
resorcinol 7 (2.04 g, 100%), which was used in the next step without further purification. 
Mp: 93-95 ºC (lit.144 97-99 ºC). Rf: 0.50 (hexane/EtOAc, 7:3). The spectroscopic data 
correspond with those previously reported.144 
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1H-NMR (CDCl3, ): 0.85 (t, J=6.5, 3H, CH3CH2), 1.16-1.22 (m, 14H, 2CH3, (CH2)4), 1.48-
1.54 (m, 2H, CH2C(CH3)2), 5.79 (br s, 2H, 2OH), 6.21 (t, J=2.1, 1H, CHAr), 6.41 (d, J=2.1, 2H, 
2CHAr). 
(-)-[(6aR,10aR)-3-(1,1-Dimethylheptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-9-yl]methyl pivalate (8). Benzochromene 8 was 
obtained following experimental procedures previously described by Mechoulam et al.84 
To a stirred solution of resorcinol 7 (2.31 g, 9.8 mmol) and alcohol (-)-6 (2.46 g, 9.8 
mmol) in dry DCM (200 mL) at -20 ºC and under an argon atmosphere, BF3∙Et2O (6.6 mL, 
7.4 mmol) was added dropwise. The mixture was allowed to warm to rt and then stirred 
for additional 20 min. The mixture was carefully washed with saturated NaHCO3 (aq) and 
extracted with Et2O. The combined organic extracts were dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The residue was purified by chromatography 
(hexane to hexane/EtOAc, 9:1) to give ester 8 (2.32 g, 50%). []D
20: -144.7 (c=2.9, EtOH). 
Rf: 0.14 (hexane/EtOAc, 95:5). 
 
1H-NMR (CDCl3, ): 0.85 (t, J=6.6, 3H, CH3CH2), 1.13 (s, 3H, CH3Ccyc), 1.17-1.28 (m, 
23H, C(CH3)3, 2CH3, (CH2)4), 1.41 (s, 3H, CH3Ccyc), 1.48-1.54 (m, 2H, CH2C(CH3)2), 1.84-1.94 
(m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.27-2.36 (m, 1H, ½CH2CH=), 2.71 (td, J=11.0, 4.6, 
1H, CHCAr), 3.36 (dd, J=16.7, 3.9, 1H, ½CH2C=), 4.52 (AB system, J=13.5, 2H, CH2O), 4.79 
(br s, 1H, OH), 5.77 (d, J=4.7, 1H, CH=), 6.24 (d, J=1.7, 1H, CHAr), 6.40 (d, J=1.7, 1H, CHAr). 
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(-)-{(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}-methanol (9). A solution of 8 (1.31 
g, 3.0 mmol), TIPS-Cl (2.0 mL, 9.2 mmol), and imidazole (832 mg, 12 mmol) in anhydrous 
DMF (18 mL) under an argon armosphere, was heated at 200 ºC for 45 min under MW 
irradiation. Once at rt, the solvent was evaporated under reduced pressure and the 
residue was redissolved in EtOAc, washed with saturated NaHCO3 (aq) and brine. The 
organic layer was dried (Na2SO4), filtered, and evaporated under reduced pressure to 
yield {(6aR,10aR)-3-(1,1-dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methyl pivalate (1.82 g, 95%), which 
was used in the next step without further purification. 1H-NMR (CDCl3, ): 0.83 (t, J=6.8, 
3H, CH3CH2), 1.05-1.30 (m, 47H, CH3Ccyc, C(CH3)3, 2CH3, 3CH(CH3)2, (CH2)4), 1.38 (s, 3H, 
CH3Ccyc), 1.46-1.52 (m, 2H, CH2C(CH3)2), 1.81-1.96 (m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 
2.19-2.27 (m, 1H, ½CH2CH=), 2.57-2.68 (m, 1H, CHCAr), 3.31 (dd, J=16.2, 3.9, 1H, 
½CH2C=), 4.42-4.51 (m, 2H, CH2O), 5.72 (d, J=4.0, 1H, CH=), 6.34 (d, J=1.8, 1H, CHAr), 6.39 
(d, J=1.8, 1H, CHAr). 
A solution of the silyl ether synthesized above (1.82 g, 2.9 mmol) in anhydrous THF 
(50 mL) was added dropwise to a suspension of LiAlH4 (441 mg, 12 mmol) in anhydrous 
THF (50 mL) at 0 ºC and under an argon atmosphere. The reaction was stirred at that 
temperature for 2 h and allowed to warm to rt. The mixture was then carefully 
quenched with water and extracted with Et2O (2x). The organic extracts were washed 
with brine, dried (Na2SO4), filtered, and evaporated under reduced pressure. The residue 
was purified by chromatography (hexane to hexane/EtOAc, 8:2) to yield alcohol 9 (1.13 
g, 72%). []D
20: -103.2 (c=0.98, chloroform). Rf: 0.17 (hexane/EtOAc, 8:2). 
 
IR (ATR, ): 3357 (OH), 1565, 1464 (Ar); 1H-NMR (CDCl3, ): 0.84 (t, J=6.8, 3H, 
CH3CH2), 1.05-1.33 (m, 38H, CH3Ccyc, 2CH3, 3CH(CH3)2, (CH2)4), 1.39 (s, 3H, CH3Ccyc), 1.40-
1.52 (m, 2H, CH2C(CH3)2), 1.79-1.89 (m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.22-2.26 (m, 
1H, ½CH2CH=), 2.63 (td, J=10.8, 4.4, 1H, CHCAr), 3.36 (dd, J=16.8, 2.8, 1H, ½CH2C=), 4.03 
(AB system, J=12.9, 2H, CH2O), 5.72 (d, J=3.7, 1H, CH=), 6.34 (d, J=1.8, 1H, CHAr), 6.39 (d, 
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J=1.7, 1H, CHAr); 
13C-NMR (CDCl3, ): 13.4 (3CHSi), 14.2 (CH3CH2), 18.2 (3CH(CH3)2), 18.3 
(CH3Ccyc), 22.8, 24.9 (2CH2), 27.6 (CH3Ccyc), 27.9 (CH2CH=), 28.9, 29.1 (2CH3), 30.2, 32.01 
(2CH2), 32.09 (CHCAr), 32.12 (CH2C=), 37.5 (ArC(CH3)2), 44.8 (CH2C(CH3)2), 45.7 
(CHC(CH3)2), 69.9 (CH2O), 76.4 (OC(CH3)2), 108.3, 109.1 (2CHAr), 113.4 (CAr), 120.3 (CH=), 
138.7 (C=), 149.4, 154.3, 155.2 (3CAr); MS (ESI, m/z): 565.4 [M+Na]
+. 
(-)-2-({(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methyl)-1H-isoindole-1,3(2H)-dione 
(10). To a solution of alcohol 9 (300 mg, 0.55 mmol), phthalimide (130 mg, 0.88 mmol), 
and PPh3 (216 mg, 0.83 mmol) in anhydrous THF (5 mL) under an argon atmosphere, 
DEAD (0.4 mL, 0.88 mmol, 40% in toluene) was added dropwise and the mixture was 
stirred at rt for 16 h. Et2O was then added, and the reaction was washed with water. The 
organic layer was dried (Na2SO4), filtered, and evaporated under reduced pressure. The 
crude was purified by chromatography (hexane to hexane/EtOAc, 8:2) to yield 
phthalimide 10 (343 mg, 93%). []D
20: -130.0 (c=0.46, chloroform). Rf: 0.29 
(hexane/EtOAc, 9:1). 
 
IR (ATR, ): 1774, 1716, 1612 (CO), 1565, 1464 (Ar); 1H-NMR (CDCl3, ): 0.83 (t, J=6.8, 
3H, CH3CH2), 1.00-1.21 (m, 38H, CH3Ccyc, 2CH3, 3CH(CH3)2, (CH2)4), 1.35 (s, 3H, CH3Ccyc), 
1.42-1.50 (m, 2H, CH2C(CH3)2), 1.76-1.90 (m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.15-
2.21 (m, 1H, ½CH2CH=), 2.65 (td, J=10.9, 4.4, 1H, CHCAr), 3.33 (dd, J=15.6, 3.9, 1H, 
½CH2C=), 4.21 (m, 2H, CH2N), 5.62 (d, J=4.7, 1H, CH=), 6.31 (d, J=1.6, 1H, CHHU), 6.36 (d, 
J=1.6, 1H, CHHU), 7.69-7.74 (m, 2H, 2CHPhth), 7.82-7.87 (m, 2H, 2CHPhth); 
13C-NMR (CDCl3, 
): 13.2 (3CHSi), 14.2 (CH3CH2), 18.17 (3CH(CH3)2), 18.21 (CH3Ccyc), 22.8, 24.9 (2CH2), 27.6 
(CH3Ccyc), 27.9 (CH2CH=), 28.9, 29.2 (2CH3), 30.2, 32.0 (2CH2), 32.1 (CHCAr), 32.9 (CH2C=), 
37.5 (ArC(CH3)2), 43.4 (CH2N), 44.8 (CH2C(CH3)2), 45.4 (CHC(CH3)2), 76.4 (OC(CH3)2), 108.2, 
109.0 (2CHHU), 113.2 (CHU), 122.3 (CH=), 123.4 (2CHPhth), 132.3 (2CPhth), 133.3 (C=), 134.0 
(2CHPhth), 149.3, 154.3, 155.0 (3CHU), 168.2 (2CO); MS (ESI, m/z): 672.2 [M+H]
+. 
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(-)-{(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methylamine (11). To a solution of 
10 (100 mg, 0.15 mmol) in EtOH (3 mL) under an argon atmosphere, hydrazine (30 L, 
0.44 mmol) was added and the mixture was stirred at reflux for 2 h. Once cooled to rt, a 
mixture of HCl/water 1:1 (0.3 mL) was added, and the reaction was refluxed for 1 h, and 
stirred at rt for 16 h. Then, toluene was added and the mixture was filtere d off and 
washed with EtOH. The filtrate was washed with 5% NaHCO3 (aq). The organic layer was 
dried (Na2SO4), filtered, and evaporated under reduced pressure. The crude was purified 
by chromatography (DCM to DCM/MeOH, 8:2) to yield amine 11 (78 mg, 96%). []D
20:     
-0.27 (c=0.18, chloroform). Rf: 0.20 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 2957, 2928 (NH), 1614, 1566, 1465, 1383 (Ar); 1H-NMR (CDCl3, ): 0.83 (t, 
J=6.8, 3H, CH3CH2), 1.05-1.32 (m, 38H, CH3Ccyc, 2CH3, 3CH(CH3)2, (CH2)4), 1.38 (s, 3H, 
CH3Ccyc), 1.46-1.51 (m, 2H, CH2C(CH3)2), 1.81-1.90 (m, 5H, ½CH2C=, ½CH2CH=, CHC(CH3)2, 
NH2), 2.17-2.26 (m, 1H, ½CH2CH=), 2.62 (td, J=10.9, 4.2, 1H, CHCAr), 3.22 (m, 2H, CH2N), 
3.28 (dd, J=15.9, 4.3, 1H, ½CH2C=), 5.63 (d, J=4.3, 1H, CH=), 6.34 (d, J=1.8, 1H, CHAr), 6.39 
(d, J=1.8, 1H, CHAr); 
13C-NMR (CDCl3, ): 13.4 (3CHSi), 14.2 (CH3CH2), 18.2 (3CH(CH3)2), 
18.3 (CH3Ccyc), 22.8, 24.9 (2CH2), 27.6 (CH3Ccyc), 27.9 (CH2CH=), 28.9, 29.1 (2CH3), 30.2, 
32.0 (2CH2), 32.2 (CHCAr), 33.2 (CH2C=), 37.5 (ArC(CH3)2), 44.8 (CH2C(CH3)2), 45.8 
(CHC(CH3)2), 48.0 (CH2N), 76.4 (OC(CH3)2), 108.3, 109.0 (2CHAr), 113.5 (CAr), 118.3 (CH=), 
140.3 (C=), 149.3, 154.3, 155.1 (3CAr); HRMS (ESI, m/z): calcd for [M+H]
+ C34H60NO2Si: 
542.4393; found: 542.4388. 
(-)-(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-carbaldehyde (12). To a solution of 
alcohol 9 (126 mg, 0.23 mmol) in dry DCM (15 mL), PCC (75 mg, 0.35 mmol) was added 
and the mixture was stirred at rt for 3 h. The reaction was filtered over silica gel, 
washing with EtOAc. The solvents were evaporated under reduced pressure and the 
residue was purified by chromathography (hexane to hexane/EtOAc, 8:2) to yield 
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aldehyde 12 (87 mg, 85%). [α]D
20: -150.2 (c=1.92, chloroform). Rf: 0.36 (hexane/EtOAc, 
95:5). 
 
IR (ATR, ): 2820, 2718, 1688 (CHO), 1613, 1566, 1462 (Ar), 1098 (COSi); 1H-NMR 
(CDCl3, ): 0.84 (t, J=6.8, 3H, CH3CH2), 0.93-1.33 (m, 38H, CH3Ccyc, 2CH3, 3CH(CH3)2, 
(CH2)4), 1.42 (s, 3H, CH3Ccyc), 1.47-1.52 (m, 2H, CH2C(CH3)2), 1.75-1.95 (m, 2H, ½CH2CH=, 
CHC(CH3)2), 2.08-2.20 (m, 1H, ½CH2CH=), 2.51-2.60 (m, 2H, ½CH2C=, CHCAr), 3.46 (dd, 
J=17.7, 2.2, 1H, ½CH2C=), 6.36 (d, J=1.7, 1H, CHAr), 6.39 (d, J=1.7, 1H, CHAr), 6.80 (m, 1H, 
CH=), 9.49 (s, 1H, CHO); 13C-NMR (CDCl3, ): 13.3 (3CHSi), 14.2 (CH3CH2), 18.2 (CH3Ccyc, 
3CH(CH3)2), 22.8, 24.9 (2CH2), 27.6 (CH3Ccyc), 27.8 (CH2CH=), 29.0, 29.1 (2CH3), 29.5, 30.2 
(2CH2), 31.6 (CHCAr), 32.0 (CH2C=), 37.6 (ArC(CH3)2), 44.8 (CH2C(CH3)2), 45.5 (CHC(CH3)2), 
75.9 (OC(CH3)2), 108.1, 109.2 (2CHAr), 112.5 (CAr), 142.7 (C=), 148.7 (CH=), 149.7, 154.1, 
155.2 (3CAr), 193.4 (CHO); MS (ESI, m/z): 541.3 [M+H]
+. 
(-)-(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-carboxylic acid (13). To a vigorously 
stirred solution of aldehyde 12 (390 mg, 0.72 mmol), 2-methyl-2-butene (1.6 mL, 0.72 
mmol), saturated KH2PO4 (aq, 0.25 mL) and tert-butanol (16 mL, 0.72 mmol), NaClO2 (1.0 
mL, 0.72 mmol) was added and the mixture was stirred at rt for 16 h. The reaction was 
quenched with water, extracted with EtOAc, dried (Na2SO4), filtered, and evaporated 
under reduced pressure. The crude was purified by chromatography (hexane to 
hexane/EtOAc, 8:2) to yield carboxylic acid 13 (296 mg, 74%). [α]D
20: -58.6 (c=0.69, 
chloroform). Rf: 0.31 (hexane/EtOAc, 9:1). 
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IR (ATR, ): 3100 (OH), 1689 (CO), 1612, 1564, 1464 (Ar); 1H-NMR (CDCl3, ): 0.84 (t, 
J=6.7, 3H, CH3CH2), 1.05-1.34 (m, 38H, CH3Ccyc, 2CH3, 3CH(CH3)2, (CH2)4), 1.40 (s, 3H, 
CH3Ccyc), 1.47-1.52 (m, 2H, CH2C(CH3)2), 1.83-2.09 (m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 
2.41-2.47 (m, 1H, ½CH2CH=), 2.55-2.63 (m, 1H, CHCAr), 3.87 (dd, J=16.8, 3.1, 1H, 
½CH2C=), 6.36 (d, J=1.6, 1H, CHAr), 6.39 (d, J=1.4, 1H, CHAr), 7.14 (d, J=2.7, 1H, CH=); 
13C-
NMR (CDCl3, ): 13.3 (3CHSi), 14.2 (CH3CH2), 18.2 (CH3Ccyc, 3CH(CH3)2), 22.8 (CH2CH=, 
CH2), 24.9 (CH2), 27.6 (CH3Ccyc), 28.9, 29.0 (2CH3), 30.2, 30.3 (2CH2), 32.0 (CHCAr, CH2C=), 
37.6 (ArC(CH3)2), 44.5 (CHC(CH3)2), 45.9 (CH2C(CH3)2), 76.0 (OC(CH3)2), 108.2, 109.2 
(2CHAr), 112.6 (CAr), 131.1 (C=), 140.3 (CH=), 149.6, 154.2, 155.3 (3CAr), 172.5 (COOH); MS 
(ESI, m/z): 555.2 [M-H]-. 
 Synthesis of the biotin derivative 15 
(+)-tert-Butyl 6-(biotinylamino)hexylcarbamate (14). To a solution of biotin (1.00 g, 
4.1 mmol) in anhydrous DMF (80 mL) under an argon atmosphere, tributylamine (1.4 
mL, 5.9 mmol) was added at rt and the mixture was stirred for 10 min prior to the 
addition of isobutyl chloroformate (0.6 mL, 5.0 mmol). The resulting mixture was stirred 
for 30 min and then added dropwise to a solution of tert-butyl (6-aminohexyl)carbamate 
(1.06 g, 4.9 mmol) in anhydrous DMF (80 mL) at 0 ºC. The reaction mixture was stirred at 
this temperature for 3 h. The solvent was evaporated under reduced pressure and the 
residue was purified by chromatography (DCM to DCM/MeOH, 8:2) to afford amide 14 
(1.45 g, 80%). Mp: 167-168 ºC (lit.145 173.7 ºC). [α]D
20: +42.6 (c=1.7, MeOH) (lit.145 +38; 
c=1.0, MeOH). Rf: 0.28 (DCM/MeOH, 9:1). The spectroscopic data correspond with those 
previously reported.145 
 
1H-NMR (CDCl3/CD3OD, 9:1, ): 1.20-1.60 (m, 23H, C(CH3)3, (CH2)4, (CH2)3), 2.08 (t, 
J=7.1, 2H, CH2CO), 2.62 (d, J=12.8, 1H, ½CH2S), 2.81 (dd, J=12.9, 5.0, 1H, ½CH2S), 2.96 (t, 
J=6.9, 2H, CH2NBoc), 3.05-3.09 (m, 3H, CHS, CH2NBiot), 4.19 (dd, J=7.6, 4.5, 1H, CHN), 
4.40 (dd, J=8.1, 4.5, 1H, CHN). 
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(+)-N-(6-Aminohexyl)biotinamide (15). To a solution of 14 (3.20 g, 7.2 mmol) in dry 
DCM (55 mL) under an argon atmosphere, TFA (17 mL, 221 mmol) was added and the 
mixture was stirred at rt for 16 h. The solvent was evaporated under reduced pressure 
and the residue was redissolved in the minimum amount of DCM. Triethylamine was 
then added until basic pH. The insoluble product was isolated by filtration and washed 
with cold Et2O to yield amine 15 (1.98 g, 81%), which was used in the next step without 
further purification. Mp: 77-79 ºC. [α]D
20: +34.5 (c=1.6, MeOH). Rf: 0.17 (DCM/MeOH, 
85:15). The spectroscopic data correspond with those previously reported. 145 
 
1H-NMR (CD3OD, ): 1.39-1.80 (m, 14H, (CH2)4, (CH2)3), 2.20 (t, J=7.3, 2H, CH2CO), 
2.70 (d, J=12.7, 1H, ½CH2S), 2.88-2.96 (m, 3H, ½CH2S, CH2NH2), 3.13-3.24 (m, 3H, CHS, 
CH2NBiot), 4.30 (dd, J=7.8, 4.4, 1H, CHN), 4.50 (dd, J=7.7, 4.7, 1H, CHN). 
 Synthesis of final compounds 1 and 2 
(-)-N-({(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methyl)-6-(biotinylamino)-
hexanamide (16). A suspension of N-(+)-biotinyl-6-aminohexanoic acid (132 mg, 0.37 
mmol), HOBt (50 mg, 0.37 mmol) and activated 4 Å molecular sieves in anhydrous DMF 
(8 mL) was heated at 77 ºC until a clear solution was obtained. Once cooled to rt, a 
solution of EDC (78 mg, 0.41 mmol) in dry DCM (3 mL) was added dropwise and the 
mixture was stirred at rt for 3 h. Then, a solution of amine 11 (100 mg, 0.18 mmol) and 
DMAP (4 mg, 37 mol) in DCM (3 mL) was added and the reaction was stirred at rt for 24 
h. The mixture was filtered, diluted with DCM, washed with saturated NaHCO3 (aq) and 
brine, dried (Na2SO4), filtered, and evaporated under reduced pressure. The crude was 
purified by chromatography (DCM to DCM/MeOH, 9:1) to afford amide 16 (98 mg, 62%). 
[α]D
20: -21.6 (c=0.32, chloroform). Rf: 0.32 (DCM/EtOH, 9:1). 
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IR (ATR, ): 3292 (NH), 1703, 1643 (CO), 1561, 1464 (Ar); 1H-NMR (CDCl3, ): 0.82 (t, 
J=6.8, 3H, CH3CH2), 1.04-1.51 (m, 53H, 2CH3Ccyc, 2CH3, 3CH(CH3)2, (CH2)4, 2(CH2)3), 1.61-
1.83 (m, 5H, CH2C(CH3)2, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.15-2.20 (m, 5H, ½CH2CH=, 
2CH2CO), 2.62 (td, J=10.8, 4.1, 1H, CHCAr), 2.70 (d, J=12.8, 1H, ½CH2S), 2.86 (dd, J=12.8, 
4.7, 1H, ½CH2S), 3.07-3.29 (m, 4H, ½CH2C=, CHS, CH2NBiot), 3.75 (d, J=5.0, 2H, CH2NHU), 
4.27 (dd, J=7.3, 4.9, 1H, CHN), 4.47 (dd, J=7.3, 5.0, 1H, CHN), 5.57 (d, J=3.6, 1H, CH=), 
5.85 (br s, 1H, NH), 5.88 (t, J=6.0, 1H, NH), 6.32 (d, J=1.5, 1H, CHAr), 6.36 (d, J=1.4, 1H, 
CHAr), 6.53 (t, J=5.6, 1H, NH), 6.76 (br s, 1H, NH); 
13C-NMR (CDCl3, ): 13.3 (3CHSi), 14.2 
(CH3CH2), 18.2 (CH3Ccyc, 3CH(CH3)2), 22.8, 24.8, 25.3, 26.0, 26.6 (5CH2), 27.6 (CH3Ccyc), 
27.9, 28.2, 28.3 (2CH2, CH2CH=), 28.8, 29.16 (2CH3), 29.23, 30.2 (2CH2), 32.0 (CH2C=), 
32.1 (CHCAr), 33.3 (CH2), 36.0, 36.5 (2CH2CO), 37.5 (ArC(CH3)2), 39.2 (CH2NBiot), 40.6 
(CH2S), 44.8 (CH2C(CH3)2), 45.0 (CH2NHU), 45.6 (CHC(CH3)2), 55.9 (CHS), 60.4, 61.8 (2CHN), 
76.4 (OC(CH3)2), 108.3, 109.1 (2CHAr), 113.2 (CAr), 120.8 (CH=), 135.2 (C=), 149.4, 154.3, 
155.1 (3CAr), 164.3 (NCON), 173.1, 173.5 (2CON); MS (ESI, m/z): 903.6 [M+Na]
+. 
(+)-N-{[(6aR,10aR)-3-(1,1-Dimethylheptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-9-yl]methyl}-6-(biotinylamino)hexanamide (1). 
Following the general procedure 6.1.1.1, probe 1 was obtained from 16 (19 mg, 22 
mol) in 80% yield (13 mg). Chromatography: DCM to DCM/MeOH, 9:1. Mp: 124-125 ºC. 
[α]D
20: +11.8 (c=0.28, chloroform). Rf: 0.15 (DCM/EtOH, 95:5). 
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IR (ATR, ): 3284 (NH, OH), 1696, 1646 (CO), 1552, 1460 (Ar); 1H-NMR (CDCl3, ): 0.83 
(t, J=7.0, 3H, CH3CH2), 1.05-1.84 (m, 37H, CHC(CH3)2, CH2C(CH3)2, (CH2)4, 2(CH2)3, ½CH2C=, 
½CH2CH=), 2.17-2.30 (m, 5H, ½CH2CH=, 2CH2CO), 2.64 (td, J=10.8, 4.2, 1H, CHCAr), 2.71 
(d, J=12.8, 1H, ½CH2S), 2.86 (dd, J=12.8, 4.8, 1H, ½CH2S), 3.08 (dd, J=11.7, 7.0, 1H, CHS), 
3.19-3.24 (m, 1H, ½CH2NBiot), 3.31-3.37 (m, 1H, ½CH2NBiot), 3.48 (dd, J=17.1, 3.6, 1H, 
½CH2C=), 3.61 (dd, J=14.1, 2.7, 1H, ½CH2NHU), 3.98 (dd, J=14.3, 6.7, 1H, ½CH2NHU), 4.22 
(dd, J=7.6, 4.5, 1H, CHN), 4.44 (dd, J=7.4, 4.9, 1H, CHN), 5.26 (br s, 1H, OH), 5.64 (d, 
J=1.6, 1H, CH=), 6.22 (br s, 1H, NH), 6.32 (d, J=1.6, 1H, CHAr), 6.37 (br s, 1H, NH), 6.54 (d, 
J=1.6, 1H, CHAr), 6.58 (br s, 1H, NH); 
13C-NMR (CDCl3, ): 14.3 (CH3CH2), 18.6 (CH3Ccyc), 
22.9, 24.8, 25.1, 25.4, 26.1 (5CH2), 27.7 (CH3Ccyc), 28.06, 28.14, 28.3 (2CH2, CH2CH=), 28.9 
(2CH3), 29.4, 30.2 (2CH2), 31.69 (CH2C=), 31.72 (CHCAr), 32.0 (CH2), 35.8, 36.4 (2CH2CO), 
37.5 (ArC(CH3)2), 39.5 (CH2NBiot), 40.8 (CH2S), 44.7 (CH2C(CH3)2), 45.2 (CHC(CH3)2), 45.8 
(CH2NHU), 55.8 (CHS), 60.3, 62.1 (2CHN), 76.4 (OC(CH3)2), 106.0, 107.0 (2CHAr), 109.6 
(CAr), 123.3 (CH=), 135.5 (C=), 150.1, 154.3, 155.9 (3CAr), 163.8 (NCON), 173.6, 174.2 
(2CON); HRMS (MALDI, m/z): calcd for [M+H]+ C41H65N4O5S: 725.4676; found: 725.4688; 
HPLC-MS (ESI, m/z): 725.3 [M+H]+; tR (method A): 13.29 min. 
(-)-(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-N-[6-(biotinylamino)hexyl]-1-
[(triisopropylsilyl)oxy]-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-carboxamide 
(17). To a solution of carboxylic acid 13 (198 mg, 0.36 mmol) and HOBt (53 mg, 0.39 
mmol) in dry DCM (10 mL) under an argon atmosphere, EDC (75 mg, 0.39 mmol) was 
added and the mixture was stirred at rt for 40 min. Then, a solution of amine 15 (188 
mg, 0.55 mmol) and DMAP (14 mg, 0.11 mmol) in DMF (1 mL) was added, and the 
mixture was stirred at rt for 48 h. The reaction was diluted with EtOAc, washed with 
saturated NaHCO3 (aq), dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The crude was purified by chromatography (DCM to DCM/MeOH, 8:2) to yield 
amide 17 (151 mg, 48%). Mp: 143-145 ºC. [α]D
20: -120.2 (c=5.1, chloroform). Rf: 0.44 
(DCM/MeOH, 9:1). 
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IR (ATR, ): 3295 (NH), 1702, 1639 (CO), 1559, 1464 (Ar); 1H-NMR (CDCl3, ): 0.82 (t, 
J=6.8, 3H, CH3CH2), 1.02-1.51 (m, 55H, 2CH3Ccyc, 2CH3, 3CH(CH3)2, 2(CH2)4, (CH2)3) 1.63-
2.02 (m, 5H, CH2C(CH3)2, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.19 (t, J=7.4, 2H, CH2CO), 2.33-
2.40 (m, 1H, ½CH2CH=), 2.62 (td, J=10.9, 4.2, 1H, CHCAr), 2.71 (d, J=12.6, 1H, ½CH2S), 2.87 
(dd, J=13.4, 5.0, 1H, ½CH2S), 3.11-3.21 (m, 3H, CHS, CH2N), 3.27 (q app, J=6.5, 2H, CH2N), 
3.61-3.67 (m, 1H, ½CH2C=), 4.28 (dd, J=7.6, 4.6, 1H, CHN), 4.48 (dd, J=7.6, 4.8, 1H, CHN), 
5.78 (br s, 2H, 2NH), 6.36 (d, J=1.5, 1H, CHAr), 6.39 (d, J=1.4, 1H, CHAr), 6.46 (m, 1H, NH), 
6.63 (br s, 1H, NH), 6.80 (d, J=4.9, 1H, CH=); 13C-NMR (CDCl3, ): 13.3 (3CHSi), 14.2 
(CH3CH2), 18.1 (CH3Ccyc), 18.2 (3CH(CH3)2), 22.8 (2CH2), 24.9, 26.0, 26.4 (3CH2), 27.6 
(CH3Ccyc), 28.2, 28.3, 28.5 (2CH2, CH2CH=), 28.8, 29.2 (2CH3), 29.5, 29.8, 30.2, 30.6 (4CH2), 
32.0 (CH2C=), 32.1 (CHCAr), 36.1 (CH2CO), 37.5 (ArC(CH3)2), 39.2, 39.4 (2CH2N), 40.6 
(CH2S), 44.7 (CH2C(CH3)2), 45.0 (CHC(CH3)2), 55.8 (CHS), 60.3, 61.9 (2CHN), 76.2 
(OC(CH3)2), 108.5, 109.2 (2CHAr), 112.7 (CAr), 133.0 (C=), 133.2 (CH=), 149.8, 154.3, 155.0 
(3CAr), 164.1 (NCON), 167.7, 172.5 (2CON); MS (ESI, m/z): 881.6 [M+H]
+. 
(-)-(6aR,10aR)-3-(1,1-Dimethylheptyl)-1-hydroxy-6,6-dimethyl-N-[6-
(biotinylamino)hexyl]-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-carboxamide (2). 
Following the general procedure 6.1.1.1, probe 2 was obtained from 17 (49 mg, 56 
mol) in 84% yield (34 mg). Chromatography: DCM to DCM/MeOH, 8:2. Mp: 116-119 ºC. 
[α]D
20: -92.1 (c=1.28, MeOH). Rf: 0.33 (DCM/MeOH, 9:1). 
 
IR (ATR, ): 3290 (NH), 1693, 1623 (CO), 1539, 1459 (Ar); 1H-NMR (CD3OD, ): 0.86 (t, 
J=6.8, 3H, CH3CH2), 1.10-1.82 (m, 37H, CHC(CH3)2, CH2C(CH3)2, 2(CH2)4, (CH2)3), 1.92-2.02 
(m, 2H, ½CH2C=, ½CH2CH=), 2.20 (t, J=7.3, 2H, CH2CO), 2.35-2.44 (m, 1H, ½CH2CH=), 2.64 
(td, J=11.1, 4.5, 1H, CHCAr), 2.70 (d, J=12.8, 1H, ½CH2S), 2.91 (dd, J=12.8, 5.6, 1H, ½CH2S), 
3.15-3.26 (m, 5H, CHS, 2CH2N), 3.75-3.81 (m, 1H, ½CH2C=), 4.29 (dd, J=8.0, 4.4, 1H, CHN), 
4.48 (dd, J=7.8, 4.8, 1H, CHN), 6.24 (d, J=1.8, 1H, CHAr), 6.36 (d, J=1.9, 1H, CHAr), 6.58 (m, 
1H, CH=); 13C-NMR (CD3OD, ): 14.4 (CH3CH2), 18.5 ( CH3Ccyc), 23.7 (2CH2), 25.8, 26.9, 27.6 
(3CH2), 27.9 (CH3Ccyc), 29.2 (CH2), 29.4 (2CH3), 29.5, 29.8, 30.3, 30.4, 31.1, 31.7 (5CH2, 
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CH2CH=), 32.8 (CHCAr), 32.9 (CH2C=), 36.8 (CH2CO), 38.2 (ArC(CH3)2), 40.2, 40.4 (2CH2N), 
41.0 (CH2S), 45.6 (CH2C(CH3)2), 46.2 (CHC(CH3)2), 57.0 (CHS), 61.6, 63.4 (2CHN), 77.1 
(OC(CH3)2), 106.3, 107.6 (2CHAr), 110.6 (CAr), 132.6 (CH=), 135.6 (C=), 150.8, 155.5, 157.6 
(3CAr), 166.1 (NCON), 171.5, 176.0 (2CO); HRMS (MALDI, m/z): calcd for [M+H]
+ 
C41H65N4O5S: 725.4676; found: 725.4697; HPLC-MS (ESI, m/z): 725.5 [M+H]
+; tR (method 
A): 12.02 min. 
 Synthesis of probe 20 
Compounds 18 and 19 were obtained following the experimental procedures 
previously described by Takenishi et al.85 
(+)-N-(6-Hydroxyhexyl)biotinylamide (18). Amide 18 was prepared from biotin (1.00 
g, 4.1 mmol) and 6-amino-1-hexanol (590 mg, 5.0 mmol) following the procedure 
described for 14 in 97% yield (1.37 g). Chromatography: DCM to DCM/MeOH, 8:2. Mp: 
182-185 ºC (lit.146 159-160 ºC). [α]D
20: +35.8 (c=1.11, DMSO). Rf: 0.13 (DCM/MeOH, 9:1). 
The spectroscopic data correspond with those previously reported. 146 
 
1H-NMR ((CD3)2SO, ): 1.24-1.67 (m, 14H, (CH2)4, (CH2)3), 2.04 (t, J=7.3, 2H, CH2CO), 
2.57 (d, J=12.4, 1H, ½CH2S), 2.82 (dd, J=12.4, 5.1, 1H, ½CH2S), 3.00 (q, J=6.4, 2H, CH2N), 
3.06-3.12 (m, 1H, CHS), 3.37 (q app, J=6.0, 2H, CH2O), 4.10-4.14 (m, 1H, CHN), 4.28-4.33 
(m, 2H, CHN, OH), 6.35 (br s, 1H, NH), 6.41 (br s, 1H, NH), 7.71 (t, J=5.5, 1H, CONH). 
(+)-N-(6-Bromohexyl)biotinylamide (19). To a solution of alcohol 18 (2.79 g, 8.1 
mmol) in anhydrous DMF (200 mL) and under an argon atmosphere, PPh3 (2.56 g, 9.8 
mmol) and carbon tetrabromide (4.04 g, 12 mmol) were added and the mixture was 
stirred at rt for 2 h. The solvent was evaporated under reduced pressure and the residue 
was redissolved in EtOAc, washed with saturated NaHCO3 (aq) and brine, dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The crude was purified by 
chromatography (DCM to DCM/MeOH, 8:2) to afford bromoderivative 19 (2.45 g, 74%). 
Mp: 147-150 ºC. [α]D
20: +41.3 (c=0.63, MeOH). Rf: 0.38 (DCM/MeOH, 9:1). 
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IR (ATR, ): 3294 (NH), 1702, 1640 (CO); 1H-NMR (CD3OD, ): 1.30-1.88 (m, 14H, 
(CH2)4, (CH2)3), 2.20 (t, J=7.3, 2H, CH2CO), 2.70 (d, J=12.7, 1H, ½CH2S), 2.93 (dd, J=12.8, 
5.0, 1H, ½CH2S), 3.15-3.25 (m, 3H, CH2N, CHS), 3.45 (t, J=6.8, 2H, CH2Br), 4.30 (dd, J=7.8, 
4.6, 1H, CHN), 4.50 (dd, J=7.8, 4.4, 1H, CHN); 13C-NMR (CD3OD, ): 26.9, 27.1, 28.9, 29.5, 
29.8, 30.3, 33.9 ((CH2)4, (CH2)3), 34.3 (CH2Br), 36.8 (CH2CO), 40.2 (CH2N), 41.0 (CH2S), 57.0 
(CHS), 61.6, 63.4 (2CHN), 166.1 (NCON), 176.0 (CON); MS (ESI, m/z): 405.6 [M(79Br)+H]+, 
407.6 [M(81Br)+H]+. 
(-)-N-(6-{[(6aR,10aR)-3-(1,1-Dimethylheptyl)-9-(hydroxymethyl)-6,6-dimethyl-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-yl]oxy}hexyl)biotinamide (20). To a 
solution of alcohol 9 (85 mg, 0.15 mmol) in anhydrous THF (2 mL) at 0 ºC and under an 
argon atmosphere, NaH (3.8 mg, 0.16 mmol, 60% in mineral oil) was added and the 
mixture was stirred at that temperature for 30 min. Then, TBAI (7.4 mg, 20 mol) and 
bromoderivative 19 (85 mg, 0.21 mmol) were added and the mixture was stirred at 
reflux for 16 h. Once at rt, the reaction was quenched with saturated NH4Cl (aq) and 
extracted with EtOAc (2x). The organic layer was washed with brine, dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
chromatography (DCM/MeOH, 85:15) to give 20 (80 mg, 75%). Mp: 137-140 ºC. []D
20:    
-141.4 (c=0.74, chloroform). Rf: 0.41 (DCM/MeOH, 85:15). 
 
IR (ATR, ): 3296 (NH, OH), 1696, 1646 (CO), 1568, 1463 (Ar); 1H-NMR (CDCl3, ): 0.84 
(t, J=6.7, 3H, CH3CH2), 1.07 (s, 3H, CH3Ccyc), 1.19-1.25 (m, 14H, 2CH3, (CH2)4), 1.38 (s, 3H, 
CH3Ccyc), 1.38-1.85 (m, 19H, (CH2)4, (CH2)3, CH2C(CH3)2, ½CH2C=, ½CH2CH=, CHC(CH3)2), 
2.15-2.26 (m, 3H, CH2CO, ½CH2CH=), 2.65 (td, J=12.8, 4.8, 1H, CHCAr), 2.71 (d, J=13.0, 1H, 
½CH2S), 2.89 (dd, J=12.8, 4.8, 1H, ½CH2S), 3.13-3.26 (m, 4H, CH2N, CH2O), 3.45 (dd, 
J=16.6, 3.7, 1H, ½CH2C=), 3.88-4.08 (m, 3H, CH2OH, CHS), 4.32 (m, 1H, CHN), 4.48 (m, 1H, 
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CHN), 5.39 (br s, 1H, OH), 5.72 (d, J=4.2, 1H, CH=), 6.31-6.35 (m, 2H, CHAr, NH), 6.41 (d, 
J=1.3, 1H, CHAr); 
13C-NMR (CDCl3, ): 14.3 (CH3CH2), 18.6 (CH3Ccyc), 22.8, 24.8, 25.8, 26.6, 
27.0 (5CH2), 27.8 (CH3Ccyc), 28.0, 28.2, 28.3 (2CH2, CH2CH=), 29.0 (2CH3), 29.7, 29.8, 30.2 
(3CH2), 31.7 (CHCAr), 31.9, 32.2 (CH2C=, CH2), 35.6 (CH2CO), 37.8 (ArC(CH3)2), 39.8 (CH2N), 
40.6 (CH2S), 44.6 (CH2C(CH3)2), 45.5 (CHC(CH3)2), 55.8 (CHS), 60.6, 62.2 (2CHN), 66.7 
(CH2OH), 67.9 (CH2O), 76.5 (OC(CH3)2), 101.4, 108.2 (2CHAr), 111.3 (CAr), 120.9 (CH=), 
138.5 (C=), 149.9, 154.1, 158.2 (3CAr), 164.2 (NCON), 174.3 (CON); HRMS (MALDI, m/z): 
calcd for [M+H]+ C41H66N3O5S: 712.4723; found: 712.4691; HPLC-MS (ESI, m/z): 712.5 
[M+H]+; tR (method A): 14.41 min. 
 Attempts of synthesis of compound 3 
Mitsunobu reaction of alcohols 9 and 18. To a solution of ADDP (45 mg, 0.18 mmol) 
in anhydrous toluene (10 mL) at rt and under an argon atmosphere, PBu3 (0.36 mL, 0.18 
mmol) and biotinylated alcohol 18 (63 mg, 0.18 mmol) were added. The mixture was 
stirred at this temperature for 30 min and then alcohol 9 (50 mg, 92 mol) was added, 
and the reaction mixture was stirred at 60 ºC for 16 h. Once cooled to rt, the solvent was 
evaporated under reduced pressure and the residue was redissolved in EtOAc and 
washed with water and brine. The organic layer was dried (Na2SO4), filtered, and 
evaporated under reduced pressure to yield a mixture of both starting materials, and 
the Mitsunobu byproduct, but not the desired allyl ether 3.  
{[(6aR,10aR)-9-(Bromomethyl)-3-(1,1-dimethylheptyl)-6,6-dimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-1-yl]oxy}(triisopropyl)silane (21). To a solution of 
alcohol 9 (56 mg, 0.10 mmol) in dry DCM (10 mL) under an argon atmosphere, PPh3 (32 
mg, 0.12 mmol) and carbon tetrabromide (51 mg, 0.16 mmol) were added and the 
mixture was stirred at rt for 1 h. The solvent was evaporated under reduced pressure 
and the reaction crude was purified by chromatography (hexane to hexane/EtOAc, 8:2) 
to provide bromoderivative 21 (41 mg, 65%). Rf: 0.34 (hexane/EtOAc, 95:5). 
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1H-NMR (CDCl3, ): 0.84 (t, J=6.8, 3H, CH3CH2), 1.07-1.34 (m, 38H, CH3Ccyc, 2CH3, 
3CH(CH3)2, (CH2)4), 1.38 (s, 3H, CH3Ccyc), 1.47-1.52 (m, 2H, CH2C(CH3)2), 1.77-2.08 (m, 3H, 
½CH2C=, ½CH2CH=, CHC(CH3)2), 2.22-2.27 (m, 1H, ½CH2CH=), 2.67 (td, J=10.9, 4.5, 1H, 
CHCAr), 3.46 (dd, J=17.0, 4.0, 1H, ½CH2C=), 3.95 (AB system, J=10.4, 2H, CH2Br), 5.90 (d, 
J=5.0, 1H, CH=), 6.36 (d, J=1.8, 1H, CHAr), 6.38 (d, J=1.7, 1H, CHAr); 
13C-NMR (CDCl3, ): 
13.4 (3CHSi), 14.2 (CH3CH2), 18.3 (CH3Ccyc, 3CH(CH3)2), 22.8, 24.9 (2CH2), 27.6 (CH3Ccy), 
28.3 (CH2CH=), 28.9, 29.1 (2CH3), 30.2 (CH2), 31.99 (CHCAr), 32.01, 33.1 (CH2C=, CH2), 37.5 
(ArC(CH3)2), 38.6 (CH2Br), 44.8 (CH2C(CH3)2), 45.0 (CHC(CH3)2), 76.2 (OC(CH3)2), 108.2, 
109.0 (2CHAr), 113.0 (CAr), 126.3 (CH=), 135.8 (C=), 149.5, 154.2, 155.2 (3CAr). 
Nucleophilic substitution of bromoderivative 21 with alcohol 18. To a solution of 
alcohol 18 (206 mg, 0.60 mmol) in anhydrous DMF (5 mL) at rt and under an argon 
atmosphere, NaH (64 mg, 1.6 mmol) was added and the reaction mixture was stirred for 
1 h. Then, a solution of bromoderivative 21 (180 mg, 0.40 mmol) in anhydrous DMF (5 
mL) was added, and the mixture was stirred at rt for 16 h. The reaction was quenched 
with saturated NH4Cl (aq), extracted with EtOAc, and washed with water and brine. The 
combined organic extracts were dried (Na2SO4), filtered, and evaporated under reduced 
pressure to yield a complex mixture of products which did not contain the desired allyl 
ether 3. 
 Synthesis of fluorescent probe 22 
(-)-tert-Butyl {6-[({(6aR,10aR)-3-(1,1-dimethylheptyl)-6,6-dimethyl-1-
[(triisopropylsilyl)oxy]-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methyl)-
amino]-6-oxohexyl}carbamate (23). To a solution of 6-[(tert-
butoxycarbonyl)amino]hexanoic acid (77 mg, 0.33 mmol) in dry DCM (0.7 mL), DCC (125 
mg, 0.60 mmol) was added under an argon atmosphere, and the mixture was stirred at 
rt for 10 min. Then, a solution of amine 11 (164 mg, 0.30 mmol) in dry DCM (2 mL) was 
added, and the mixture was stirred at rt for 16 h. The reaction mixture was filtered, 
washing with EtOAc. The filtrate was washed with water, dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The crude was purified by chromatography (DCM 
to DCM/EtOAc, 9:1) to give compound 23 (169 mg, 74%). Mp: 53 ºC. [α]D
20: -87.9 (c=0.96, 
chloroform). Rf: 0.25 (DCM/EtOAc, 9:1). 
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IR (ATR, ): 3319 (NH), 1692, 1649 (CO), 1564, 1463 (Ar); 1H-NMR (CDCl3, ): 0.84 (t, 
J=6.8, 3H, CH3CH2), 1.05-1.71 (m, 61H, C(CH3)3, 3CH(CH3)2, CHC(CH3)2, CH2C(CH3)2, (CH2)4, 
(CH2)3, ½CH2C=, ½CH2CH=), 2.15-2.23 (m, 3H, ½CH2CH=, CH2CO), 2.64 (td, J=10.8, 4.4, 1H, 
CHCAr), 3.07-3.13 (m, 2H, CH2NBoc), 3.28 (dd, J=16.1, 3.7, 1H, ½CH2C=), 3.79 (d, J=16.1, 
2H, CH2NHU), 4.53 (br s, 1H, NH), 5.43 (t, J=4.9, 1H, NH), 5.60 (d, J=4.5, 1H, CH=), 6.34 (d, 
J=1.4, 1H, CHAr), 6.38 (d, J=1.6, 1H, CHAr); 
13C-NMR (CDCl3, ): 13.4 (3CHSi), 14.2 (CH3CH2), 
18.3 (CH3Ccyc, 3CH(CH3)2), 22.8, 24.9, 25.5, 26.6 (4CH2), 27.6 (CH3Ccyc), 28.0 (CH2CH=), 
28.6 (C(CH3)3), 28.9, 29.2 (2CH3), 30.2, 31.1, 32.0 (3CH2), 32.2 (CHCAr), 33.4 (CH2C=), 34.1 
(CH2NBoc), 36.8 (CH2CO), 37.6 (ArC(CH3)2), 44.8 (CH2C(CH3)2), 45.1 (CH2NHU), 45.6 
(CHC(CH3)2), 76.4 (OC(CH3)2), 77.4 (C(CH3)3), 108.4, 109.1 (2CHAr), 113.2 (CAr), 121.2 
(CH=), 135.4 (C=), 149.5, 154.3, 155.1 (3CAr), 156.1 (NCOO), 172.7 (CON); MS (ESI, m/z): 
753.6 [M-H]-. 
(-)-tert-Butyl [6-({[(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methyl}amino)-6-oxohexyl]-
carbamate (24). Following the general procedure 6.1.1.1, phenol 24 was obtained from 
23 (62 mg, 83 mol) in 81% yield (40 mg). Chromatography: DCM to DCM/EtOAc, 8:2. 
Mp: 83-85 ºC. [α]D
20: -101.5 (c=0.54, chloroform). Rf: 0.35 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 3308 (NH, OH), 1686, 1649 (CO), 1575, 1523, 1457 (Ar); 1H-NMR (CDCl3, 
): 0.84 (t, J=6.8, 3H, CH3CH2), 1.04-1.86 (m, 40H, C(CH3)3, CHC(CH3)2, CH2C(CH3)2, (CH2)4, 
(CH2)3, ½CH2C=, ½CH2CH=), 2.17-2.24 (m, 3H, ½CH2CH=, CH2CO), 2.68 (td, J=10.9, 4.6, 1H, 
CHCAr), 3.15 (q, J=6.8, 2H, CH2NBoc), 3.48 (d, J=17.2, 1H, ½CH2C=), 3.69 (d, J=13.2, 1H, 
½CH2NHU), 3.99 (dd, J=13.8, 7.3, 1H, ½CH2NHU), 4.68 (t, J=5.4, 1H, NH), 5.47 (br s, 1H, NH), 
5.68 (d, J=4.3, 1H, CH=), 6.32 (d, J=1.7, 1H, CHAr), 6.44 (m, 1H, CHAr), 7.80 (br s, 1H, OH); 
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13C-NMR (CDCl3, ): 14.2 (CH3CH2), 18.6 (CH3Ccyc), 22.8, 24.8, 25.5, 26.1 (4CH2), 27.8 
(CH3Ccyc), 28.0 (CH2CH=), 28.6 (C(CH3)3), 28.7, 29.0 (2CH3), 30.2 (2CH2), 31.7 (CHCAr), 31.8 
(CH2C=), 32.0 (CH2), 36.8 (CH2CO), 37.5 (ArC(CH3)2), 40.5 (CH2NBoc), 44.7 (CH2C(CH3)2), 
45.2 (CHC(CH3)2), 45.7 (CH2NHU), 76.4 (OC(CH3)2), 77.2 (C(CH3)3), 105.6, 107.0 (2CHAr), 
109.7 (CAr), 123.5 (CH=), 135.7 (C=), 150.0, 154.3, 156.1 (3CAr), 156.8 (NCOO), 172.9 
(CON); MS (ESI, m/z): 599.4 [M+H]+. 
(-)-6-Amino-N-{[(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methyl}hexanamide (25). Phenol 24 
(32 mg, 53 mol) was treated with a mixture of TFA/DCM 1:1 (0.1 mL) under an argon 
atmosphere, and the mixture was stirred at rt for 1 h. The solvent was evaporated under 
reduced pressure and the residue was redissolved in DCM, washed with saturated 
NaHCO3 (aq) and brine. The organic layer was dried (Na2SO4), filtered, and evaporated 
under reduced pressure to yield amine 25 (22 mg, 84), which was used in the next step 
without further purification. [α]D
20: -145.1 (c=0.46, chloroform). Rf: 0.10 (DCM/MeOH, 
95:5). 
 
IR (ATR, ): 3302 (NH, OH), 1646 (CO), 1568, 1449 (Ar); 1H-NMR (CDCl3, ): 0.84 (t, 
J=6.7, 3H, CH3CH2), 1.06-1.82 (m, 31H, CHC(CH3)2, CH2C(CH3)2, (CH2)4, (CH2)3, ½CH2C=, 
½CH2CH=), 2.08-2.21 (m, 2H, CH2CO), 2.31-2.37 (m, 1H, ½CH2CH=), 2.62 (td, J=10.8, 4.5, 
1H, CHCAr), 2.58-2.65 (m, 2H, CH2NH2), 3.54 (dd, J=14.0, 3.2, 1H, ½CH2NH), 3.60 (dd, 
J=17.7, 3.6, 1H, ½CH2C=), 4.19 (dd, J=13.9, 8.3, 1H, ½CH2NH), 5.42-5.45 (m, 1H, NH), 5.62 
(d, J=3.6, 1H, CH=), 6.12 (d, J=1.6, 1H, CHAr), 6.28 (d, J=1.5, 1H, CHAr); 
13C-NMR (CDCl3, ): 
14.2 (CH3CH2), 18.5 (CH3Ccyc), 22.8, 24.8, 25.6, 26.2 (4CH2), 27.7 (CH3Ccyc), 28.0 (CH2CH=), 
28.8, 29.0 (2CH3), 30.2, 31.2, 31.4 (3CH2), 31.7 (CHCAr), 32.0 (CH2C=), 36.5 (CH2CO), 37.3 
(ArC(CH3)2), 41.6 (CH2NH2), 44.7 (CH2C(CH3)2), 45.2 (CHC(CH3)2), 45.4 (CH2NH), 76.4 
(OC(CH3)2), 105.1, 106.3 (2CHAr), 110.2 (CAr), 123.2 (CH=), 136.3 (C=), 149.7, 154.3, 156.6 
(3CAr), 172.8 (CON); MS (ESI, m/z): 499.3 [M+H]
+. 
 
Experimental section 
 
122 
 
2-(6-Amino-3-imino-4,5-disulfo-3H-xanthen-9-yl)-5-({[6-({[3-(1,1-dimethylheptyl)-
1-hydroxy-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methyl}-
amino)-6-oxohexyl]amino}carbonyl)benzoic acid (22). To a solution of Alexa Fluor 488 
TFP ester (12.5 mg, 18 mol) in anhydrous DMF (0.2 mL) protected from light and under 
an argon atmosphere, a solution of amine 25 (11.7 mg, 23 mol) in dry DCM (0.26 mL) 
was added and the resulting mixture was stirred at rt for 30 min. The solvent was 
evaporated under reduced pressure and the crude was purified by chromatography 
(glass column, DCM to DCM/MeOH/ammonia, 1:1:0.02) to yield probe 22 (12 mg, 66%). 
 
HRMS (ESI, m/z): calcd for [M+H]+ C52H61N4O13S2: 1013.3688; found: 1013.3682. 
6.1.3. Synthesis of polar compounds 26-28 
 Synthesis of polar chains 29-31 
6-[(Aminocarbonyl)amino]hexanoic acid (29). Carboxylic acid 29 was obtained 
following the experimental procedure previously described by Huryn et al.147 
To a solution of 6-aminohexanoic acid (555 mg, 4.2 mmol) in water (9 mL) at rt and 
under an argon atmosphere, potassium cyanate (1.00 g, 12 mmol) was added 
portionwise for 10 min. The reaction mixture was stirred at 60 ºC for 3 h. The solution 
was then cooled to 0 ºC and acidified with 1 M HCl (aq) until pH 1. The obtained 
precipitate was filtered, washed with cold water, and dried under high vacuum to obtain 
29 (725 mg, 100%), which was used in the next step without further purification. Mp: 
175-178 ºC (lit.148 175-176 ºC). 
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IR (ATR, ): 3404, 3342, 3206 (NH, OH), 1707, 1656 (CO); 1H-NMR ((CD3)2SO, ): 1.18-
1.38 (m, 4H, 2CH2), 1.43-1.53 (qt, J=7.4, 2H, CH2), 2.19 (t, J=7.3, 2H, CH2CO), 2.92 (t, 
J=6.6, 2H, CH2N), 5.91 (br s, 1H, NH); 
13C-NMR ((CD3)2SO, ): 24.3, 26.0, 29.8 ((CH2)3), 
33.7 (CH2CO), 39.1 (CH2N), 158.7 (NCON), 174.5 (COO); MS (ESI, m/z): 175.1 [M+H]
+. 
6-{[(Acetylamino)carbonyl]amino}hexanoic acid (30). To a refluxing suspension of 
KOAc (41 mg, 0.42 mmol) in acetic anhydride (1.7 mL) under an argon atmosphere, urea 
29 was added (100 mg, 0.57 mmol). After stirring for 15 min under reflux, the reaction 
mixture was poured into ice and stirred for 30 min to remove the excess of acetic 
anhydride. Then, the solvent was evaporated under reduced pressure. Toluene was then 
added and further evaporated. The crude was purified by chromatography (DCM to 
MeOH) to obtain 30 (35 mg, 28%). Mp: 115-117 ºC. 
 
IR (ATR, ): 3318, 3235, 3118 (NH, OH), 1700, 1549 (CO); 1H-NMR (CD3OD, ): 1.33-
1.43 (m, 2H, CH2), 1.52-1.68 (m, 4H, 2CH2), 2.06 (s, 3H, CH3), 2.30 (t, J=7.4, 2H, CH2CO), 
3.25 (t, J=7.0, 2H, CH2N); 
13C-NMR (CD3OD, ): 23.6 (CH3), 25.7, 27.4, 30.4 ((CH2)3), 34.8 
(CH2CO), 40.3 (CH2N), 155.7 (NCON), 174.2 (CON), 177.4 (COO); MS (ESI, m/z): 217.1 
[M+H]+. 
Methyl 6-aminohexanoate (35). A solution of SOCl2 (1.0 mL, 15 mmol) in anhydrous 
MeOH (5 mL) under an argon atmosphere was stirred at 0 ºC for 10 min. Then, 6-
aminohexanoic acid (525 mg, 4.0 mmol) was added and the mixture was stirred at that 
temperature for 20 min. The solvent was evaporated under reduced pressure to yield 35 
(580 mg, 100%), which was used in the next step without further purification, mp: 93-96 
ºC (lit.149 80-85 ºC). Rf: 0.17 (DCM/MeOH, 85:15). 
 
IR (ATR, ): 1729 (CO); 1H-NMR (CD3OD, ): 1.37-1.47 (m, 2H, CH2), 1.62-1.71 (m, 4H, 
2CH2), 2.37 (t, J=7.3, 2H, CH2CO), 2.92 (t, J=7.6, 2H, CH2N), 3.66 (s, 3H, CH3); 
13C-NMR 
(CD3OD, ): 25.4, 27.0, 28.3 ((CH2)3), 34.5 (CH2CO), 41.1 (CH2N), 52.3 (CH3), 175.4 (CO); 
MS (ESI, m/z): 146.0 [M+H]+. 
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Methyl 6-{[N-(tert-butoxycarbonyl)--alanyl]amino}hexanoate (36). To a solution 
of N-(tert-butoxycarbonyl)--alanine (0.76 g, 4.0 mmol) in dry DCM at 0 ºC and under an 
argon atmosphere, EDC (1.0 g, 5.2 mmol) and HOBt (0.71 g, 5.2 mmol) were added, and 
the mixture was stirred at 0 ºC for 30 min. Then, amine 35 (0.64 g, 4.4 mmol) and 
triethylamine (2.8 mL, 20 mmol) were added and the resulting mixture was allowed to 
warm to rt and stirred for 8 h. The reaction was quenched with water and the organic 
layer was separated, dried (Na2SO4), filtered, and evaporated under reduced pressure. 
The residue was purified by chromatography (DCM to DCM/MeOH, 8:2) to afford 36 
(1.27 g, 100%). Rf: 0.21 (DCM/MeOH, 8:2). 
 
IR (ATR, ): 3316 (NH), 1707, 1649 (CO); 1H-NMR (CDCl3, ): 1.34-1.69 (m, 15H, 
(CH2)3, C(CH3)3), 2.31 (t, J=7.4, 2H, CH2COO), 2.38 (t, J=5.8, 2H, CH2CON), 3.25 (q app, 
J=6.6, 2H, CH2NCO), 3.36-3.42 (m, 2H, CH2NBoc), 3.66 (s, 3H, OCH3), 5.18 (br s, 1H, NH), 
5.80 (br s, 1H, NH); 13C-NMR (CDCl3, ): 24.5, 26.4 (2CH2), 28.5 (C(CH3)3) 29.3 (CH2), 34.0 
(CH2COO), 36.5, 36.8 (2CH2N), 39.3 (CH2CON), 51.7 (OCH3), 79.5 (C(CH3)3), 156.3 (NCOO), 
171.4 (CON), 174.2 (COO). 
Methyl 6-(-alanylamino)hexanoate (37). To a solution of 36 (512 mg, 1.6 mmol) in 
dry DCM (8 mL) under an argon atmosphere, TFA (2.5 mL, 32 mmol) was added 
dropwise and the reaction mixture was stirred at rt for 8 h. The solvent was evaporated 
under reduced pressure and the residue was redissolved in the minimum amount of 
DCM. Triethylamine was then added until basic pH was achieved and the solvent was 
evaporated under reduced pressure. The residue was purified by chromatography (DCM 
to DCM/MeOH, 8:2) to yield amine 37 (329 mg, 94%). Rf: 0.26 (DCM/MeOH, 85:15). 
 
IR (ATR, ): 3304, 3110 (NH), 1679 (CO); 1H-NMR (CDCl3, ): 1.32-1.35 (m, 2H, CH2), 
1.51 (qt, J=7.3, 2H, CH2), 1.60 (qt, J=7.5, 2H, CH2), 2.32 (t, J=7.2, 2H, CH2COO), 2.68 (t, 
J=6.4, 2H, CH2CON), 3.21 (q app, J=6.4, 2H, CH2NH), 3.31 (m, 2H, CH2NH2), 3.66 (s, 3H, 
CH3), 6.87 (br s, 1H, NH), 7.89 (br s, 2H, NH2); 
13C-NMR (CDCl3, ): 24.2, 26.1, 28.5 
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((CH2)3), 31.6 (CH2NH2), 33.8 (CH2COO), 36.8 (CH2NH), 39.6 (CH2CON), 51.8 (CH3), 171.4 
(CON), 174.9 (COO); MS (ESI, m/z): 217.1 [M+H]+. 
Methyl 6-{[N-(1H-tetrazol-5-ylacetyl)--alanyl]amino}hexanoate (38). To a solution 
of 1H-tetrazol-5-ylacetic acid (223 mg, 1.7 mmol), 37 (377 mg, 1.7 mmol) and 
triethylamine (0.5 mL, 3.5 mmol) in dry DCM (3.5 mL) at 10 ºC and under an argon 
atmosphere, BOP-Cl (444 mg, 1.7 mmol) was added and the reaction mixture was stirred 
at rt for 1 h. The reaction was quenched with water and 2 M HCl (aq) was added until pH 
1-2. The obtained precipitate was filtered and washed with DCM to obtain 38 (254 mg, 
57%), which was used in the next step without further purification. Rf: 0.29 
(DCM/MeOH/ammonia, 8:2:0.3). 
 
1H-NMR (CD3OD/(CD3)2CO, 9:1, ): 1.26-1.39 (m, 2H, CH2), 1.50 (qt, J=7.2, 2H, CH2), 
1.60 (qt, J=7.5, 2H, CH2), 2.33 (t, J=7.4, 2H, CH2COO), 2.41 (t, J=6.7, 2H, CH2CON), 3.17 (t, 
J=7.0, 2H, CH2N), 3.48 (t, J=6.7, 2H, CH2N), 3.65 (s, 3H, CH3), 3.95 (s, 2H, CH2CN). 
6-{[N-(1H-Tetrazol-5-ylacetyl)--alanyl]amino}hexanoic acid (31). To a solution of 
methyl ester 38 (224 mg, 0.69 mmol) in MeOH (2.5 mL) under an argon atmosphere, 1 
M NaOH (aq, 2.1 mL, 2.1 mmol) was added and the mixture was stirred at rt for 3 h. The 
solvent was evaporated under reduced pressure and the residue was acidified with 1 M 
HCl (aq) until an acid pH was achieved. The obtained precipitate was isolated by 
filtration and washed with water to afford acid 31 (214 mg, 100%), which was used in 
the next step without further purification. Mp: 190-193 ºC. Rf: 0.28 (DCM/MeOH, 1:1). 
 
IR (ATR, ): 3314 (NH), 2143 (NN), 1729, 1644, 1551 (CO); 1H-NMR ((CD3)2SO, ): 
1.19-1.29 (m, 2H, CH2), 1.38 (qt, J=7.2, 2H, CH2), 1.48 (qt, J=7.4, 2H, CH2), 2.19 (t, J=7.5, 
2H, CH2COO), 2.24 (t, J=7.0, 2H, CH2CON), 3.02 (q app, J=6.3, 2H, CH2N), 3.27 (q app, 
J=6.5, 2H, CH2N), 3.85 (s, 2H, CH2CN), 4.05 (br s, 1H, NH), 7.85 (t, J=5.4, 1H, NH), 8.37 (t, 
J=5.5, 1H, NH); 13C-NMR ((CD3)2SO, ): 24.2, 26.0, 28.8 ((CH2)3), 30.4 (CH2N), 33.6, 35.1 
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(CH2CN, CH2COO), 35.6 (CH2N), 38.3 (CH2CON), 154.2 (CN), 166.0, 169.9 (2CON), 174.4 
(COO); MS (ESI, m/z): 313.1 [M+H]+. 
General procedure for the synthesis of intermediates 32-34. To a suspension of the 
corresponding carboxylic acid (1-2 equiv), HOBt (1.2-2.2 equiv), and activated 4 Å 
molecular sieves in anhydrous DMF (11 mL/mmol of acid) under an argon armosphere, a 
solution of EDC (1.2-2.2 equiv) in dry DCM (18 mL/mmol of acid) was added dropwise 
and the mixture was stirred at rt for 3 h. Then, a solution of the corresponding amine (1 
equiv) and DMAP (0.2 equiv) in dry DCM (46 mL/mmol of amine) was added and the 
reaction was stirred at rt for 16 h. The mixture was filtered, diluted with DCM, washed 
with saturated NaHCO3 (aq) and brine. The organic layer was dried (Na2SO4), filtered, 
and evaporated under reduced pressure. The crude was purified by chromatography 
using the appropriate eluent to afford the corresponding amide. 
(-)-6-[(Aminocarbonyl)amino]-N-({(6aR,10aR)-3-(1,1-dimethylheptyl)-6,6-dimethyl-
1-[(triisopropylsilyl)oxy]-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methyl)-
hexanamide (32). Obtained from acid 29 (68 mg, 0.28 mmol) and amine 11 (146 mg, 
0.27 mmol) in 75% yield (141 mg). Chromatography: DCM to DCM/MeOH, 95:5. Mp: 86-
88 ºC. [α]D
20: -120.2 (c=1.03, chloroform). Rf: 0.20 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 3312 (NH), 1647, 1610 (CO), 1564, 1463 (Ar); 1H-NMR (CDCl3, ): 0.83 (t, 
J=7.2, 3H, CH3CH2), 1.05-1.37 (m, 43H, 3CH(CH3)2, 2CH3Ccyc, 2CH3, (CH2)4, CH2), 1.46-1.54 
(m, 4H, CH2C(CH3)2, CH2), 1.59-1.69 (m, 2H, CH2), 1.74-1.88 (m, 3H, ½CH2C=, ½CH2CH=, 
CHC(CH3)2), 2.16-2.21 (m, 3H, ½CH2CH=, CH2CO), 2.62 (td, J=10.7, 4.1, 1H, CHCAr), 3.15 
(m, 2H, CH2NCON), 3.28 (dd, J=16.1, 3.6, 1H, ½CH2C=), 3.71-3.85 (m, 2H, CH2NHU), 5.10 
(br s, 1H, NH), 5.59 (d, J=4.2, 1H, CH=), 5.64 (t, J=5.4, 1H, NH), 6.34 (d, J=1.4, 1H, CHAr), 
6.38 (d, J=1.4, 1H, CHAr); 
13C-NMR (CDCl3, ): 13.3 (3CHSi), 14.2 (CH3CH2), 18.22 
(3CH(CH3)2), 18.25 (CH3Ccyc), 22.8, 24.8, 25.3, 26.5 (4CH2), 27.6 (CH3Ccyc), 27.9 (CH2CH=), 
28.8, 29.2 (2CH3), 29.8, 30.2, 32.0 (3CH2), 32.1 (CHCAr), 33.3 (CH2C=), 36.5 (CH2CO), 37.5 
(ArC(CH3)2), 40.2 (CH2NCON), 44.8 (CH2C(CH3)2), 45.1 (CH2NHU), 45.5 (CHC(CH3)2), 76.4 
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(OC(CH3)2), 108.3, 109.1 (2CHAr), 113.2 (CAr), 121.1 (CH=), 135.2 (C=), 149.5, 154.2, 155.1 
(3CAr), 159.4 (NCON), 173.2 (CON); MS (ESI): 696.5 [M-H]
-. 
(-)-6-{[(Acetylamino)carbonyl]amino}-N-({(6aR,10aR)-3-(1,1-dimethylheptyl)-6,6-
dimethyl-1-[(triisopropylsilyl)oxy]-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-
yl}methyl)hexanamide (33). Obtained from acid 30 (35 mg, 0.16 mmol) and amine 11 
(87 mg, 0.16 mmol) in 51% yield (60 mg). Chromatography: DCM to DCM/MeOH, 95:5. 
[α]D
20: -101.9 (c=0.97, chloroform). Rf: 0.42 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 3306, 3104 (NH), 1696, 1649 (CO), 1560, 1463 (Ar);1H-NMR (CDCl3, ): 
0.83 (t, J=6.8, 3H, CH3CH2), 1.04-1.41 (m, 43H, 3CH(CH3)2, 2CH3Ccyc, 2CH3, (CH2)4, CH2), 
1.45-1.51 (m, 2H, CH2C(CH3)2), 1.53-1.71 (m, 4H, 2CH2), 1.74-1.85 (m, 3H, ½CH2C=, 
½CH2CH=, CHC(CH3)2), 2.10 (s, 3H, CH3CO), 2.15-2.20 (m, 3H, ½CH2CH=, CH2CO), 2.62 (td, 
J=10.7, 4.3, 1H, CHCAr), 3.23-3.29 (m, 3H, CH2NCON, ½CH2C=), 3.78 (d, J=5.0, 2H, 
CH2NHU), 5.47 (t, J=5.2, 1H, NH), 5.58 (d, J=3.7, 1H, CH=), 6.32 (d, J=1.4, 1H, CHAr), 6.37 (d, 
J=1.4, 1H, CHAr), 8.46 (t, J=5.3, 1H, NH), 9.80 (br s, 1H, NH); 
13C-NMR (CDCl3, ): 13.3 
(3CHSi), 14.2 (CH3CH2), 18.22 (3CH(CH3)2), 18.25 (CH3Ccyc), 22.8 (CH2), 24.1 (CH3CO), 24.8, 
25.4, 26.7 (3CH2), 27.6 (CH3Ccyc), 27.9 (CH2CH=), 28.8, 29.1 (2CH3), 29.4, 30.2, 32.0 
(3CH2), 32.1 (CHCAr), 33.3 (CH2C=), 36.7 (CH2CO), 37.5 (ArC(CH3)2), 39.5 (CH2NCON), 44.8 
(CH2C(CH3)2), 45.0 (CH2NHU), 45.5 (CHC(CH3)2), 76.3 (OC(CH3)2), 108.3, 109.0 (2CHAr), 
113.2 (CAr), 121.1 (CH=), 135.3 (C=), 149.4, 154.3 (2CAr), 154.7 (NCON), 155.1 (CAr), 172.5, 
172.6 (2CON); MS (ESI, m/z): 738.5 [M-H]-. 
(-)-N-({(6aR,10aR)-3-(1,1-Dimethylheptyl)-6,6-dimethyl-1-[(triisopropylsilyl)oxy]-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}methyl)-6-{[N-(1H-tetrazol-5-
ylacetyl)--alanyl]amino}hexanamide (34). Obtained from acid 31 (28 mg, 89 mol) and 
amine 11 (24 mg, 44 mol) in 49% yield (16 mg). Chromatography: DCM to DCM/MeOH, 
8:2. Mp: 86-87 ºC. [α]D
20: -20.0 (c=0.11, chloroform). Rf: 0.35 (DCM/MeOH, 8:2). 
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IR (ATR, ): 3286 (NH), 1647, 1561 (CO), 1464 (Ar); 1H-NMR (CD3OD, ): 0.86 (t, J=6.8, 
3H, CH3CH2), 1.06-1.64 (m, 49H, 3CH(CH3)2, 2CH3Ccyc, CH2C(CH3)2, (CH2)4, (CH2)3), 1.73-
1.88 (m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.16-2.23 (m, 3H, ½CH2CH=, CH2CO), 2.39 (t, 
J=6.8, 2H, CH2CO), 2.66 (td, J=10.9, 4.3, 1H, CHCAr), 3.14 (t, J=6.9, 2H, CH2N), 3.32-3.38 
(m, 1H, ½CH2C=), 3.45 (t, J=6.6, 2H, CH2N), 3.67 (d, J=15.4, 1H, ½CH2NHU), 3.80 (d, J=14.7, 
1H, ½CH2NHU), 3.90 (m, 2H, CH2CN), 5.61 (m, 1H, CH=), 6.34-6.35 (m, 2H, 2CHAr); 
13C-NMR 
(CDCl3, ): 13.3 (3CHSi), 14.3 (CH3CH2), 18.2 (3CH(CH3)2), 18.3 (CH3Ccyc), 22.8, 24.9, 25.2, 
26.2 (4CH2), 27.6 (CH3Ccyc), 27.9 (CH2CH=), 28.83 (CH3), 28.85 (CH2), 29.2 (CH3), 29.8, 30.2 
(2CH2), 32.0 (CH2CN), 32.1 (CHCAr), 33.3 (CH2CN), 35.8, 36.3 (2CH2CO), 36.6 (CH2N), 37.6 
(ArC(CH3)2), 39.2 (CH2N), 44.8 (CH2C(CH3)2), 45.46 (CH2NHU), 45.51 (CHC(CH3)2), 76.4 
(OC(CH3)2), 108.4, 109.1 (2CHAr), 113.2 (CAr), 121.8 (CH=), 134.7 (C=), 149.6 (CAr), 154.3 
(CAr, CN), 155.4 (CAr), 171.6, 171.8, 174.1 (3CON); MS (ESI, m/z): 834.6 [M-H]
-. 
 Synthesis of final compounds 26-28 
(-)-6-[(Aminocarbonyl)amino]-N-{[(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-
6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methyl}hexanamide 
(26). Following the general procedure 6.1.1.1, phenol 26 was obtained from amide 32 
(110 mg, 0.16 mmol) in 93% yield (81 mg). Chromatography: DCM to DCM/MeOH, 8:2. 
Mp: 104-106 ºC. [α]D
20: -121.4 (c=0.63, MeOH). Rf: 0.10 (DCM/MeOH, 97:3). 
 
IR (ATR, ): 3330 (NH, OH), 1648 (CO), 1568, 1457 (Ar); 1H-NMR (CD3OD, ): 0.86 (t, 
J=6.7, 3H, CH3CH2), 1.01-1.41 (m, 22H, 2CH3Ccyc, 2CH3, (CH2)4, CH2), 1.45-1.55 (m, 4H, 
CH2C(CH3)2, CH2), 1.60-1.92 (m, 5H, CH2, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.20-2.25 (m, 
3H, ½CH2CH=, CH2CO), 2.64 (td, J=11.0, 4.4, 1H, CHCAr), 3.08 (t, J=7.0, 2H, CH2NCON), 
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3.40 (dd, J=17.9, 4.1, 1H, ½CH2C=), 3.68-3.79 (m, 2H, CH2NHU), 5.63 (d, J=3.2, 1H, CH=), 
6.22 (d, J=1.6, 1H, CHAr), 6.34 (d, J=1.8, 1H, CHAr); 
13C-NMR (CD3OD, ): 14.4 (CH3CH2), 
18.6 (CH3Ccyc), 23.6, 25.8, 26.8, 27.5 (4CH2), 28.0 (CH3Ccyc), 28.8 (CH2CH=), 29.4, 29.5 
(2CH3), 30.9, 31.1, 32.9 (3CH2), 33.0 (CHCAr), 33.7 (CH2C=), 37.0 (CH2CO), 38.2 (ArC(CH3)2), 
40.9 (CH2NCON), 45.5 (CH2C(CH3)2), 46.0 (CH2NHU), 46.8 (CHC(CH3)2), 77.3 (OC(CH3)2), 
106.4, 107.6 (2CHAr), 111.2 (CAr), 122.2 (CH=), 136.6 (C=), 150.6, 155.5, 157.6 (3CAr), 
162.3 (NCON), 176.1 (CON); HRMS (MALDI, m/z): calcd for [M+H]+ C32H52N3O4: 542.3958; 
found: 542.3945; HPLC-MS (ESI, m/z): 542.3 [M+H]+; tR (method A): 18.50 min. 
(-)-6-{[(Acetylamino)carbonyl]amino}-N-{[(6aR,10aR)-3-(1,1-dimethylheptyl)-1-
hydroxy-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methyl}-
hexanamide (27). Following the general procedure 6.1.1.1, phenol 27 was obtained 
from amide 33 (46 mg, 62 mol) in 89% yield (32 mg). Chromatography: DCM to 
DCM/MeOH, 98:2. Mp: 97-99 ºC. [α]D
20: -132.9 (c=0.55, MeOH). Rf: 0.20 (DCM/MeOH, 
97:3). 
 
IR (ATR, ): 3291 (NH), 1695, 1651 (CO), 1552, 1462 (Ar); 1H-NMR (CD3OD, ): 0.86 (t, 
J=6.7, 3H, CH3CH2), 1.08-1.42 (m, 22H, 2CH3Ccyc, 2CH3, (CH2)4, CH2), 1.49-1.88 (m, 9H, 
CH2C(CH3)2, 2CH2, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.05 (s, 3H, CH3CO), 2.20-2.25 (m, 3H, 
½CH2CH=, CH2CO), 2.64 (td, J=11.0, 4.5, 1H, CHCAr), 3.23 (t, J=6.9, 2H, CH2NCON), 3.40 
(dd, J=17.8, 3.2, 1H, ½CH2C=), 3.68-3.79 (m, 2H, CH2NHU), 5.62 (m, 1H, CH=), 6.22 (d, 
J=1.6, 1H, CHAr), 6.32 (d, J=1.7, 1H, CHAr); 
13C-NMR (CD3OD, ): 14.4 (CH3CH2), 18.6 
(CH3Ccyc), 23.61 (CH3CO), 23.64, 25.8, 26.7, 27.5 (4CH2), 28.0 (CH3Ccyc), 28.8 (CH2CH=), 
29.4, 29.5 (2CH3), 30.4, 31.1, 32.9 (3CH2), 33.0 (CHCAr), 33.7 (CH2C=), 37.0 (CH2CO), 38.2 
(ArC(CH3)2), 40.3 (CH2NCON), 45.5 (CH2C(CH3)2), 46.0 (CH2NHU), 46.8 (CHC(CH3)2), 77.3 
(OC(CH3)2), 106.3, 107.6 (2CHAr), 111.2 (CAr), 122.2 (CH=), 136.7 (C=), 150.6, 155.5 (2CAr), 
155.7 (NCON), 157.6 (CAr), 174.2, 176.0 (2CON); HRMS (MALDI, m/z): calcd for [M+H]
+ 
C34H54N3O5: 584.4063; found: 584.4079; HPLC-MS (ESI, m/z): 584.3 [M+H]
+; tR (method 
A): 13.10 min. 
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(-)-N-{[(6aR,10aR)-3-(1,1-Dimethylheptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-9-yl]methyl}-6-{[N-(1H-tetrazol-5-ylacetyl)--alanyl]-
amino}hexanamide (28). Following the general procedure 6.1.1.1, phenol 28 was 
obtained from amide 34 (58 mg, 69 mol) in 32% yield (15 mg). Chromatography: DCM 
to DCM/MeOH, 8:2. Mp: 140-143 ºC. [α]D
20: -78.2 (c=0.22, MeOH). Rf: 0.38 (DCM/MeOH, 
8:2). 
 
IR (ATR, ): 3289, 3083 (NH, OH), 1647, 1560 (CO), 1457 (Ar); 1H-NMR (500 MHz, 
CD3OD/CDCl3 9:1, ): 0.85 (t, J=6.9, 3H, CH3CH2), 1.08 (s, 3H, CH3Ccyc), 1.19-1.37 (m, 19H, 
CH3Ccyc, 2CH3, (CH2)4, CH2), 1.42-1.53 (m, 4H, CH2C(CH3)2, CH2), 1.59-1.65 (m, 2H, CH2), 
1.70-1.90 (m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.19-2.22 (m, 3H, ½CH2CH=, CH2CO), 
2.40 (m, 2H, CH2CO), 2.64 (td, J=10.7, 4.3, 1H, CHCAr), 3.14 (app t, J=6.9, 2H, CH2N), 3.37-
3.42 (m, 1H, ½CH2C=), 3.50 (m, 2H, CH2N), 3.70 (d, J=15.9, 1H, ½CH2NHU), 3.76 (d, J=15.8, 
1H, ½CH2NHU), 3.84 (m, 2H, CH2CN), 5.61 (m, 1H, CH=), 6.23 (d, J=1.5, 1H, CHAr), 6.34 (d, 
J=1.4, 1H, CHAr); 
13C-NMR (125 MHz, CD3OD/CDCl3 9:1, ): 14.4 (CH3CH2), 18.6 (CH3Ccyc), 
23.6, 25.7, 26.6, 27.4 (4CH2), 28.0 (CH3Ccyc), 28.7 (CH2CH=), 29.4 (2CH3), 29.9, 30.7, 31.1 
(3CH2), 32.8 (CH2CN), 32.9 (CHCAr), 33.6 (CH2C=), 36.7, 36.9 (2CH2CO), 37.3 (CH2N), 38.1 
(ArC(CH3)2), 40.2 (CH2N), 45.5 (CH2C(CH3)2), 45.9 (CH2NHU), 46.7 (CHC(CH3)2), 77.3 
(OC(CH3)2), 106.3, 107.5 (2CHAr), 111.1 (CAr), 122.1 (CH=), 136.5 (C=), 150.5 (CAr), 155.4 
(CAr, CN), 157.5 (CAr), 173.4, 173.7, 176.0 (3CON); HRMS (MALDI, m/z): calcd for [M+H]
+ 
C37H58N7O5: 680.4499; found: 680.4470; HPLC-MS (ESI, m/z): 680.4 [M+H]
+; tR (method 
A): 15.20 min. 
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6.1.4. Synthesis of probes 39-41, and 54 
(-)-(6aR,10aR)-3-(1,1-Dimethylheptyl)-9-(hydroxymethyl)-6,6-dimethyl-
6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol (HU210, 42). Phenol 42 was obtained 
following the experimental procedure previously described by Mechoulam et al.84  
A solution of pivaloyl ester 8 (611 mg, 1.3 mmol)in anhydrous THF (25 mL) was 
added dropwise to a suspension of LiAlH4 (198 mg, 5.4 mmol) in anhydrous THF (25 mL) 
at 0 ºC and under an argon atmosphere. The reaction was stirred at that temperature for 
2 h and allowed to warm to rt. The mixture was then carefully quenched with water and 
extracted with Et2O (2x). The organic extracts were washed with brine, dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
chromatography (hexane to hexane/EtOAc, 9:1) to yield alcohol 42 (400 mg, 100%). Mp: 
120-123 ºC. [α]D
20: -16.7 (c=1.0, EtOH). Rf: 0.15 (hexane/EtOAc, 7:3). 
 
1H-NMR (CDCl3, ): 0.87 (t, J=6.8, 3H, CH3CH2), 1.15 (s, 3H, CH3Ccyc), 1.21-1.25 (m, 8H, 
(CH2)4), 1.28 (s, 6H, 2CH3), 1.42 (s, 3H, CH3Ccyc), 1.47-1.52 (m, 2H, CH2C(CH3)2), 1.82-1.98 
(m, 3H, ½CH2C=, ½CH2CH=, CHC(CH3)2), 2.19-2.27 (m, 1H, ½CH2CH=), 2.75 (td, J=11.0, 6.1, 
1H, CHCAr), 3.40 (dd, J=15.7, 4.5, 1H, ½CH2C=), 4.09 (AB system, J=13.0, 2H, CH2O), 4.70 
(br s, 2H, 2OH), 5.77 (d, J=5.1, 1H, CH=), 6.25 (d, J=1.7, 1H, CHAr), 6.42 (d, J=1.7, 1H, 
CHAr). 
 Synthesis of amine 43 
(+)-[(1S,5R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl]methanol (44). Alcohol 44 
was obtained following the experimental procedure previously described by Harwood et 
al.150 The spectroscopic data correspond with those reported.151 
A solution of (+)--pinene (13.00 g, 95 mmol) in dry DCM (50 mL) was stirred at rt 
with SeO2 (5.29 g, 48 mmol) and t-butylhydroperoxide (24 mL, 80%, 191 mmol) for 24 h. 
The mixture was washed with 10% KOH (aq, 4x). The organic phase was dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was dissolved in  Et2O (100 
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mL) and LiAlH4 (3.80 g, 100 mmol) was added portionwise to the stirred solution at 0 ºC 
and under an argon atmosphere. After 4 h, the excess of hydride was carefully 
destroyed with water and the organic phase was separated, dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The residue was purified by chromatography 
(hexane/EtOAc, 9:1) to give alcohol 44 (7.86 g, 54%). []D
20: +35.0 (c=3.2, EtOH), lit.150 
+44.3 (c=3.2, chloroform). Rf: 0.56 (hexane/EtOAc, 7:3). 
 
1H-NMR (CDCl3, ): 0.82 (s, 3H, CH3), 1.17 (d, J=8.6, 1H, ½CH2cyc), 1.28 (s, 3H, CH3), 
2.07-2.20 (m, 2H, 2CH), 2.24-2.28 (m, 2H, CH2CH=), 2.39 (dt, J=8.6, 5.5, 1H, ½CH2cyc), 3.96 
(dd, J=3.4, 1.7, 2H, CH2O), 5.45-5.49 (m, 1H, CH=). 
(+)-[(1S,5R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl pivalate [(+)-4)]. 
Pivaloyl ester (+)-4 was prepared from alcohol 44 (7.80 g, 51 mmol), following the 
procedure described for (-)-4 in 100% yield (12.12 g). []D
20: +26.8 (c=3.8, EtOH). 
 
The spectroscopic data of (+)-4 were identical to those obtained for (-)-4. 
(+)-[(1S,5R)-6,6-Dimethyl-4-oxobicyclo[3.1.1]hept-2-en-2-yl]methyl pivalate       
[(+)-5)]. Ketone (+)-5 was prepared from compound (+)-4 (12.11 g, 51 mmol), following 
the procedure described for (-)-5 in 40% yield (5.10 g). []D
20: +135.3 (c=1.8, EtOH). 
 
The spectroscopic data of (+)-5 were identical to those obtained for (-)-5. 
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(+)-[(1S,5R)-4-Hydroxy-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl pivalate 
[(+)-6)]. Alcohol (+)-6 was prepared from ketone (+)-5 (4.41 g, 18 mmol), following the 
procedure described for (-)-6 in 63% yield (2.80 g). []D
20: +10.0 (c=2.0, EtOH). 
 
The spectroscopic data of (+)-6 were identical to those obtained for (-)-6. 
(+)-{(1S,4S,5S)-4-[4-(1,1-Dimethylheptyl)-2,6-dihydroxyphenyl]-6,6-dimethyl-
bicyclo[3.1.1]hept-2-en-2-yl}methyl pivalate (45). To a solution of resorcinol 7 (1.64 g, 
7.0 mmol) and anhydrous p-TSA (383 mg, 2.2 mmol) in dry DCM (255 mL) at 0 ºC and 
under an argon atmosphere, a solution of alcohol (+)-6 in dry DCM (50 mL) was added 
over a period of 30 min. The reaction was stirred at rt for 1 h and then washed with 
saturated NaHCO3 (aq). The aqueous layer was extracted with DCM and the combined 
organic extracts were dried (Na2SO4), filtered, and evaporated under reduced pressure. 
The residue was purified by chromatography (hexane to hexane/EtOAc, 9:1) to give 
resorcinol 45 (2.69 g, 82%). []D
20: +66.5 (c=0.75, EtOH). Rf: 0.11 (hexane/DCM, 1:1). 
 
IR (ATR, ): 3402 (OH), 1730 (CO), 1546, 1454 (Ar); 1H-NMR (CDCl3, ): 0.86 (t, J=6.6, 
3H, CH3CH2), 0.99 (s, 3H, CH3Ccyc), 1.05-1.29 (m, 23H, 2CH3, C(CH3)3, (CH2)4), 1.35 (s, 3H, 
CH3Ccyc), 1.48-1.53 (m, 3H, CH2C(CH3)2, ½CH2cyc), 2.30-2.42 (m, 3H, CHCHCAr, CHC=, 
½CH2cyc), 4.01 (m, 1H, CHCAr), 4.58 (AB system, J=13.5, 2H, CH2O), 5.70 (br s, 2H, 2OH), 
6.01-6.02 (m, 1H, CH=), 6.35 (s, 2H, 2CHAr); 
13C-NMR (CDCl3, ): 14.1 (CH3CH2), 20.8 
(CH3Ccyc), 22.7, 24.7 (2CH2), 25.9 (CH3Ccyc), 27.3 (C(CH3)3), 28.1 (CH2cyc), 28.7 (2CH3), 30.1, 
31.8 (2CH2), 37.4 (CHCAr), 37.8 (ArC(CH3)2), 39.0 (C(CH3)3), 40.9 (Ccyc(CH3)2), 44.1 (CHC=), 
44.4 (CH2C(CH3)2), 47.3 (CHCHCAr), 66.4 (CH2O), 106.4 (2CHAr), 111.5 (CAr), 120.2 (CH=), 
149.5 (CAr, C=), 150.6, 154.9 (2CAr), 178.5 (CO). 
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(+)-{(1S,4S,5S)-4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-
bicyclo[3.1.1]hept-2-en-2-yl}methyl pivalate (46). To a solution of 45 (2.90 g, 6.2 mmol) 
in anhydrous DMF (55 mL) under an argon atmosphere, NaH (60% in mineral oil, 542 
mg, 14 mmol) was added portionwise. Iodomethane (2.21 g, 15 mmol) was then added 
dropwise and the reaction was stirred at rt for 3 h. The mixture was poured into water 
and extracted with Et2O (4x). The combined organic extracts were separated, washed 
with water, dried (Na2SO4), filtered, and evaporated under reduced pressure. The 
residue was purified by chromatography (hexane/EtOAc, 8:2) to give the title compound 
46 (2.49 g, 81%). []D
20: +78.7 (c=0.7, EtOH). Rf: 0.28 (hexane/DCM, 1:1). 
 
IR (ATR, ): 1730 (CO), 1556, 1460 (Ar); 1H-NMR (CDCl3, ): 0.86 (t, J=6.6, 3H, 
CH3CH2), 0.98 (s, 3H, CH3Ccyc), 1.10-1.23 (m, 17H, C(CH3)3, (CH2)4), 1.28 (s, 6H, 2CH3), 1.30 
(s, 3H, CH3Ccyc), 1.54-1.60 (m, 2H, CH2C(CH3)2), 1.73 (d, J=7.9, 1H, ½CH2cyc), 2.05-2.08 (m, 
1H, CHCHCAr), 2.16-2.20 (m, 2H, CHC=, ½CH2cyc), 3.75 (s, 6H, 2CH3O), 4.00 (m, 1H, CHCAr), 
4.55 (AB system, J=13.5, 2H, CH2O), 5.79 (m, 1H, CH=), 6.49 (s, 2H, 2CHAr); 
13C-NMR 
(CDCl3, ): 14.1 (CH3CH2), 20.1 (CH3Ccyc), 22.7, 24.7 (2CH2), 26.3 (CH3Ccyc), 27.3 (C(CH3)3), 
27.6 (CH2cyc), 28.9, 29.0 (2CH3), 30.1, 31.8 (2CH2), 37.6 (CHCAr), 38.0 (ArC(CH3)2), 39.0 
(C(CH3)3), 40.9 (Ccyc(CH3)2), 43.8 (CHC=), 44.6 (CH2C(CH3)2), 47.4 (CHCHCAr), 55.7 (2CH3O), 
67.5 (CH2O), 102.7 (2CHAr), 117.5 (CAr), 126.4 (CH=), 137.2 (C=), 149.5 (CAr), 158.4 (2CAr), 
178.5 (CO). 
(+)-{(1S,4S,5S)-4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-
bicyclo[3.1.1]hept-2-en-2-yl}methanol (47). To a suspension of LiAlH4 (171 mg, 4.5 
mmol) in anhydrous Et2O (12 mL) under an argon atmosphere, a solution of pivaloyl 
ester 46 (900 mg, 1.8 mmol) in anhydrous Et2O (20 mL) was added dropwise. The 
mixture was refluxed for 3 h. The reaction was carefully quenched with water. The 
organic layer was separated, dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by chromatography (hexane to hexane/EtOAc, 8:2) to 
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give alcohol 47 (346 mg, 45%). []D
20: +95.0 (c=0.5, EtOH); lit.31 +127.0 (c=0.3, 
chloroform). Rf: 0.13 (hexane/DCM, 1:9). 
 
1H-NMR (CDCl3, ): 0.86 (t, J=6.7, 3H, CH3CH2), 0.98 (s, 3H, CH3Ccyc), 1.10-1.28 (m, 
14H, 2CH3, (CH2)4), 1.32 (s, 3H, CH3Ccyc), 1.54-1.60 (m, 2H, CH2C(CH3)2), 1.72 (d, J=7.8, 1H, 
½CH2cyc), 2.06-2.10 (m, 1H, CHCHCAr), 2.17-2.24 (m, 2H, CHC=, ½CH2cyc), 3.75 (s, 6H, 
2CH3O), 4.01 (m, 1H, CHCAr), 4.01-4.09 (m, 2H, CH2O), 5.71 (m, 1H, CH=), 6.49 (s, 2H, 
2CHAr); 
13C-NMR (CDCl3, ): 14.1 (CH3CH2), 21.1 (CH3Ccyc), 22.7, 24.7 (2CH2), 26.3 (CH3Ccyc), 
27.9 (CH2cyc), 28.9, 29.0 (2CH3), 30.1, 31.8 (2CH2), 37.5 (CHCAr), 38.0 (ArC(CH3)2), 40.8 
(Ccyc(CH3)2), 43.8 (CHC=), 44.6 (CH2C(CH3)2), 47.4 (CHCHCAr), 55.8 (2CH3O), 66.7 (CH2O), 
102.7 (2CHAr), 117.6 (CAr), 123.8 (CH=), 141.5, 141.9 (CAr, C=), 158.4 (2CAr). 
(+)-2-({(1S,4S,5S)-4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-
bicyclo[3.1.1]hept-2-en-2-yl}methyl)-1H-isoindole-1,3(2H)-dione (48). Phthalimide 48 
was prepared from alcohol 47 (307 mg, 0.74 mmol), following the procedure described 
for 10, in 47% yield (189 mg). Chromatography: hexane to hexane/EtOAc, 8:2. []D
20: 
+62.2 (c=1.27, chloroform). Rf: 0.30 (hexane/EtOAc, 8:2). 
 
IR (ATR, ): 1773 (CO), 1606, 1572, 1460 (Ar); 1H-NMR (CDCl3, ): 0.85 (t, J=6.7, 3H, 
CH3CH2), 0.96 (s, 3H, CH3Ccyc), 1.21-1.28 (m, 17H, CH3Ccyc, 2CH3, (CH2)4), 1.53-1.59 (m, 2H, 
CH2C(CH3)2), 1.76 (d, J=7.7, 1H, ½CH2cyc), 2.00-2.06 (m, 1H, CHCHCAr), 2.13-2.21 (m, 2H, 
CHC=, ½CH2cyc), 3.74 (s, 6H, 2CH3O), 3.97 (m, 1H, CHCAr), 4.29 (AB system, J=15.4, 2H, 
CH2N), 5.58 (m, 1H, CH=), 6.46 (s, 2H, 2CHHU), 7.69-7.71 (m, 2H, 2CHPhth), 7.84-7.87 (m, 
2H, 2CHPhth); 
13C-NMR (CDCl3, ): 14.2 (CH3CH2), 20.9 (CH3Ccyc), 22.8, 24.7 (2CH2), 26.4 
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(CH3Ccyc), 27.6 (CH2cyc), 29.0 (2CH3), 30.1, 31.8 (2CH2), 37.4 (CHCAr), 38.0 (ArC(CH3)2), 41.1 
(Ccyc(CH3)2), 42.5 (CH2N), 44.2 (CHC=), 44.6 (CH2C(CH3)2), 47.5 (CHCHCAr), 55.7 (2CH3O), 
102.5 (2CHHU), 117.4 (CHU), 123.2 (2CHPhth), 123.6 (CH=), 132.3 (2CPhth), 133.8 (2CHPhth), 
135.9 (C=), 149.4 (CHU), 158.5 (2CHU), 168.2 (2CO); MS (ESI, m/z): 566.4 [M+Na]
+. 
(+)-{(1S,4S,5S)-4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-
bicyclo[3.1.1]hept-2-en-2-yl}methylamine (43). Amine 43 was prepared from 
phtalimide 48 (84 mg, 0.15 mmol), following the procedure described for 11 in 80% yield 
(50 mg). This compound was used in the next step without further purification.  []D
20: 
+86.0 (c=1.04, chloroform). Rf: 0.21 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 2926 (NH2), 1605, 1571, 1459 (Ar); 
1H-NMR (CDCl3, ): 0.85 (t, J=6.6, 3H, 
CH3CH2), 0.96 (s, 3H, CH3Ccyc), 1.06-1.27 (m, 14H, 2CH3, (CH2)4), 1.30 (s, 3H, CH3Ccyc), 1.54-
1.59 (m, 2H, CH2C(CH3)2), 1.72 (d, J=8.2, 1H, ½CH2cyc), 1.72 (br s, 2H, NH2), 2.05-2.22 (m, 
3H, CHCHCAr, CHC=, ½CH2cyc), 3.23 (m, 2H, CH2N), 3.74 (s, 6H, 2CH3O), 3.99 (m, 1H, 
CHCAr), 5.55 (m, 1H, CH=), 6.49 (s, 2H, 2CHAr); 
13C-NMR (CDCl3, ): 14.2 (CH3CH2), 21.2 
(CH3Ccyc), 22.8, 24.7 (2CH2), 26.4 (CH3Ccyc), 28.1 (CH2cyc), 29.0 (2CH3), 30.1, 31.8 (2CH2), 
37.5 (CHCAr), 38.0 (ArC(CH3)2), 40.9 (Ccyc(CH3)2), 44.58 (CHC=), 44.61 (CH2C(CH3)2), 47.52 
(CHCHCAr), 47.55 (CH2N), 55.9 (2CH3O), 102.8 (2CHAr), 118.0 (CAr), 121.0 (CH=), 143.4 
(C=), 149.4 (CAr), 158.5 (2CAr); MS (ESI, m/z): 397.4 [M-CH3+H]
+. 
 Synthesis of tag 49 
(+)-Methyl 4-benzoyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalaninate 
(50). A suspension of 4-benzoyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanine 
(263 mg, 0.54 mmol) and K2CO3 (89 mg, 0.64 mmol) in anhydrous DMF (4.8 mL), under 
an argon atmosphere, was stirred at rt for 30 min. Iodomethane (100 μL, 1.6 mmol) was 
then added at 0 ºC and the reaction was stirred at rt for 90 min. The mixture was diluted 
with water, extracted with Et2O (3x), and the combined organic extracts were dried 
(Na2SO4), filtered, and evaporated under reduced pressure. The residue was purified by 
Experimental section 
 
137 
 
chromatography (hexane to hexane/EtOAc, 1:1) to afford methyl ester 50 (246 mg, 
91%), mp: 58-62 ºC. []D
20: +43.0 (c=1.0, chloroform). Rf: 0.30 (hexane/EtOAc, 7:3). 
 
IR (ATR, ): 1723, 1656 (CO), 1605, 1526, 1445 (Ar); 1H-NMR (CDCl3, ): 3.22 (AB 
system, J=13.8, 5.8, 2H, CH2Bzph), 3.77 (s, 3H, CH3), 4.22 (t, J=6.7, 1H, CHFmoc), 4.40 (dd, 
J=10.5, 6.8, 1H, ½CH2O), 4.52 (dd, J=10.6, 7.0, 1H, ½CH2O), 4.71-4.78 (m, 1H, CHN), 5.36 
(d, J=8.1, 1H, NH), 7.21 (d, J=7.9, 2H, 2CHBzph), 7.32 (t, J=7.4, 2H, 2CHFmoc), 7.41 (t, J=7.5, 
2H, 2CHFmoc), 7.48 (t, J=7.5, 2H, 2CHBzph), 7.57-7.63 (m, 3H, 2CHFmoc, CHBzph), 7.74-7.80 (m, 
6H, 2CHFmoc, 4CHBzph); 
13C-NMR (CDCl3, ): 38.6 (CH2Bzph), 47.6 (CHFmoc), 52.9 (CH3), 55.0 
(CHN), 67.3 (CH2O), 120.4 (2CHFmoc), 125.4, 125.5 (2CHFmoc), 127.5 (2CHFmoc), 128.2 
(2CHFmoc), 128.7 (2CHBzph), 129.7 (2CHBzph), 130.4 (2CHBzph), 130.8 (2CHBzph), 132.8 (CHBzph), 
136.8 (2CBzph), 138.0, 141.2, 141.8, 144.1, 144.2 (CBzph, 4CFmoc), 155.9 (NCOO), 172.0 
(COO), 196.7 (CO); MS (ESI, m/z): 284.1 [M-Fmoc]+, 506.1 [M+H]+, 528.1 [M+Na]+. 
(+)-Methyl 4-benzoyl-L-phenylalaninate (51). To a solution of 50 (240 mg, 0.48 
mmol) in dry DCM (0.3 mL) at 0 ºC and under an argon atmosphere, a solution of 
piperidine (0.24 mL, 2.4 mmol) in dry DCM (4.5 mL) was added dropwise. The reaction 
was stirred at rt for 1 h. The mixture was then quenched with 5% citric acid, washed 
with water and extracted with EtOAc (3x). The organic layers were dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
chromatography (DCM to DCM/MeOH, 98:2) to afford the title compound 51 (118 mg, 
88%). []D
20: +6.9 (c=1.0, chloroform). Rf: 0.21 (DCM/MeOH, 95:5). The spectroscopic 
data correspond with those previously reported.117 
 
1H-NMR (CDCl3, ): 1.56 (br s, 2H, NH2), 2.95 (dd, J=13.5, 7.9, 1H, ½CH2), 3.18 (dd, 
J=13.5, 5.2, 1H, ½CH2), 3.74 (s, 3H, CH3), 3.79 (dd, J=7.9, 5.2, 1H, CHN), 7.32 (d, J=8.2, 2H, 
2CHAr), 7.45-7.50 (m, 2H, 2CHAr), 7.59 (t, J=7.5, 1H, CHAr), 7.75-7.81 (m, 4H, 4CHAr). 
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(+)-Methyl 4-benzoyl-N-biotinyl-L-phenylalaninate (52). Following the procedure 
described for the synthesis of biotin derivative 16, amide 52 was obtained from biotin 
(204 mg, 0.84 mmol) and amine 51 (118 mg, 0.42 mmol) in 59% yield (126 mg). 
Chromatography: DCM to DCM/MeOH, 95:5. Mp: 85-86 ºC. [α]D
20: +63.6 (c=0.59, 
chloroform). Rf: 0.30 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 3272 (NH), 1738, 1698, 1656 (CO), 1606, 1539, 1448 (Ar); 1H-NMR (CDCl3, 
): 1.31-1.40 (m, 2H, CH2), 1.54-1.72 (m, 4H, 2CH2), 2.18 (t, J=7.2, 2H, CH2CO), 2.26 (d, 
J=12.8, 1H, ½CH2S), 2.81 (dd, J=12.8, 4.9, 1H, ½CH2S), 3.04-3.15 (m, 2H, CHS, ½CH2Ar), 
3.24 (dd, J=13.9, 5.5, 1H, ½CH2Ar), 3.72 (s, 3H, CH3), 4.26 (dd, J=7.6, 4.7, 1H, CHNBiot), 
4.47 (dd, J=7.6, 4.9, 1H, CHNBiot), 4.85-4.92 (m, 1H, CHN), 6.00 (br s, 1H, NH), 6.77 (br s, 
1H, NH), 7.23 (d, J=7.9, 1H, NH), 7.28 (d, J=8.2, 2H, 2CHAr), 7.46 (t, J=7.4, 2H, 2CHAr), 7.59 
(t, J=7.5, 1H, CHAr), 7.73-7.77 (m, 4H, 4CHAr); 
13C-NMR (CDCl3, ): 25.5, 28.1, 28.5 ((CH2)3), 
35.7, 37.7 (CH2CO, CH2Ar), 40.6 (CH2S), 52.6 (CH3), 53.1 (CHN), 56.0 (CHS), 60.3, 62.0 
(2CHNBiot), 128.4 (2CHAr), 129.3 (2CHAr), 130.1 (2CHAr), 130.5 (2CHAr), 132.6 (CHAr), 136.3, 
137.6, 141.6 (3CAr), 164.5 (NCON), 173.1, 173.5 (CON, COO), 196.5 (CO); MS (ESI, m/z): 
510.5 [M+H]+. 
(+)-4-Benzoyl-N-biotinyl-L-phenylalanine (49). To a solution of ester 52 (40 mg, 78 
mol) in anhydrous THF (0.2 mL) under an argon atmosphere, a solution of LiOH·H2O (6 
mg, 0.16 mmol) in water (0.2 mL) was added dropwise. The reaction was stirred at rt for 
1 h and THF was evaporated under reduced pressure. The mixture was acidified with 1 
M HCl (aq). The resulting precipitate was filtered, washed with cold water and dried 
under high vacuum at 35 ºC to afford acid 49 (39 mg, 100%), which was used in the next 
step without further purification. Mp: 129-133 ºC. []D
20: +61.3 (c=0.69, DCM/MeOH 
1:1). Rf: 0.35 (DCM/MeOH, 1:1). 
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IR (ATR, ): 3420 (NH, OH), 1696, 1651 (CO), 1540, 1453 (Ar); 1H-NMR ((CD3)2SO, ): 
1.14-1.22 (m, 2H, CH2), 1.37-1.61 (m, 4H, 2CH2), 2.06 (t, J=7.2, 2H, CH2CO), 2.49-2.55 (m, 
1H, ½CH2S), 2.73 (dd, J=12.4, 5.0, 1H, ½CH2S), 2.91-3.02 (m, 2H, CHS, ½CH2Ar), 3.18 (dd, 
J=13.7, 4.5, 1H, ½CH2Ar), 4.03-4.07 (m, 1H, CHNBiot), 4.22-4.26 (m, 1H, CHNBiot), 4.47-4.55 
(m, 1H, CHN), 6.35 (br s, 1H, NH), 6.39 (br s, 1H, NH), 7.42 (d, J=8.2, 2H, 2CHAr), 7.56 (t, 
J=7.3, 2H, 2CHAr), 7.65-7.72 (m, 5H, 5CHAr), 8.21 (d, J=8.3, 1H, NH), 12.77 (br s, 1H, OH); 
13C-NMR ((CD3)2SO, ): 25.1 (CH2), 27.9 (2CH2), 34.8, 36.7 (CH2CO, CH2Ar), 39.8 (CH2S), 
52.9 (CHN), 55.4 (CHS), 59.1, 61.0 (2CHNBiot), 128.5 (2CHAr), 129.3 (2CHAr), 129.5 (2CHAr), 
129.6 (2CHAr), 132.6 (CHAr), 135.1, 137.2, 143.1 (3CAr), 162.6 (NCON), 172.1, 172.9 (CON, 
COO), 195.4 (CO); MS (ESI, m/z): 494.0 [M-H]-. 
 Synthesis of probes 39-41 
General procedure. A suspension of carboxylic acid 49 (1.5 equiv), HOBt (1.5 equiv), 
EDC (1.5 equiv) and 4 Å molecular sieves in anhydrous DMF and dry DCM (1:1, 16 
mL/mmol) was stirred at 36 ºC for 1 h under an argon atmosphere. Then, a solution of 
the corresponding alcohol or amine (1 equiv) in the minimum amount of dry DCM was 
added, and the mixture was stirred at rt for 14 h. The mixture was filtered and washed 
with DCM/MeOH (1:1). The solvents were removed under reduced pressure  and the 
residue was purified by chromatography using the appropriate eluent to afford the 
corresponding ester or amide. 
(-)-[(6aR,10aR)-3-(1,1-Dimethylheptyl)-1-hydroxy-6,6-dimethyl-6a,7,10,10a-
tetrahydro-6H-benzo[c]chromen-9-yl]methyl 4-benzoyl-N-biotinylphenylalaninate 
(39). Obtained from carboxylic acid 49 (42 mg, 85 μmol) and alcohol 42 (27 mg, 70 μmol) 
in 32% yield (19 mg). Chromatography: DCM/MeOH, 9:1. Mp: 122-125 ºC. []D
20:-26.3 
(c=0.9, EtOH). Rf: 0.36 (DCM/MeOH, 9:1). 
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IR (ATR, ): 3265 (NH, OH), 1695, 1657 (CO), 1574, 1454 (Ar); 1H-NMR ((CD3)2CO, ): 
0.83 (t, J=6.6, 3H, CH3CH2), 1.07 (s, 3H, CH3Ccyc), 1.19-1.41 (m, 17H, CH3Ccyc, 2CH3, (CH2)4), 
1.50-1.61 (m, 6H, CH2C(CH3)2, (CH2)2), 1.70-1.77 (m, 3H, CH2, CHC(CH3)2), 1.84-1.90 (m, 
2H, ½CH2CH=, ½CH2C=), 2.21-2.28 (m, 3H, ½CH2CH=, CH2CO), 2.63-2.73 (m, 2H, CHCAr, 
½CH2S), 2.91 (dd, J=12.6, 4.9, 1H, ½CH2S), 3.09-3.17 (m, 2H, CHS, ½CH2Bzph), 3.30-3.37 
(m, 1H, ½CH2Bzph), 3.50-3.61 (m, 1H, ½CH2C=), 4.25-4.32 (m, 1H, CHNBiot), 4.46-4.51 (m, 
1H, CHNBiot), 4.56-4.66 (m, 2H, CH2O), 4.82-4.90 (m, 1H, CHN), 5.80-5.83 (m, 2H, CH=, 
NH), 6.02 (br s, 1H, NH), 6.17 (br s, 1H, NH), 6.25 (s, 1H, CHHU), 6.44 (dd, J=8.7, 1.8, 1H, 
CHHU), 7.46 (t, J=8.3, 2H, 2CHBzph), 7.52-7.59 (m, 2H, 2CHBzph), 7.63-7.66 (m, 1H, CHBzph), 
7.71-7.79 (m, 4H, 4CHBzph); 
13C-NMR ((CD3)2CO, ): 14.3 (CH3CH2), 18.7 (CH3Ccyc), 23.3, 
25.4, 26.3 (3CH2), 27.9 (CH3Ccyc), 28.4, 28.9, 29.0 (CH2CH=, 2CH2), 29.2, 29.3 (2CH3), 30.8 
(CH2), 32.3 (CHCAr), 32.5 (CH2), 35.6, 35.9 (CH2C=, CH2CO), 37.8 (ArC(CH3)2), 38.2 
(CH2Bzph), 40.9 (CH2S), 45.1 (CH2C(CH3)2), 45.9 (CHC(CH3)2), 54.1 (CHN), 56.3 (CHS), 60.9, 
62.3 (2CHNBiot), 69.4 (CH2O), 76.6 (OC(CH3)2), 106.0, 107.2 (2CHHU), 110.4 (CHU), 125.4 
(CH=), 129.3 (2CHBzph), 130.3 (2CHBzph), 130.5 (2CHBzph), 130.8 (2CHBzph), 133.2 (CHBzph), 
134.5, 136.8 (CBzph), 138.6 (C=), 143.5 (CBzph), 150.1, 155.3, 157.2 (3CHU), 164.0 (NCON), 
172.3, 173.4 (2CON), 196.2 (CO); HRMS (ESI, m/z): calcd for [M+Na]+ C51H65N3NaO7S: 
886.4435; found: 886.4415; HPLC-MS (ESI, m/z): 864.4 [M+H]+; tR (method A): 15.65 min. 
(-)-4-Benzoyl-N-biotinyl-N-({(6aR,10aR)-3-(1,1-dimethylheptyl)-6,6-dimethyl-1-
[(triisopropylsilyl)-oxy]-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl}-methyl)-L-
phenyl-alaninamide (53). Obtained from carboxylic acid 49 (50 mg, 0.11 mmol) and 
amine 11 (50 mg, 92 μmol) in 31% yield (28 mg). Chromatography: DCM/MeOH, 95:5. 
Mp: 128-130 ºC. []D
20:-51.4 (c=0.46, chloroform). Rf: 0.32 (DCM/MeOH 9:1). 
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IR (ATR, ): 3271 (NH), 1696, 1652 (CO), 1563, 1462 (Ar); 1H-NMR (CD3OD/CDCl3 9:1, 
): mixture of rotamers (1:1), 0.85 (t, J=6.8, 3H, CH3CH2), 1.02-1.33 (m, 41H, 2CH3Ccyc, 
2CH3, 3CH(CH3)2, (CH2)4), 1.47-1.82 (m, 11H, (CH2)3, CH2C(CH3)2, ½CH2C=, ½CH2CH=, 
CHC(CH3)2), 2.13-2.23 (m, 3H, ½CH2CH=, CH2CO), 2.58 (td, J=11.1, 4.2, 1H, CHCAr), 2.65 (d, 
J=13.0, 1H, ½CH2S rotamer), 2.66 (d, J=12.7, 1H, ½CH2S rotamer), 2.87 (dd, J=12.7, 4.9, 
1H, ½CH2S), 2.95-3.26 (m, 3H, CHS, CH2Bzph), 3.49-3.56 (m, 1H, ½CH2C=), 3.64-3.92 (m, 
2H, CH2N), 4.19 (dd, J=7.9, 4.5, 1H, CHNBiot rotamer), 4.26 (dd, J=7.8, 4.5, 1H, CHNBiot 
rotamer), 4.43 (dd, J=8.3, 4.7, 1H, CHNBiot rotamer), 4.46 (dd, J=8.2, 4.8, 1H, CHNBiot 
rotamer), 4.69-4.76 (m, 1H, CHN), 5.37 (m, 1H, CH=), 6.22 (d, J=1.6, 1H, CHHU rotamer), 
6.34 (m, 3H, 3CHHU rotamers), 7.38 (d, J=8.2, 1H, CHBzph), 7.44 (d, J= 8.2, 1H, CHBzph), 7.52 
(td, J=7.4, 3.0, 2H, 2CHBzph), 7.61-7.67 (m, 2H, 2CHBzph), 7.71-7.77 (m, 3H, 3CHBzph); 
13C-
NMR (CD3OD/CDCl3 9:1, ): mixture of rotamers, 14.3 (3CHSi), 14.4 (CH3CH2), 18.4 
(CH3Ccyc), 18.6 (3CH(CH3)2), 23.6, 25.8, 26.6, 26.7 (4CH2), 28.0 (CH3Ccyc), 28.8 (CH2CH=), 
29.3 (CH2), 29.4, 29.5, 29.6, 29.7 (2CH3 rotamers), 31.1, 32.9 (2CH2), 33.3 (CHCAr), 34.5 
(CH2C=), 36.3, 36.4 (CH2CO rotamers), 38.2 (ArC(CH3)2), 39.0, 39.2 (CH2Bzph rotamers), 
41.0 (CH2S), 45.5, 45.6, 45.7 (CH2C(CH3)2, CH2N rotamers), 46.8, 46.9 (CHC(CH3)2 
rotamers), 55.5 (CHN), 56.7 (CHS), 61.5, 63.1 (2CHNBiot), 77.3 (OC(CH3)2), 109.4 (CHHU), 
109.8, 109.9 (CHHU rotamers), 114.5 (CHU), 121.5 (CH=), 129.4 (2CHBzph), 130.4, 130.5, 
130.9, 131.0 (4CHBzph), 131.2 (2CHBzph), 133.7 (CHBzph), 135.6, 135.8 (CBzph rotamers), 
137.0 (CBzph), 138.7 (C=), 143.7, 144.0 (CBzph rotamers), 150.1, 155.5, 156.1 (3CHU), 165.8 
(NCON), 172.8, 175.6 (2CON), 198.0 (CO); MS (ESI, m/z): 1017.6 [M-H]-. 
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(+)-4-Benzoyl-N-biotinyl-N-({(1S,4S,5S)-4-[2,6-dimethoxy-4-(1,1-dimethylheptyl)-
phenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl}methyl)-L-phenylalaninamide (41). 
Obtained from carboxylic acid 49 (43 mg, 86 mol) and amine 43 (32 mg, 78 mol) in 
35% yield (25 mg). Chromatography: DCM/MeOH, 95:5. Mp: 139-143 ºC. []D
20: +69.0 
(c=0.30, chloroform). Rf: 0.16 (DCM/MeOH 95:5). 
 
IR (ATR, ): 3289 (NH), 1649, 1607 (CO), 1572, 1449, 1411 (Ar); 1H-NMR 
(CDCl3/CD3OD 9:1, ): 0.71 (t, J=6.6, 3H, CH3CH2), 0.78 (s, 3H, CH3Ccyc), 0.93-1.21 (m, 19H, 
CH3Ccyc, 2CH3, (CH2)4, CH2), 1.39-1.55 (m, 6H, CH2C(CH3)2, (CH2)2), 1.80-2.07 (m, 6H, 
CHCHCAr, CHC=, CH2cyc, CH2CO), 2.56 (d, J=12.8, 1H, ½CH2S), 2.72-2.79 (m, 1H, ½CH2S), 
2.83-3.11 (m, 3H, CH2Bzph, CHS), 3.59-3.70 (m, 8H, CH2N, 2CH3O), 3.79-3.81 (m, 1H, 
CHCAr), 4.12 (td, J=13.2, 4.5, 1H, CHNBiot), 4.34 (td, J=6.0, 0.9, 1H, CHNBiot), 4.57 (t, J=7.4, 
1H, CHN), 5.42 (d, J=11.9, 1H, CH=), 6.34 (s, 2H, 2CHHU), 7.23 (dd, J=8.3, 2.0, 2H, 2CHBzph), 
7.35 (t, J=7.0, 2H, 2CHBzph), 7.47 (t, J=6.9, 1H, CHBzph), 7.58 (t, J=8.2, 2H, 2CHBzph), 7.93 (d, 
J=7.9, 2H, 2CHBzph); 
13C-NMR (125 MHz, CDCl3/CD3OD 9:1, ): mixture of rotamers, 14.1 
(CH3CH2), 20.9, 21.0 (CH3Ccyc rotamers), 22.8, 24.8 (2CH2), 25.4, 25.5 (CH2 rotamers), 26.3 
(CH3Ccyc), 27.8 (CH2cyc), 28.2, 28.4 (2CH2), 29.0 (2CH3), 29.8, 30.1 (CH2 rotamers), 31.9 
(CH2), 35.6, 35.8 (CH2CO rotamers), 37.6 (CHCAr), 38.1 (ArC(CH3)2), 38.3 (CH2Bzph), 40.4, 
40.5 (CH2S rotamers), 40.9 (Ccyc(CH3)2), 44.3 (CHC=), 44.5 (CH2N), 44.6 (CH2C(CH3)2), 47.4 
(CHCHCAr), 54.1 (CHN), 55.5, 55.6 (CHS rotamers), 55.8, 55.9 (2CH3O), 60.3, 62.0 
(2CHNBiot), 102.9, 103.0 (2CHHU), 117.5 (CHU), 124.0, 124.2 (CH= rotamers), 128.5 
(2CHBzph), 129.4 (2CHBzph), 130.1 (2CHBzph), 130.5 (2CHBzph), 132.7 (CHBzph), 136.0, 137.6 
(2CBzph), 137.8, 137.9 (C= rotamers), 142.4, 142.5 (CBzph rotamers), 149.7 (CHU), 158.5 
(2CHU), 164.3 (NCON), 171.4, 174.0 (2CON), 197.2 (CO); HRMS (MALDI, m/z): calcd for 
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[M+H]+ C53H71N4O6S: 891.5094; found: 891.5102; HPLC-MS (ESI, m/z): 891.4 [M+H]
+; tR 
(method A): 19.55 min. 
(-)-4-Benzoyl-N-biotinyl-N-{[(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-
dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methyl}-L-
phenylalaninamide (40). Following the general procedure 6.1.1.1, phenol 40 was 
obtained from amide 53 (24 mg, 25 mol) in 36% yield (6 mg). Chromatography: DCM to 
DCM/MeOH, 9:1. Mp: 138-140 ºC. [α]D
20: -39.1 (c=0.19, chloroform). Rf: 0.28 
(DCM/MeOH, 9:1). 
 
IR (ATR, ): 3264 (NH, OH), 1693, 1654 (CO), 1576, 1458, 1416 (Ar); 1H-NMR (500 
MHz, CD3OD/CDCl3 9:1, ): mixture of rotamers (1:1), 0.85 (t, J=7.0, 3H, CH3CH2), 1.03-
1.33 (m, 20H, 2CH3Ccyc, 2CH3, (CH2)4), 1.48-1.83 (m, 11H, (CH2)3, CH2C(CH3)2, ½CH2C=, 
½CH2CH=, CHC(CH3)2), 2.12-2.23 (m, 3H, ½CH2CH=, CH2CO), 2.58 (td, J=11.2, 4.7, 1H, 
CHCAr rotamer), 2.62 (dd, J=11.2, 4.6, 1H, CHCAr rotamer), 2.65 (d, J=12.5, 1H, ½CH2S 
rotamer), 2.66 (d, J=12.7, 1H, ½CH2S rotamer), 2.86 (dd, J=12.9, 5.0, 1H, ½CH2S), 2.98-
3.12 (m, 2H, CH2Bzph), 3.20-3.27 (m, 1H, CHS), 3.35-3.40 (m, 1H, ½CH2C=), 3.62 (d, 
J=14.7, 1H, ½CH2N rotamer), 3.67 (d, J=14.7, 1H, ½CH2N rotamer), 3.78 (d, J=14.6, 1H, 
½CH2N rotamer), 3.82 (d, J=14.3, 1H, ½CH2N rotamer), 4.19 (dd, J=7.9, 4.4, 1H, CHNBiot 
rotamer), 4.25 (dd, J=7.9, 4.5, 1H, CHNBiot rotamer), 4.42 (dd, J=7.8, 4.4, 1H, CHNBiot 
rotamer), 4.45 (dd, J=8.0, 4.5, 1H, CHNBiot rotamer), 4.74 (t, J=6.3, 1H, CHN rotamer), 
4.76 (t, J=6.8, 1H, CHN rotamer), 5.43-5.46 (m, 1H, CH=), 6.15 (d, J=1.8, 1H, CHHU 
rotamer), 6.22 (d, J=1.8, 1H, CHHU rotamer), 6.32-6.33 (m, 2H, 2CHHU rotamers), 7.41 (d, 
J=8.2, 1H, CHBzph), 7.46 (d, J=8.2, 1H, CHBzph), 7.50-7.54 (m, 2H, 2CHBzph), 7.62-7.66 (m, 2H, 
2CHBzph), 7.72-7.77 (m, 3H, 3CHBzph); 
13C-NMR (125 MHz, CD3OD/CDCl3 9:1, ): mixture of 
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rotamers, 14.4 (CH3CH2), 18.6 (CH3Ccyc), 23.7, 25.8 (2CH2), 26.6, 26.7 (CH2 rotamers), 28.0 
(CH3Ccyc), 28.8 (CH2CH=), 29.35 (CH2), 29.41, 29.5 (2CH3), 29.6, 31.1 (2CH2), 32.8 (CHCAr), 
32.9 (CH2), 33.7 (CH2C=), 36.4, 36.5 (CH2CO rotamers), 38.2 (ArC(CH3)2), 39.2 (CH2Bzph), 
41.0 (CH2S), 45.6 (CH2C(CH3)2), 45.8, 46.0 (CH2N rotamers), 46.6, 46.8 (CHC(CH3)2 
rotamers), 55.7 (CHN), 56.8, 56.9 (CHS rotamers), 61.6 (CHNBiot), 63.2, 63.3 (CHNBiot 
rotamers), 77.3 (OC(CH3)2), 106.3, 107.6 (2CHHU), 111.1 (CHU), 122.1 (CH=), 129.5, 129.6, 
130.5, 130.6 (4CHBzph), 131.0 (2CHBzph), 131.3 (2CHBzph), 133.8 (CHBzph), 136.2, 136.3 (CBzph 
rotamers), 137.2 (CBzph), 138.9 (C=), 144.0, 144.3 (CBzph rotamers), 150.5, 150.6 (CHU 
rotamers), 155.5 (CHU), 157.5, 157.6 (CHU rotamers), 166.1 (NCON), 173.1, 173.2 (CON 
rotamers), 175.8 (CON), 198.2 (CO); HRMS (MALDI, m/z): calcd for [M+H]+ C51H67N4O6S: 
863.4781; found: 863.4747; HPLC-MS (ESI, m/z): 863.5 [M+H]+; tR (method A): 13.52 min. 
 Synthesis of fluorescent probe 54 
5-({[(1S)-2-(4-Benzoylphenyl)-1-carboxyethyl]amino}sulfonyl)-2-[6-(diethylamino)-
3-(diethyliminio)-3H-xanthen-9-yl]benzenesulfonate (55). To a solution 4-benzoyl-L-
phenylalanine (200 mg, 0.74 mmol) in 2 M NaOH (aq, 0.8 mL) at 0 ºC and under an argon 
atmosphere, a solution of sulforhodamine B acid chloride (lissamine chloride, 471 mg, 
0.82 mmol) and DIPEA (106 mg, 0.82 mmol) in acetone (0.8 mL) was added and the 
reaction mixture was stirred for 10 min at this temperature. Then, the mixture was 
allowed to warm to rt and stirred for 18 h. The crude was diluted with water and 
washed with Et2O (3x). The aqueous layer was acidified with 1 M HCl (aq) and extracted 
with EtOAc (3x). The combined organic layers were dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The residue was purified by chromatography (DCM 
to DCM/MeOH, 8:2) to afford sulfonamide 55 (133 mg, 22%). Mp: 266-267 ºC. Rf: 0.45 
(DCM/MeOH, 8:2). 
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IR (ATR, ): 3320 (NH, OH), 1653 (CO), 1450, 1413 (Ar), 1114, 1015 (SO2); 
1H-NMR 
(500 MHz, CD3OD, ): 1.29 (t, J=6.4, 12H, 4CH3), 3.07 (dd, J=13.6, 7.8, 1H, ½CH2Bzph), 
3.26 (dd, J=13.7, 4.6, 1H, ½CH2Bzph), 3.61-3.68 (m, 8H, 4CH2N), 4.08 (dd, J=7.5, 4.7, 1H, 
CHN), 6.90 (m, 2H, 2CHLiss), 6.96 (dd, J=9.6, 2.2, 2H, 2CHLiss), 7.08 (d, J=9.4, 2H, 2CHLiss), 
7.33 (d, J=8.0, 1H, CHLiss), 7.44-7.49 (m, 4H, 4CHBzph), 7.60 (t, J=7.4, 1H, CHBzph), 7.68 (t, 
J=7.6, 4H, 4CHBzph), 7.88 (dd, J=8.0, 1.8, 1H, CHLiss), 8.64 (d, J=1.7, 1H, CHLiss); 
13C-NMR 
(125 MHz, CD3OD, ): 12.8 (4CH3), 40.6 (CH2Bzph), 46.8 (4CH2N), 60.6 (CHN), 96.9 
(2CHLiss), 115.1 (2CHLiss), 115.2, 115.3 (2CLiss), 127.9, 129.2 (2CHLiss), 129.4 (2CHBzph), 130.9 
(2CHBzph), 131.0 (2CHBzph), 131.1 (2CHBzph), 132.2 (CHLiss), 133.6 (CHBzph), 133.8 (2CHLiss), 
135.1 (CLiss), 137.0, 138.9 (2CBzph), 144.0 (CLiss), 144.8 (CBzph), 146.8 (CLiss), 157.2 (2CLiss), 
158.0, 159.3, 159.4 (3CLiss), 176.7 (COOH), 198.5 (CO); MS (ESI, m/z): 891.4 [M+H]
+. 
5-({[(1S)-2-(4-Benzoylphenyl)-1-({[(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-
6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-9-yl]methoxy}carbonyl)-
ethyl]amino}sulfonyl)-2-[6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-yl]-
benzenesulfonate (54). To a solution of carboxylic acid 55 (98 mg, 0.12 mmol) in dry 
DCM (2 mL), anhydrous DMF (3 mL) and activated 4 Å molecular sieves under an argon 
atmosphere, EDC (26 mg, 0.14 mmol) and HOBt (18 mg, 0.14 mmol) were added. The 
reaction was stirred at rt for 1 h before a solution of alcohol 42 (40 mg, 0.10 mmol) in 
dry DCM (2 mL) was added. The mixture was stirred at rt for 48 h and the solvents were 
evaporated under reduced pressure. The residue was resuspended in DCM, filtered and 
washed with saturated NaHCO3 (aq). The aqueous layer was extracted with DCM (2x) 
and the combined organic layers were dried (Na2SO4), filtered, and evaporated under 
reduced pressure. The residue was purified by chromatography (DCM to DCM/MeOH, 
95:5) to yield ester 54 (24 mg, 20%). Mp: 148-149 ºC. Rf: 0.42 (DCM/MeOH, 95:5). 
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IR (ATR, ): 3332 (NH, OH), 1649 (CO), 1592, 1467 (Ar), 1340, 1182 (SO2); 
1H-NMR 
(700 MHz, CD3OD, ): 0.83 (t, J=7.1, 3H, CH3CH2), 1.00 (s, 3H, CH3Ccyc), 1.16-1.29 (m, 29H, 
CH3Ccyc, 2CH3, 4CH3CH2N, (CH2)4), 1.48-1.51 (m, 2H, CH2C(CH3)2), 1.57-1.62 (m, 2H, 
½CH2C=, CHC(CH3)2), 1.78-1.82 (m, 1H, ½CH2CH=), 2.13-2.16 (m, 1H, ½CH2CH=), 2.58 (td, 
J=11.3, 4.7, 1H, CHCAr), 3.10 (dd, J=13.8, 8.7, 1H, ½CH2Bzph), 3.26 (dd, J=13.7, 5.9, 1H, 
½CH2Bzph), 3.39-3.41 (m, 1H, ½CH2C=), 3.57-3.65 (m, 8H, 4CH2N), 4.40 (dd, J=8.4, 6.0, 
1H, CHN), 4.44 (AB system, J=12.1, 2H, CH2O), 5.68 (m, 1H, CH=), 6.20 (d, J=1.8, 1H, 
CHHU), 6.32 (d, J=1.8, 1H, CHHU), 6.85 (d, J=2.4, 1H, CHLiss), 6.88 (dd, J=9.5, 2.4, 1H, CHLiss), 
6.90-6.93 (m, 2H, 2CHLiss), 7.08 (d, J=5.6, 1H, CHLiss), 7.09 (d, J=5.4, 1H, CHLiss), 7.30 (d, 
J=7.9, 1H, CHLiss), 7.44 (d, J=8.2, 2H, 2CHBzph), 7.47 (t, J=7.8, 2H, 2CHBzph), 7.60 (t, J=7.4, 
1H, CHBzph), 7.69-7.72 (m, 4H, 4CHBzph), 7.90 (dd, J=7.9, 1.9, 1H, CHLiss), 8.62 (d, J=1.9, 1H, 
CHLiss); 
13C-NMR (175 MHz, CD3OD, ): 12.9 (4CH3CH2N), 14.4 (CH3CH2), 18.6 (CH3Ccyc), 
23.7, 25.8, 27.1 (3CH2), 27.9 (CH3Ccyc), 28.7 (CH2CH=), 29.4, 29.5 (2CH3), 31.2 (CH2), 32.7 
(CHCAr), 33.0 (CH2C=), 38.2 (ArC(CH3)2), 39.9 (CH2Bzph), 45.5 (CH2C(CH3)2), 46.5 
(CHC(CH3)2), 46.8 (4CH2N), 58.9 (CHN), 69.8 (CH2O), 77.2 (OC(CH3)2), 96.9, 97.0 (2CHLiss), 
106.4, 107.6 (2CHHU), 110.8 (CHU), 114.9, 115.0 (2CHLiss), 115.1, 115.2 (2CLiss), 125.5 (CH=), 
127.8, 129.2 (2CHLiss), 129.5 (2CHBzph), 130.8 (2CHBzph), 131.0 (2CHBzph), 131.4 (2CHBzph), 
132.3, 133.6 (2CHLiss), 133.8 (CHBzph, CHLiss), 134.5 (CLiss), 135.4 (C=), 137.5, 138.7 (2CBzph), 
143.1 (CLiss), 143.9 (CBzph), 147.1 (CLiss), 150.7, 155.5 (2CHU), 157.1 (2CLiss), 157.6 (CLiss), 
157.8 (CBzph), 159.3, 159.4 (2CLiss), 172.0 (COO), 198.2 (CO); HRMS (MALDI, m/z): calcd for 
[M+H]+ C68H80N3O11S2: 1178.5234; found: 1178.5193. 
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6.1.5. Synthesis of honokiol-based probes 56-59 
 First attempts of synthesis of azide 60 
4-Allylphenol (66). To a solution of 4-allylanisole (10 mL, 65 mmol) in dry 
dochloromethane (200 mL) at -78 ºC and under an argon atmosphere, BBr3 (70 mL, 1 M 
in DCM) was added dropwise and the mixture was allowed to warm to rt and stirred for 
50 min. The reaction was carefully quenched with water and the organic layer was 
separated, washed with brine, dried (Na2SO4), filtered, and evaporated under reduced 
pressure to give phenol 66 (9.91 g, 93%), which was used in the next step without 
further purification. Rf: 0.36 (hexane/EtOAc, 85:15). The spectroscopic data correspond 
with those previously reported.152 
 
1H-NMR (CDCl3, ): 3.32 (d, J=6.7, 2H, CH2), 4.69 (br s, 1H, OH), 5.02-5.10 (m, 2H, 
CH2=), 5.95 (ddt, J=15.9, 10.8, 6.6, 1H, CH=), 6.77 (d, J=8.5, 2H, H2, H6), 7.06 (d, J=9.2, 2H, 
H3, H5). 
1-Allyl-4-ethoxybenzene (67). Following the general procedure 6.1.1.2, ether 67 was 
obtained from phenol 66 (500 mg, 3.7 mmol) and bromoethane (0.33 mL, 4.5 mmol) in 
98% yield (593 mg), and used in the next step without further purification. Rf: 0.46 
(hexane/EtOAc 95:5). 
 
1H-NMR (CDCl3, ): 1.40 (t, J=7.0, 3H, CH3), 3.33 (d, J=6.6, 2H, CH2C1), 4.01 (q, J=7.0, 
2H, CH2O), 5.02-5.09 (m, 2H, CH2=), 5.96 (ddt, J=16.9, 10.3, 6.7, 1H, CH=), 6.83 (d, J=8.6, 
2H, H3, H5), 7.09 (d, J=8.6, 2H, H2, H6). 
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Reaction of 67 with trimethylborate under basic conditions. To a solution of sec-
butillithium (5.5 mL, 1.4 M in cyclohexane) in anhydrous THF (40 mL) at -78 ºC and under 
an argon atmosphere, tetramethylethylenediamine (TMEDA, 1.2 mL, 7.7 mmol) was 
added. After stirring at that temperature for 30 min, a solution of 67 (1.00 g, 6.4 mmol) 
in anhydrous THF (20 mL) was added dropwise and the mixture was stirred at -78 ºC for 
2 h. Trimethyl borate (1.4 mL, 13 mmol) was then added and the reaction was allowed 
to warm to rt and stirred for an additional 1 h. 2 M HCl (aq) was added and the aqueous 
phase was extracted with EtOAc (2x). The organic layer was washed with 2 M HCl (aq) 
and brine, dried (Na2SO4), filtered, and evaporated under reduced pressure to yield a 
complex mixture of products which did not contain the desired boronic acid.  
4-Allyl-2-bromophenol (68). Derivative 68 was obtained following the experimental 
procedure previously described by Lin et al. and the spectroscopic data correspond with 
those reported.127 
To a solution of 66 (1.20 g, 9.2 mmol) in anhydrous Et2O (120 mL) at -78 ºC and 
under an argon atmosphere, isopropyl magnesium chloride (4.6 mL, 2 M in THF) was 
added dropwise and the mixture was stirred at -78 ºC for 1 h before DBDMH (1.30 g, 4.6 
mmol) was added. The reaction was stirred at -78 ºC for 20 h, and then warmed up to rt 
over 1 h. The reaction was quenched with 10% NaHSO3 (aq) and extracted with Et2O 
(3x). The organic extracts were dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by chromatography (hexane to hexane/DCM, 7:3) to 
afford bromoderivative 68 (650 mg, 33%). Rf: 0.59 (hexane/DCM, 2:8). 
 
1H-NMR (CDCl3, ): 3.30 (d, J=6.7, 2H, CH2), 5.03-5.10 (m, 2H, CH2=), 5.37 (br s, 1H, 
OH), 5.91 (ddt, J=18.0, 9.2, 6.7, 1H, CH=), 6.95 (d, J=8.3, 1H, H6), 7.04 (dd, J=8.3, 1.9, 1H, 
H5), 7.28 (d, J=2.0, 1H, H3). 
4-Allyl-2-bromo-1-ethoxybenzene (69). Following the general procedure 6.1.1.2, 
ethoxy derivative 69 was obtained from phenol 68 (500 mg, 2.3 mmol) and 
bromoethane (210 L, 2.8 mmol) in 87% yield (482 mg), and used in the next step 
without further purification. Rf: 0.62 (hexane/EtOAc, 9:1). 
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IR (ATR, ): 1639, 1603, 1494 (Ar), 1279, 1248 (COC); 1H-NMR (CDCl3, ): 1.46 (t, 
J=7.0, 3H, CH3), 3.30 (d, J=6.7, 2H, CH2C4), 4.08 (q, J=7.0, 2H, CH2O), 5.03-5.10 (m, 2H, 
CH2=), 5.85-5.99 (m, 1H, CH=), 6.82 (d, J=8.4, 1H, H6), 7.05 (dd, J=8.3, 2.2, 1H, H5), 7.37 
(d, J=2.1, 1H, H3); 
13C-NMR (CDCl3, ): 14.9 (CH3), 39.1 (CH2C4), 65.1 (CH2O), 112.2 (C2), 
113.5 (C6), 116.2 (CH2=), 128.5 (C5), 133.5 (C3), 133.7 (C4), 137.2 (CH=), 158.8 (C1); MS 
(ESI, m/z): 262.9 [M(79Br)+Na]+, 264.9 [M(81Br)+Na]+. 
1-(Allyloxy)-4-bromobenzene (70). Following the general procedure 6.1.1.2, 
bromoderivative 70 was obtained from 4-bromophenol (450 mg, 2.6 mmol) and allyl 
bromide (270 L, 3.1 mmol) in 97% yield (537 mg), and used in the next step without 
further purification. Rf: 0.32 (hexane/DCM, 9:1). The spectroscopic data correspond with 
those previously reported.153 
 
1H-NMR (CDCl3, ): 4.51 (dt, J=5.3, 1.5, 2H, CH2O), 5.30 (dq, J=10.5, 1.4, 1H, ½CH2=), 
5.40 (dq, J=17.2, 1.6, 1H, ½CH2=), 6.03 (ddt, J=17.3, 10.5, 5.3, 1H, CH=), 6.80 (d, J=9.1, 
2H, H2, H6), 7.37 (d, J=9.0, 2H, H3, H5). 
2-Allyl-4-bromophenol (71). A solution of 70 (1.00 g, 4.7 mmol) in 1,2-
dichlorobenzene under an argon atmosphere was heated at 250 ºC for 1 h under MW 
irradiation. The solvent was removed under reduced pressure and the residue was 
purified by chromatography (hexane to hexane/DCM 9:1) to obtain phenol 71 (729 mg, 
73%). Mp: 58-59 ºC (lit.154 58.1-59.6 ºC). Rf: 0.45 (hexane/EtOAc, 85:15). The 
spectroscopic data correspond with those previously reported.153 
 
1H-NMR (CDCl3, ): 3.39 (d, J=6.3, 2H, CH2), 5.15-5.23 (m, 2H, CH2=), 6.00 (ddt, 
J=16.7, 10.4, 6.3, 1H, CH=), 6.71 (d, J=8.4, 1H, H6), 7.22- 7.27 (m, 2H, H3, H5). 
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(2-Allyl-4-bromophenoxy)(tert-butyl)dimethylsilane (72). A solution of 71 (1.60 g, 
7.6 mmol), imidazole (1.50 g, 23 mmol), and TBS-Cl (2.90 g, 19 mmol) in anhydrous DMF 
(16 mL), and under an argon atmosphere, was heated at 100 ºC for 15 min under MW 
irradiation. Then, 1 M H3PO4 (aq) was added and the mixture was extracted with DCM. 
The organic phase was washed with saturated NaHCO3 (aq) and brine, dried (Na2SO4), 
filtered, and evaporated under reduced pressure to afford silyl ether 72 (2.40 g, 97%), 
which was used in the next step without further purification. Rf: 0.78 (hexane/DCM, 8:2). 
The spectroscopic data correspond with those previously reported.155 
 
1H-NMR (CDCl3, ): 0.22 (s, 6H, 2CH3Si), 1.00 (s, 9H, C(CH3)3), 3.32 (d, J=6.6, 2H, CH2), 
5.02-5.11 (m, 2H, CH2=), 5.92 (ddt, J=16.9, 10.3, 6.7, 1H, CH=), 6.66 (d, J=8.5, 1H, H6), 
7.18 (dd, J=8.6, 2.6, 1H, H5), 7.28 (d, J=2.6, 1H, H3). 
Derivatives 73-75 were obtained following experimental procedures previously 
described by Liang et al. and their spectroscopic data correspond with those reported.155 
3-(5-Bromo-2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)propan-1-ol (73). To a well-
stirred solution of 72 (2.40 g, 7.4 mmol) in anhydrous THF (16 mL) at 0 ºC and under an 
argon atmosphere, BH3 (15 mL, 1 M in THF) was added. After 2 h, 30% H2O2 (aq, 15 mL, 
481 mmol) and saturated NaHCO3 (aq, 15 mL) were slowly added, and the mixture was 
allowed to warm to rt and stirred for 16 h. The reaction was quenched with saturated 
NH4Cl (aq) and extracted with EtOAc (3x). The combined organic extracts were 
sequentially washed with saturated NH4Cl (aq, 2x) and brine, dried (Na2SO4), filtered, 
and evaporated under reduced pressure. The residue was purified by chromatography 
(hexane to hexane/DCM, 1:1) to yield alcohol 73 (1.97 g, 77%). Rf: 0.30 (hexane/EtOAc, 
85:15). 
 
1H-NMR (CDCl3, ): 0.22 (s, 6H, 2CH3Si), 1.00 (s, 9H, C(CH3)3), 1.78-1.87 (m, 2H, CH2), 
2.64 (dd, J=8.3, 6.7, 2H, CH2C1), 3.62 (q app, J=5.4, 2H, CH2O), 5.30 (br s, 1H, OH), 6.66 (d, 
J=8.6, 1H, H3), 7.17 (dd, J=8.5, 2.6, 1H, H4), 7.26 (d, J=2.8, 1H, H6). 
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3-(5-Bromo-2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)propyl methanesulfonate (74). 
To a well-stirred solution of alcohol 73 (455 mg, 1.3 mmol) in dry DCM (5 mL) at -20 ºC 
and under an argon atmosphere, MsCl (123 μL, 1.6 mmol) and triethylamine (278 μL, 2.0 
mmol) were added. Then, the solution became cloudy and the mixture was allowed to 
warm to rt and stirred for 16 h. The reaction was cooled to 0 °C, quenched with 
saturated NH4Cl (aq) and extracted with EtOAc (3x). The combined organic extracts were 
sequentially washed with saturated NH4Cl (aq, 2x) and brine, dried (Na2SO4), filtered, 
and evaporated under reduced pressure to obtain 74 (562 mg, 100%), which was used in 
the next step without further purification. Rf: 0.51 (hexane/DCM, 2:8). 
 
1H-NMR (CDCl3, ): 0.23 (s, 6H, 2CH3Si), 1.00 (s, 9H, C(CH3)3), 1.98-2.07 (m, 2H, CH2), 
2.67 (dd, J=8.3, 6.7, 2H, CH2C1), 3.00 (s, 3H, CH3S), 4.22 (t, J=6.3, 2H, CH2O), 6.66 (d, 
J=8.5, 1H, H3), 7.19 (dd, J=8.5, 2.6, 1H, H4), 7.24 (d, J=2.6, 1H, H6). 
[2-(3-Azidopropyl)-4-bromophenoxy](tert-butyl)dimethylsilane (75). To a solution 
of mesylate 74 (1.60 g, 3.7 mmol) in anhydrous DMF (8.3 mL), NaN3 (362 mg, 5.6 mmol) 
was added and the mixture was stirred at 90 ºC for 2 h. The reaction was cooled to 0 ºC 
and water was added. The mixture was extracted with EtOAc (2x) and the organic 
extracts were dried (Na2SO4), filtered, and evaporated under reduced pressure to yield 
azide 75 (1.28 g, 93%), which was used in the next step without further purification. Rf: 
0.65 (hexane/DCM, 1:1). 
 
1H-NMR (CDCl3, ): 0.23 (s, 6H, 2CH3Si), 1.01 (s, 9H, C(CH3)3), 1.83-1.90 (m, 2H, CH2), 
2.62 (dd, J=8.5, 6.7, 2H, CH2C2), 3.28 (t, J=6.9, 2H, CH2N3), 6.66 (d, J=8.6, 1H, H6), 7.18 
(dd, J=8.6, 2.6, 1H, H5), 7.24 (d, J=2.5, 1H, H3). 
2-(3-Azidopropyl)-4-bromophenol (76). Following the general procedure 6.1.1.1, 
phenol 76 was obtained from 75 (1.28 g, 3.5 mmol) in 93% yield (824 mg). 
Chromatography: hexane to hexane/DCM, 2:8. Rf: 0.11 (hexane/DCM, 2:8). 
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IR (ATR, ): 3373 (OH), 2098 (N3), 1655, 1583, 1490 (Ar); 
1H-NMR (CDCl3, ): 1.85-
1.94 (m, 2H, CH2), 2.68 (t, J=7.4, 2H, CH2C2), 3.32 (t, J=6.6, 2H, CH2N3), 5.11 (br s, 1H, OH), 
6.66 (d, J=8.3, 1H, H6), 7.20 (dd, J=8.3, 2.4, 1H, H5), 7.22 (d, J=2.4, 1H, H3); 
13C-NMR 
(CDCl3, ): 26.8 (CH2C2), 28.9 (CH2), 50.7 (CH2N3), 113.0 (C4), 117.4 (C6), 129.4 (C2), 130.4 
(C5), 133.1 (C3), 153.0 (C1); MS (ESI, m/z): 227.7 [M(
79Br)-N2+H]
+, 229.8 [M(81Br)-N2+H]
+. 
2-(3-Azidopropyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (77). 
Bromoderivative 76 (68 mg, 0.26 mmol), Pd(dppf)Cl2 (10 mg, 13 mol), and KOAc (52 
mg, 0.53 mmol) were introduced into a flask previously dried under vacuum and flushed 
with argon. Anhydrous 1,4-dioxane (1.8 mL) was added and the mixture was stirred at 
80 ºC for 30 min. Then, a solution of B2pin2 (74 mg, 0.29 mmol) in anhydrous 1,4-dioxane 
(0.8 mL) was added and the reaction was stirred at 80 ºC for 16 h. Once cooled to rt, the 
suspension was filtered through activated carbon and celite and evaporated under 
reduced pressure. The residue was redissolved in EtOAc, washed with water and brine, 
dried (Na2SO4), filtered, and evaporated under reduced pressure. The crude was purified 
by chromatography (hexane to DCM) to afford boronate 77 (62 mg, 78%). Rf: 0.11 
(DCM). 
 
IR (ATR, ): 3338 (OH), 2094 (N3), 1604 (Ar), 1352 (BO), 1268 (COC), 1144, 1117 (BC); 
1H-NMR (CDCl3, ): 1.33 (s, 12H, 2C(CH3)2), 1.87-1.98 (m, 2H, CH2), 2.71 (t, J=7.4, 2H, 
CH2C2), 3.31 (t, J=6.7, 2H, CH2N3), 5.33 (br s, 1H, OH), 6.76 (d, J=8.3, 1H, H6), 7.571 (dd, 
J=8.2, 1.6, 1H, H5), 7.573 (d, J=1.4, 1H, H3); 
13C-NMR (CDCl3, ): 25.0 (2C(CH3)2), 26.9 
(CH2C2), 29.2 (CH2), 51.0 (CH2N3), 83.7 (2C(CH3)2), 100.1 (C4), 115.2 (C6), 126.4 (C2), 134.9, 
137.5 (C3, C5), 156.7 (C1); MS (ESI, m/z): 302.1 [M-H]
-. 
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Suzuki coupling of bromoderivative 69 and boronate 77. Boronate 77 (93 mg, 0.39 
mmol), KF (112 mg, 1.9 mmol) and bromoderivative 69 (130 mg, 0.39 mmol) were 
introduced in a Shlenk falsk previously dried under vacuum and refilled with argon. 
Then, a 10:1 mixture of 1,4-dioxane/water (8.5 mL) was added and the mixture was 
stirred in an ultrasound bath for 1 min. Pd2dba3 (20.0 mg, 19 mol) and S-PHOS (51 mg, 
0.12 mmol) were added and the reaction mixture was stirred at 110 ºC for 16 h. Once 
cooled to rt, the resulting suspension was filtered through a pad of celite, washing with 
EtOAc, dried (Na2SO4), filtered, and evaporated under reduced pressure. The crude was 
analyzed by NMR, observing a mixture of the desired coupling product, together with 
the product resulting from the double bond isomerization, which could not be separated 
by chromatography. 
 Linear synthesis of azide 60 
2-Bromo-4-chloro-1-ethoxybenzene (78). Following the general procedure 6.1.1.2, 
compound 78 was obtained from 2-bromo-4-chlorophenol (2.00 g, 9.6 mmol) and 
bromoethane (0.9 mL, 12 mmol) in 96% yield (2.20 g). Chromatography: hexane. Rf: 0.49 
(hexane/EtOAc, 96:4). 
 
 
IR (ATR, ): 1585, 1470 (Ar), 1285, 1253 (COC); 1H-NMR (CDCl3, ): 1.46 (t, J=7.0, 3H, 
CH3), 4.07 (q, J=7.0, 2H, CH2), 6.80 (d, J=8.8, 1H, H6), 7.21 (dd, J=8.8, 2.5, 1H, H5), 7.53 (d, 
J=2.6, 1H, H3); 
13C-NMR (CDCl3, ): 14.8 (CH3), 63.4 (CH2), 112.8 (C2), 114.0 (C6), 126.0 
(C4), 128.4 (C5), 133.0 (C3), 154.4 (C1); MS (ESI, m/z): 232.6 [M(
35Cl, 79Br)-H]-, 234.6 
[M(37Cl, 79Br)-H]- and [M(35Cl, 81Br)-H]-, 236.6 [M(37Cl, 81Br)-H]-. 
5'-Chloro-2'-ethoxybiphenyl-4-ol (79). Following the general procedure 6.1.1.3, 
biphenyl 79 was obtained from bromoderivative 78 (100 mg, 0.42 mmol) and 4-
hydroxyphenylboronic acid (88 mg, 0.64 mmol) in 92% yield (96 mg). Chromatography: 
hexane to hexane/EtOAc, 9:1. Mp: 123.0-123.8 ºC. Rf: 0.16 (hexane/EtOAc, 9:1). 
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IR (ATR, ): 3288, 3258 (OH), 1610, 1515, 1485 (Ar), 1262, 1232 (COC); 1H-NMR 
(CDCl3, ): 1.34 (t, J=7.0, 3H, CH3), 4.00 (q, J=7.0, 2H, CH2), 4.76 (br s, 1H, OH), 6.87 (d, 
J=8.6, 3H, H3, H5, H3’), 7.20 (dd, J=8.7, 2.7, 1H, H4’), 7.27 (d, J=2.7, 1H, H6’), 7.43 (d, J=8.6, 
2H, H2, H6); 
13C-NMR (CDCl3, ): 14.8 (CH3), 64.6 (CH2), 114.1 (C3’), 115.1 (C3, C5), 125.8 
(C5’), 127.7 (C4’), 130.1 (C1), 130.4 (C6’), 130.9 (C2, C6), 132.2 (C1’), 154.6 (C2’), 155.0 (C4); 
MS (ESI, m/z): 247.1 [M(35Cl)-H]-, 249.1 [M(37Cl)-H]-. 
4'-(Allyloxy)-5-chloro-2-ethoxybiphenyl (80). Following the general procedure 
6.1.1.2, allyl ether 80 was obtained from phenol 79 (157 mg, 0.63 mmol) and allyl 
bromide (60 µL, 0.70 mmol) in 98% yield (178 mg), and was used in the next step 
without further purification. Rf: 0.36 (hexane/EtOAc, 95:5). 
 
IR (ATR, ): 1609, 1515, 1484 (Ar), 1292, 1240 (COC); 1H-NMR (CDCl3, ): 1.35 (t, 
J=7.0, 3H, CH3), 4.00 (q, J=7.0, 2H, CH2CH3), 4.58 (dt, J=5.2, 1.3, 2H, CH2CH=), 5.29-5.33 
(m, 1H, ½CH2=), 5.44 (dq, J=17.3, 1.4, 1H, ½CH2=), 6.09 (ddt, J=17.1, 10.5, 5.3, 1H, CH=), 
6.87 (d, J=8.7, 1H, H3), 6.96 (d, J=8.8, 2H, H3’, H5’), 7.20 (dd, J=8.7, 2.7, 1H, H4), 7.28 (d, 
J=2.7, 1H, H6), 7.47 (d, J=8.8, 2H, H2’, H6’); 
13C-NMR (CDCl3, ): 14.8 (CH3), 64.6 (CH2CH3), 
69.0 (CH2CH=), 114.0 (C3), 114.4 (C3’, C5’), 117.9 (CH2=), 125.8 (C5), 127.7 (C4), 130.0 (C1’), 
130.4 (C6), 130.6 (C2’, C6’), 132.2 (C1), 133.4 (CH=), 154.6 (C2), 158.1 (C4’); MS (ESI, m/z): 
289.2 [M(35Cl)+H]+, 291.0 [M(37Cl)+H]+. 
3-Allyl-5'-chloro-2'-ethoxybiphenyl-4-ol (81). Trimethyl aluminium (0.6 mL, 2 M in 
hexanes) was introduced in a flask and cooled at -20 ºC. Then, water (5.3 μL, 0.29 mmol) 
was added and the mixture was allowed to warm to rt. The resulting solution was then 
cooled to -20 ºC prior to the addition of a solution of 80 (85 mg, 0.29 mmol) in dry DCM 
(0.5 mL) and the reaction was stirred at that temperature for 3 h. The crude was diluted 
with DCM, washed with water and brine, dried (Na2SO4), filtered, and evaporated under 
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reduced pressure. The residue was purified by chromatography (hexane to 
hexane/EtOAc 9:1) to yield phenol 81 (75 mg, 90%). Mp: 69.3-70.3 ºC. Rf: 0.19 
(hexane/EtOAc, 9:1). 
 
IR (ATR, ): 3422 (OH), 1609, 1509, 1436 (Ar), 1270, 1235 (COC); 1H-NMR (CDCl3, ): 
1.34 (t, J=7.0, 3H, CH3), 3.45 (d, J=6.4, 2H, CH2C3), 4.00 (q, J=7.0, 2H, CH2O), 5.15-5.24 (m, 
2H, CH2=), 6.05 (ddt, J=16.5, 10.1, 6.4, 1H, CH=), 6.84 (d, J=8.9, 1H, H5), 6.86 (d, J=8.7, 1H, 
H3’), 7.19 (dd, J=8.7, 2.7, 1H, H4’), 7.28 (d, J=2.7, 1H, H6’), 7.320 (d, J=2.1, 1H, H2), 7.323 
(dd, J=8.8, 2.3, 1H, H6); 
13C-NMR (CDCl3, ): 14.8 (CH3), 35.3 (CH2C3), 64.6 (CH2O), 114.0 
(C3’), 115.6 (C5), 116.8 (CH2=), 125.0 (C3), 125.8 (C5’), 127.6 (C4’), 129.1 (C6), 130.1 (C1), 
130.4 (C6’), 131.7 (C2), 132.2 (C1’), 136.5 (CH=), 153.6 (C4), 154.6 (C2’); MS (ESI, m/z): 
287.0 [M(35Cl)-H]-, 289.1 [M(37Cl)-H]-. 
5'-Chloro-2'-ethoxy-3-(3-hydroxypropyl)biphenyl-4-ol (82). Following the general 
procedure 6.1.1.4, primary alcohol 82 was obtained from 81 (1.19 g, 4.1 mmol) in 84% 
yield (1.06 g). Chromatography: hexane to hexane/EtOAc, 7:3. Mp: 89.4-90.8 ºC. Rf: 0.12 
(hexane/EtOAc, 7:3). 
 
IR (ATR, ): 3300 (OH), 1608, 1509, 1471 (Ar), 1259, 1234 (COC); 1H-NMR (CDCl3, ): 
1.34 (t, J=7.0, 3H, CH3), 1.87-1.96 (m, 2H, CH2), 2.81 (t, J=6.7, 2H, CH2C3), 3.69 (t, J=5.8, 
2H, CH2OH), 4.00 (q, J=7.0, 2H, CH2O), 6.86 (d, J=8.7, 1H, H5), 6.88 (d, J=8.8, 1H, H3’), 7.18 
(dd, J=8.7, 2.7, 1H, H4’), 7.28 (d, J=2.7, 1H, H6’), 7.28-7.31 (m, 2H, H2, H6); 
13C-NMR (CDCl3, 
): 14.9 (CH3), 25.4 (CH2C3), 32.3 (CH2), 60.9 (CH2OH), 64.5 (CH2O), 114.0 (C3’), 116.0 (C5), 
125.8 (C5’), 126.8 (C3), 127.5 (C4’), 128.8 (C6), 129.8 (C1), 130.3 (C6’), 131.3 (C2), 132.3 (C1’), 
154.2 (C4), 154.5 (C2’); MS (ESI, m/z): 305.1 [M(
35Cl)-H]-, 307.1 [M(37Cl)-H]-. 
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Representative example of the Stille coupling of 82 with allyltributylstannane. 
Pd[P(t-Bu)3]2 (2 mg, 4 μmol) and CsF (52 mg, 0.34 mmol) were introduced in a MW vial. 
The vial was evacuated and refilled with argon twice. Then,  a solution of 
chloroderivative 82 (26 mg, 85 mol) in anhydrous 1,4-dioxane (3.8 mL) was added 
followed by allyltributylstannane (40 μL, 0.13 mmol). The mixture was heated at 200 ºC 
for 90 min under MW irradiation. Once cooled to rt, the reaction was filtered through 
celite, washing with EtOAc, and evaporated under reduced pressure to yield a mixture of 
the coupling product 83 and starting material 82 (analyzed by NMR of the reaction 
crude). 
2'-Ethoxy-3-(3-hydroxypropyl)-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)biphenyl-4-ol (84). Following the general procedure 6.1.1.5, boronate 84 was 
obtained from chloroderivative 82 (800 mg, 2.6 mmol) in 89% yield (929 mg). 
Chromatography: DCM to DCM/EtOAc, 9:1. Mp: 69.7-70.5 ºC. Rf: 0.30 (DCM/EtOAc, 9:1). 
 
IR (ATR, ): 3319 (OH), 1601, 1484 (Ar), 1262 (COC), 1097, 1031 (BC); 1H-NMR (CDCl3, 
): 1.34 (s, 12H, 2C(CH3)2), 1.36 (t, J=7.0, 3H, CH3), 1.78 (br s, 1H, CH2OH), 1.90 (qt, J=6.3, 
2H, CH2), 2.80 (t, J=6.7, 2H, CH2C3), 3.67 (t, J=5.8, 2H, CH2OH), 4.00 (q, J=7.0, 2H, CH2O), 
6.85 (d, J=8.0, 1H, H5), 6.94 (d, J=8.2, 1H, H3’), 7.32 (dd, J=8.1, 2.3, 1H, H6), 7.34 (d, J=2.2, 
1H, H2), 7.72 (dd, J=8.1, 1.7, 1H, H4’), 7.75 (d, J=1.6, 1H, H6’); 
13C-NMR (CDCl3, ): 14.8 
(CH3), 25.0 (2C(CH3)2), 25.4 (CH2C3), 32.4 (CH2), 61.0 (CH2OH), 63.9 (CH2O), 83.8 
(2C(CH3)2), 111.7 (C3’), 115.7 (C5), 121.0 (C5’), 126.5 (C3), 129.0 (C6), 130.0 (C1’), 131.0 (C1), 
132.0 (C2), 135.3 (C4’), 137.4 (C6’), 153.7 (C4), 158.5 (C2’); MS (ESI, m/z): 397.2 [M-H]
-. 
5'-Allyl-2'-ethoxy-3-(3-hydroxypropyl)biphenyl-4-ol (83). Following the general 
procedure 6.1.1.6, allyl derivative 83 was obtained from boronate 84 (247 mg, 0.62 
mmol) in 60% yield (116 mg). Chromatography: DCM to DCM/EtOAc, 9:1. Rf: 0.26 
(DCM/EtOAc, 85:15). 
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IR (ATR, ): 3357 (OH), 1606, 1492 (Ar), 1269, 1236 (COC); 1H-NMR (CDCl3, ): 1.34 (t, 
J=7.0, 3H, CH3), 1.87-1.96 (m, 2H, CH2), 2.66 (br s, 1H, CH2OH), 2.82 (t, J=6.8, 2H, CH2C3), 
3.37 (d, J=6.7, 2H, CH2C5’), 3.69 (t, J=5.8, 2H, CH2OH), 4.00 (q, J=7.0, 2H, CH2O), 5.03-5.13 
(m, 2H, CH2=), 5.99 (ddt, J=16.9, 10.1, 6.8, 1H, CH=), 6.87 (d, J=8.2, 1H, H5), 6.89 (d, J=8.3, 
1H, H3’), 7.07 (dd, J=8.3, 2.3, 1H, H4’), 7.14 (d, J=2.2, 1H, H6’), 7.31 (dd, J=8.2, 2.3, 1H, H6), 
7.35 (d, J=2.2, 1H, H2); 
13C-NMR (CDCl3, ): 15.0 (CH3), 25.4 (CH2C3), 32.3 (CH2), 39.6 
(CH2C5’), 60.9 (CH2OH), 64.3 (CH2O), 113.0 (C3’), 115.6 (CH2=), 115.9 (C5), 126.4 (C3), 128.0 
(C4’), 128.9 (C6), 130.6 (C1’), 131.0 (C6’), 132.00 (C2), 132.04 (C1), 132.4 (C5’), 138.0 (CH=), 
153.8 (C4), 154.3 (C2’); MS (ESI, m/z): 311.0 [M-H]
-. 
3-(5'-Allyl-2'-ethoxy-4-hydroxybiphenyl-3-yl)propyl methanesulfonate (85). 
Following the general procedure 6.1.1.7, mesylate 85 was obtained from primary 
alcohol 83 (210 mg, 0.67 mmol) in 42% yield (110 mg). Chromatography: DCM to 
DCM/EtOAc, 99:1. Rf: 0.35 (DCM/EtOAc, 98:2). 
 
IR (ATR, ): 3420 (OH), 1608, 1494 (Ar), 1265, 1234 (COC), 1171 (SO2); 
1H-NMR 
(CDCl3, ): 1.34 (t, J=7.0, 3H, CH3CH2), 2.12 (qt, J=6.9, 2H, CH2), 2.79 (t, J=7.4, 2H, CH2C3), 
2.99 (s, 3H, CH3S), 3.36 (d, J=6.7, 2H, CH2C5’), 4.01 (q, J=7.0, 2H, CH2O), 4.30 (t, J=6.3, 2H, 
CH2OMs), 4.97 (br s, 1H, OH), 5.03-5.12 (m, 2H, CH2=), 5.98 (ddt, J=16.9, 10.1, 6.8, 1H, 
CH=), 6.77 (d, J=8.1, 1H, H5), 6.89 (d, J=8.3, 1H, H3’), 7.07 (dd, J=8.3, 2.1, 1H, H4’), 7.12 (d, 
J=2.1, 1H, H6’), 7.30 (dd, J=8.2, 2.2, 1H, H6), 7.34 (d, J=1.9, 1H, H2); 
13C-NMR (CDCl3, ): 
15.0 (CH3CH2), 26.2 (CH2C3), 29.4 (CH2), 37.6 (CH3S), 39.6 (CH2C5’), 64.3 (CH2O), 69.9 
(CH2OMs), 113.0 (C3’), 115.2 (C5), 115.7 (CH2=), 126.0 (C3), 128.2 (C4’), 128.9 (C6), 130.4 
(C1’), 131.0 (C6’), 131.6 (C1), 131.8 (C2), 132.5 (C5’), 138.0 (CH=), 152.7 (C4), 154.3 (C2’); MS 
(ESI, m/z): 413.1 [M+Na]+. 
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5'-Allyl-3-(3-azidopropyl)-2'-ethoxybiphenyl-4-ol (60). Following the general 
procedure 6.1.1.8, azide 60 was obtained from mesylate 85 (12 mg, 31 mol) in 70% 
yield (7 mg). Chromatography: DCM to DCM/EtOAc, 95:5. Rf: 0.54 (DCM/EtOAc, 99:1). 
 
IR (ATR, ): 2930 (OH), 2096 (N3), 1638, 1580, 1493 (Ar), 1264, 1231 (COC); 
1H-NMR 
(500 MHz, CDCl3, ): 1.34 (t, J=7.0, 3H, CH3), 1.96 (qt, J=7.0, 2H, CH2), 2.75 (t, J=7.3, 2H, 
CH2C3), 3.357 (t, J=6.9, 2H, CH2N3), 3.364 (d, J=6.9, 2H, CH2C5’), 4.01 (q, J=7.0, 2H, CH2O), 
4.99 (br s, 1H, OH), 5.05-5.11 (m, 2H, CH2=), 5.98 (ddt, J=16.9, 10.1, 6.8, 1H, CH=), 6.79 
(d, J=8.2, 1H, H5), 6.89 (d, J=8.3, 1H, H3’), 7.07 (dd, J=8.3, 2.0, 1H, H4’), 7.12 (d, J=1.9, 1H, 
H6’), 7.30 (dd, J=8.2, 2.1, 1H, H6), 7.34 (d, J=1.8, 1H, H2); 
13C-NMR (125 MHz, CDCl3, ): 
15.0 (CH3), 27.1 (CH2C3), 29.1 (CH2), 39.6 (CH2C5’), 50.9 (CH2N3), 64.3 (CH2O), 113.0 (C3’), 
115.2 (C5), 115.7 (CH2=), 126.3 (C3), 128.1 (C4’), 128.8 (C6), 130.5 (C1’), 131.0 (C6’), 131.5 
(C1), 131.8 (C2), 132.5 (C5’), 138.0 (CH=), 152.8 (C4), 154.3 (C2’); HPLC-MS (ESI, m/z): 335.7 
[M-H]-; tR (method A): 11.91 min. 
 Synthesis of azide 61 
2'-Ethoxy-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)biphenyl-4-ol (86). 
Following the general procedure 6.1.1.5, boronate 86 was obtained from 
chloroderivative 79 (460 mg, 1.8 mmol) in 75% yield (472 mg). Chromatography: hexane 
to hexane/EtOAc, 8:2. Mp: 168.2-169.1 ºC. Rf: 0.08 (hexane/EtOAc, 9:1). 
 
 
IR (ATR, ): 3370 (OH), 1599, 1515, 1471 (Ar), 1353 (BO), 1262, 1231 (COC), 1139 
(BC); 1H-NMR (CDCl3, ): 1.34 (s, 12H, 2C(CH3)2), 1.36 (t, J=7.0, 3H, CH3), 4.08 (q, J=7.0, 
2H, CH2), 4.91 (br s, 1H, OH), 6.84 (d, J=8.7, 2H, H3, H5), 6.94 (d, J=8.1, 1H, H3’), 7.45 (d, 
J=8.7, 2H, H2, H6), 7.73 (dd, J=8.2, 1.7, 1H, H4’), 7.75 (d, J=1.5, 1H, H6’); 
13C-NMR (CDCl3, 
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): 14.8 (CH3), 25.0 (2C(CH3)2), 63.9 (CH2), 83.8 (2C(CH3)2), 111.7 (C3’), 114.8 (C3, C5), 
120.5 (C5’), 129.9 (C1’), 131.0 (C2, C6), 131.2 (C1), 135.5 (C4’), 137.6 (C6’), 154.6 (C4), 158.5 
(C2’); MS (ESI, m/z): 338.8 [M-H]
-. 
5'-Allyl-2'-ethoxybiphenyl-4-ol (87). Following the general procedure 6.1.1.6, allyl 
derivative 87 was obtained from boronate 86 (536 mg, 1.6 mmol) in 75% yield (301 mg). 
Chromatography: hexane to hexane/EtOAc, 9:1. Rf: 0.21 (hexane/EtOAc, 9:1). 
 
IR (ATR, ): 3404 (OH), 1609, 1515, 1495, 1394 (Ar), 1264, 1234 (COC); 1H-NMR 
(CDCl3, ): 1.33 (t, J=7.0, 3H, CH3), 3.36 (d, J=6.7, 2H, CH2C5’), 4.00 (q, J=7.0, 2H, CH2O), 
4.73 (br s, 1H, OH), 5.03-5.12 (m, 2H, CH2=), 5.98 (ddt, J=16.9, 10.1, 6.8, 1H, CH=), 6.86 
(d, J=8.8, 2H, H3, H5), 6.89 (d, J=8.9, 1H, H3’), 7.07 (dd, J=8.3, 2.2, 1H, H4’), 7.12 (d, J=2.2, 
1H, H6’), 7.45 (d, J=8.7, 2H, H2, H6); 
13C-NMR (CDCl3, ): 15.0 (CH3), 39.6 (CH2C5), 64.4 
(CH2O), 113.1 (C3’), 114.9 (C3, C5), 115.7 (CH2=), 128.1 (C4’), 130.5 (C1), 130.9 (C2, C6), 
131.0 (C6’), 131.4 (C1’), 132.5 (C5’), 138.0 (CH=), 154.4 (C2’), 154.6 (C4); MS (ESI, m/z): 
252.8 [M-H]-. 
2'-Ethoxy-5'-(3-hydroxypropyl)biphenyl-4-ol (88). Following the general procedure 
6.1.1.4, primary alcohol 88 was obtained from 87 (400 mg, 1.6 mmol) in 53% yield (227 
mg). Chromatography: hexane to hexane/EtOAc, 6:4. Mp: 88.1-88.8 ºC. Rf: 0.15 
(hexane/EtOAc, 6:4). 
 
IR (ATR, ): 3314 (OH), 1610, 1516, 1495, 1446 (Ar), 1262, 1234 (COC); 1H-NMR 
(CDCl3, ): 1.33 (t, J=7.0, 3H, CH3), 1.62 (br s, 1H, CH2OH), 1.86-1.96 (m, 2H, CH2), 2.69 (t, 
J=7.6, 2H, CH2C5’), 3.71 (t, J=6.4, 2H, CH2OH), 4.00 (q, J=7.0, 2H, CH2O), 5.51 (br s, 1H, 
OH), 6.85 (d, J=8.7, 2H, H3, H5), 6.88 (d, J=8.4, 1H, H3’), 7.08 (dd, J=8.3, 2.3, 1H, H4’), 7.14 
(d, J=2.3, 1H, H6’), 7.44 (d, J=8.7, 2H, H2, H6); 
13C-NMR (CDCl3, ): 15.0 (CH3), 31.4 (CH2C5’), 
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34.4 (CH2), 62.6 (CH2OH), 64.4 (CH2O), 113.2 (C3’), 115.0 (C3, C5), 127.9 (C4’), 130.6 (C1’), 
130.8 (C6’), 130.9 (C2, C6), 131.2 (C1), 134.1 (C5’), 154.2 (C2’), 154.8 (C4); MS (ESI, m/z): 
270.8 [M-H]-. 
3-[4'-(Allyloxy)-6-ethoxybiphenyl-3-yl]propan-1-ol (89). Following the general 
procedure 6.1.1.2, allyl ether 89 was obtained from phenol 88 (220 mg, 0.81 mmol) and 
allyl bromide (84 µL, 0.97 mmol) in 92% yield (235 mg) and was used in the next step 
without further purification. Mp: 55.9-56.3 ºC. Rf: 0.39 (hexane/EtOAc, 6:4). 
 
IR (ATR, ): 3357 (OH), 1608, 1515, 1494 (Ar), 1239 (COC); 1H-NMR (CDCl3, ): 1.33 (t, 
J=7.0, 3H, CH3), 1.85-1.95 (m, 2H, CH2), 2.69 (t, J=7.7, 2H, CH2C3), 3.69 (t, J=6.4, 2H, 
CH2OH), 4.00 (q, J=7.0, 2H, CH2CH3), 4.58 (dt, J=5.3, 1.5, 2H, CH2CH=), 5.30 (dq, J=10.5, 
1.4, 1H, ½CH2=), 5.44 (dq, J=17.3, 1.6, 1H, ½CH2=), 6.09 (ddt, J=17.2, 10.6, 5.3, 1H, CH=), 
6.88 (d, J=8.3, 1H, H5), 6.95 (d, J=8.8, 2H, H3’, H5’), 7.08 (dd, J=8.3, 2.2, 1H, H4), 7.15 (d, 
J=2.2, 1H, H2), 7.49 (d, J=8.9, 2H, H2’, H6’); 
13C-NMR (CDCl3, ): 15.0 (CH3), 31.4 (CH2C3), 
34.6 (CH2), 62.5 (CH2OH), 64.4 (CH2CH3), 69.0 (CH2CH=), 113.1 (C5), 114.3 (C3’, C5’), 117.8 
(CH2=), 127.9 (C4), 130.5 (C1), 130.7 (C2’, C6’), 130.9 (C2), 131.4 (C1’), 133.6 (CH=), 134.2 
(C3), 154.2 (C6), 157.7 (C4’); MS (ESI, m/z): 313.1 [M+H]
+. 
3-Allyl-2'-ethoxy-5'-(3-hydroxypropyl)biphenyl-4-ol (90). Following the general 
procedure 6.1.1.9, phenol 90 was obtained from allyl ether 89 (30 mg, 96 mol) in 97% 
yield (29 mg), and was used in the next step without further purification. Rf: 0.27 
(hexane/EtOAc, 6:4). 
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IR (ATR, ): 3316 (OH), 1608, 1510, 1491, 1441 (Ar), 1268, 1236 (COC); 1H-NMR 
(CDCl3, ): 1.34 (t, J=7.0, 3H, CH3), 1.86-1.95 (m, 2H, CH2), 2.69 (app t, J=7.7, 2H, CH2C5’), 
3.45 (d, J=6.4, 2H, CH2C3), 3.70 (t, J=6.4, 2H, CH2OH), 4.00 (q, J=7.0, 2H, CH2O), 5.08 (br s, 
1H, OH), 5.14-5.24 (m, 2H, CH2=), 6.06 (ddt, J=16.9, 10.3, 6.5, 1H, CH=), 6.84 (d, J=8.9, 
1H, H5), 6.88 (d, J=8.3, 1H, H3’), 7.08 (dd, J=8.3, 2.2, 1H, H4’), 7.14 (d, J=2.2, 1H, H6’), 7.32-
7.35 (m, 2H, H2, H6); 
13C-NMR (CDCl3, ): 15.0 (CH3), 31.4 (CH2C5’), 34.6 (CH2), 35.4 
(CH2C3), 62.5 (CH2OH), 64.4 (CH2O), 113.1 (C3’), 115.4 (C5), 116.6 (CH2=), 124.8 (C3), 127.9 
(C4’), 129.1 (C6), 130.6 (C1’), 130.8 (C6’), 131.4 (C1), 131.8 (C2), 134.2 (C5’), 136.7 (CH=), 
153.2 (C4), 154.2 (C2’); MS (ESI, m/z): 311.1 [M-H]
-. 
3-(3'-Allyl-6-ethoxy-4'-hydroxybiphenyl-3-yl)propyl methanesulfonate (91). 
Following the general procedure 6.1.1.7, mesylate 91 was obtained from primary 
alcohol 90 (330 mg, 1.1 mmol) in 77% yield (319 mg). Chromatography: DCM/EtOAc, 
99:1. Rf: 0.16 (hexane/EtOAc, 7:3). 
 
IR (ATR, ): 3468 (OH), 1608, 1494 (Ar), 1350, 1171 (SO2), 1269, 1237 (COC); 
1H-NMR 
(CDCl3, ): 1.34 (t, J=7.0, 3H, CH3CH2), 2.03-2.12 (m, 2H, CH2), 2.72 (t, J=7.5, 2H, CH2C3), 
2.99 (s, 3H, CH3S), 3.46 (d, J=6.4, 2H, CH2C3’), 4.00 (q, J=7.0, 2H, CH2O), 4.24 (t, J=6.3, 2H, 
CH2OMs), 4.95 (br s, 1H, OH), 5.15-5.24 (m, 2H, CH2=), 6.06 (ddt, J=16.9, 10.3, 6.5, 1H, 
CH=), 6.84 (d, J=8.9, 1H, H5’), 6.88 (d, J=8.3, 1H, H5), 7.06 (dd, J=8.3, 2.2, 1H, H4), 7.12 (d, 
J=2.2, 1H, H2), 7.33 (dd, J=8.7, 2.2, 1H, H6’), 7.34 (d, J=2.1, 1H, H2’); 
13C-NMR (CDCl3, ): 
14.9 (CH3CH2), 30.8 (CH2C3), 30.9 (CH2), 35.2 (CH2C3’), 37.4 (CH3S), 64.3 (CH2O), 69.4 
(CH2OMs), 113.0 (C5), 115.4 (C5’), 116.5 (CH2=), 124.9 (C3’), 127.9 (C4), 128.9 (C6’), 130.7 
(C1), 130.8 (C2), 131.1 (C1’), 131.7 (C2’), 132.6 (C3), 136.6 (CH=), 153.3 (C4’), 154.4 (C6); MS 
(ESI, m/z): 389.1 [M-H]-. 
3-Allyl-5'-(3-azidopropyl)-2'-ethoxybiphenyl-4-ol (61). Following the general 
procedure 6.1.1.8, azide 61 was obtained from mesylate 91 (260 mg, 0.67 mmol) in 67% 
yield (152 mg). Chromatography: hexane to hexane/EtOAc, 9:1. Rf: 0.36 (hexane/EtOAc, 
8:2). 
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IR (ATR, ): 3444 (OH), 2098 (N3), 1609, 1495 (Ar), 1266, 1238 (COC); 
1H-NMR (500 
MHz, CDCl3, ): 1.34 (t, J=7.0, 3H, CH3), 1.91 (qt, J=7.2, 2H, CH2), 2.68 (t, J=7.5, 2H, 
CH2C5’), 3.30 (t, J=6.8, 2H, CH2N3), 3.46 (d, J=6.3, 2H, CH2C3), 4.00 (q, J=7.0, 2H, CH2O), 
5.16-5.23 (m, 2H, CH2=), 6.06 (ddt, J=16.9, 10.3, 6.5, 1H, CH=), 6.84 (d, J=8.9, 1H, H5), 
6.88 (d, J=8.3, 1H, H3’), 7.06 (dd, J=8.3, 2.2, 1H, H4’), 7.12 (d, J=2.2, 1H, H6’), 7.33 (dd, 
J=6.8, 2.0, 1H, H6), 7.34 (br s, 1H, H2); 
13C-NMR (125 MHz, CDCl3, ): 15.0 (CH3), 30.8 
(CH2), 32.1 (CH2C5’), 35.4 (CH2C3), 50.8 (CH2N3), 64.3 (CH2O), 113.1 (C3’), 115.5 (C5), 116.7 
(CH2=), 124.8 (C3), 127.9 (C4’), 129.1 (C6), 130.7 (C1’), 130.8 (C6’), 131.4 (C1), 131.8 (C2), 
133.2 (C5’), 136.6 (CH=), 153.3 (C4), 154.4 (C2’); HRMS (ESI): calcd for [M+Na]
+ 
C20H23N3NaO2: 360.1688; found: 360.1682; HPLC-MS (ESI, m/z): 336.1 [M-H]
-; tR (method 
A): 13.24 min. 
 Synthesis of azide 62 
3-(2-Bromo-4-chlorophenoxy)propan-1-ol (92). Following the general procedure 
6.1.1.2, ether 92 was obtained from 2-bromo-4-chlorophenol (2.00 g, 9.6 mmol) and 3-
bromopropan-1-ol (1.0 mL, 12 mmol) in 85% yield (2.20 g). Chromatography: hexane to 
hexane/EtOAc, 7:3. Rf: 0.16 (hexane/EtOAc, 7:3). 
 
IR (ATR, ): 3362 (OH), 1585, 1471, (Ar), 1286, 1258 (COC); 1H-NMR (CDCl3, ): 2.00 
(t, J=4.8, 1H, OH), 2.10 (qt, J=5.7, 2H, CH2), 3.91 (q app, J=5.1, 2H, CH2OH), 4.17 (t, J=5.8, 
2H, CH2O), 6.84 (d, J=8.8, 1H, H6), 7.23 (dd, J=8.8, 2.5, 1H, H5), 7.53 (d, J=2.5, 1H, H3); 
13C-
NMR (CDCl3, ): 31.8 (CH2), 60.8 (CH2OH), 67.9 (CH2O), 112.7 (C2), 113.7 (C6), 126.4 (C4), 
128.5 (C5), 132.9 (C3), 154.1 (C1); MS (ESI, m/z): 264.6 [M(
35Cl, 79Br)+H]+, 266.6 [M(35Cl, 
81Br)+H]+ and [M(37Cl, 79Br)+H]+, 268.6 [M(37Cl, 81Br)+H]+. 
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5'-Chloro-2'-(3-hydroxypropoxy)biphenyl-4-ol (93). Following the general procedure 
6.1.1.3, biphenyl derivative 93 was obtained from bromoderivative 92 (262 mg, 0.99 
mmol) and 4-hydroxyphenylboronic acid (204 mg, 1.5 mmol) in 82% yield (226 mg). 
Chromatography: DCM to DCM/EtOAc, 8:2. Mp: 114.3-115.0 ºC. Rf: 0.19 (DCM/EtOAc, 
8:2). 
 
IR (ATR, ): 3316 (OH), 1611, 1516, 1486, 1466 (Ar), 1263, 1232 (COC); 1H-NMR 
(CDCl3, ): 2.02 (qt, J=5.6, 2H, CH2), 2.23 (t, J=5.6, 1H, CH2OH), 3.76 (q app, J=5.3, 2H, 
CH2OH), 4.14 (t, J=5.6, 2H, CH2O), 6.63 (s, 1H, OH), 6.84 (d, J=8.6, 2H, H3, H5), 6.89 (d, 
J=8.9, 1H, H3’), 7.23-7.27 (m, 2H, H4’, H6’), 7.31 (d, J=8.6, 2H, H2, H6); 
13C-NMR (CDCl3, ): 
31.6 (CH2), 61.8 (CH2OH), 68.5 (CH2O), 113.3 (C3’), 115.5 (C3, C5), 126.3 (C5’), 127.8 (C4’), 
128.9 (C1), 130.6 (C2, C6, C6’), 132.7 (C1’), 154.2 (C2’), 156.2 (C4); MS (ESI, m/z): 276.7 
[M(35Cl)-H]-, 278.7 [M(37Cl)-H]-. 
2'-(3-Hydroxypropoxy)-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)biphenyl-4-
ol (94). Following the general procedure 6.1.1.5, boronate 94 was obtained from 
chloroderivative 93 (625 mg, 2.5 mmol) in 78% yield (710 mg). Chromatography: DCM to 
DCM/EtOH, 98:2. Rf: 0.15 (DCM/EtOH, 98:2). 
 
IR (ATR, ): 3358 (OH), 1600, 1518, 1469 (Ar), 1355 (BO), 1264, 1234 (COC), 1140 
(BC); 1H-NMR (CDCl3, ): 1.34 (s, 12H, 2C(CH3)2), 1.92 (br s, 1H, CH2OH), 1.97 (qt, J=5.6, 
2H, CH2), 3.74 (q app, J=4.8, 2H, CH2OH), 4.17 (t, J=5.7, 2H, CH2O), 5.66 (br s, 1H, OH), 
6.83 (d, J=8.6, 2H, H3, H5), 6.96 (d, J=8.0, 1H, H3’), 7.35 (d, J=8.7, 2H, H2, H6), 7.73-7.76 (m, 
2H, H4’, H6’); 
13C-NMR (CDCl3, ): 24.9 (2C(CH3)2), 31.5 (CH2), 61.4 (CH2OH), 67.5 (CH2O), 
83.8 (2C(CH3)2), 111.2 (C3’), 115.3 (C3, C5), 121.1 (C5’), 129.7 (C1), 130.4 (C1’), 130.6 (C2, 
C6), 135.4 (C4’), 137.5 (C6’), 155.8 (C4), 158.1 (C2’); MS (ESI, m/z): 368.7 [M-H]
-. 
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3-{[5-Allyl-4'-(allyloxy)biphenyl-2-yl]oxy}propan-1-ol (95). A suspension of boronate 
94 (100 mg, 0.27 mmol), allyl bromide (70 L, 0.69 mmol), Pd2dba3 (67 mg, 61 mol), 
and K2CO3 (224 mg, 1.6 mmol) in anhydrous toluene (2 mL) was heated at 150 ºC for 45 
min under MW irradiation. The mixture was filtered through a pad of celite, washed 
with EtOAc and evaporated under reduced pressure. The residue was purifie d by 
chromatography (DCM to DCM/EtOAc 98:2) to obtain 95 (41 mg, 47%). Rf: 0.29 
(DCM/EtOAc 98:2). 
 
IR (ATR, ): 3388 (OH), 1608, 1513, 1494 (Ar), 1238 (COC); 1H-NMR (CDCl3, ): 1.64 (t, 
J=5.7, 1H, CH2OH), 1.96 (qt, J=5.7, 2H, CH2), 3.36 (d, J=6.7, 2H, CH2C5), 3.72 (q, J=5.7, 2H, 
CH2OH), 4.08 (t, J=5.8, 2H, CH2OC2), 4.57 (dt, J=5.3, 1.5, 2H, CH2OC4’), 5.03-5.12 (m, 2H, 
CH2=CHCH2C5), 5.30 (dq, J=10.5, 1.4, 1H, ½CH2=CHCH2O), 5.44 (dq, J=17.2, 1.5, 1H, 
½CH2=CHCH2O), 5.98 (ddt, J=16.9, 10.1, 6.6, 1H, CHCH2C5), 6.04-6.15 (m, 1H, CHCH2O), 
6.92 (d, J=8.2, 1H, H3), 6.96 (d, J=8.8, 2H, H3’, H5’), 7.07-7.12 (m, 2H, H4, H6), 7.42 (d, 
J=8.8, 2H, H2’, H6’); 
13C-NMR (CDCl3, ): 32.1 (CH2), 39.5 (CH2C5), 61.1 (CH2OH), 67.3 
(CH2OC2), 68.9 (CH2OC4’), 112.8 (C3), 114.4 (C3’, C5’), 115.8 (CH2=CHCH2C5), 117.8 
(CH2=CHCH2O), 128.2 (C4), 130.6 (C2’, C6’), 130.8 (C1’), 131.10 (C6), 131.11 (C1), 132.8 (C5), 
133.5 (CHCH2O), 137.8 (CHCH2C5), 154.2 (C2), 157.8 (C4’); MS (ESI, m/z): 324.8 [M+H]
+. 
3,5'-Diallyl-2'-(3-hydroxypropoxy)biphenyl-4-ol (96). Following the general 
procedure 6.1.1.9, phenol 96 was obtained from allyl ether 95 (26 mg, 80 mol) in 70% 
yield (18 mg). Chromatography: hexane to hexane/EtOAc, 6:4. Rf: 0.26 (hexane/EtOAc, 
6:4). 
 
 
 
Experimental section 
 
165 
 
IR (ATR, ): 3319 (OH), 1640 (CH=CH2), 1606, 1492, 1427 (Ar), 1269, 1235 (COC); 
1H-
NMR (CDCl3, ): 2.00 (qt, J=5.3, 2H, CH2), 3.39 (d, J=6.7, 2H, CH2C5’), 3.47 (d, J=6.5, 2H, 
CH2C3), 3.77 (t, J=5.2, 2H, CH2OH), 4.14 (t, J=5.6, 2H, CH2O), 5.09-5.19 (m, 4H, 2CH2=), 
6.01 (ddt, J=16.7, 9.8, 6.7, 1H, CHCH2C5’), 6.09 (ddt, J=16.8, 10.1, 6.6, 1H, CHCH2C3), 6.74 
(d, J=8.1, 1H, H5), 6.91 (d, J=8.1, 1H, H3’), 7.10-7.14 (m, 2H, H4’, H6’), 7.21 (dd, J=8.1, 2.2, 
1H, H6), 7.24 (d, J=2.1, 1H, H2); 
13C-NMR (CDCl3, ): 31.5 (CH2), 34.6 (CH2C3), 39.5 (CH2C5’), 
61.9 (CH2OH), 68.2 (CH2O), 112.1 (C3’), 115.2 (C5), 115.7, 115.9 (2CH2=), 126.1 (C3), 128.0, 
128.3 (C4’, C6), 130.0 (C1), 131.1 (C2/C6’), 131.2 (C2/C6’, C1’), 132.9 (C5’), 137.0 (CHCH2C3), 
137.8 (CHCH2C5’), 153.9, 154.0 (C2’, C4); MS (ESI, m/z): 323.1 [M-H]
-. 
3-[(3',5-Diallyl-4'-hydroxybiphenyl-2-yl)oxy]propyl methanesulfonate (97). 
Following the general procedure 6.1.1.7, mesylate 97 was obtained from primary 
alcohol 96 (58 mg, 0.18 mmol) in 53% yield (38 mg). Chromatography: DCM/EtOAc, 99:1. 
Rf: 0.18 (hexane/EtOAc, 7:3). 
 
IR (ATR, ): 3478 (OH), 1640 (CH=CH2), 1608, 1493, 1470 (Ar), 1353, 1173 (SO2), 
1270, 1236 (COC); 1H-NMR (CDCl3, ): 2.11 (qt, J=5.9, 2H, CH2), 2.80 (s, 3H, CH3), 3.35 (d, 
J=6.7, 2H, CH2C5), 3.44 (d, J=6.4, 2H, CH2C3’), 4.03 (t, J=5.7, 2H, CH2O), 4.25 (t, J=6.1, 2H, 
CH2OMs), 5.03-5.17 (m, 4H, 2CH2=), 5.97 (ddt, J=16.9, 10.1, 6.8, 1H, CHCH2C5), 6.04 (ddt, 
J=17.0, 10.3, 6.6, 1H, CHCH2C3’), 6.86 (d, J=8.1, 1H, H5’), 6.88 (d, J=8.2, 1H, H3), 7.07 (dd, 
J=8.3, 2.2, 1H, H4), 7.11 (d, J=2.2, 1H, H6), 7.23 (dd, J=8.2, 2.2, 1H, H6’), 7.26 (d, J=1.9, 1H, 
H2’); 
13C-NMR (CDCl3, ): 29.1 (CH2), 34.9 (CH2C3’), 36.8 (CH3), 39.5 (CH2C5), 63.9 (CH2O), 
67.0 (CH2OMs), 112.9 (C3), 115.2 (C5’), 115.7 (CH2=CHCH2C5), 116.1 (CH2=CHCH2C3’), 125.4 
(C3’), 128.1 (C4), 128.8 (C6’), 130.7, 130.9 (C1, C1’), 131.0 (C6), 131.5 (C2’), 133.0 (C5), 136.8 
(CHCH2C3’), 137.8 (CHCH2C5), 153.6, 153.7 (C2, C4’); MS (ESI, m/z): 401.1 [M-H]
-. 
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3,5'-Diallyl-2'-(3-azidopropoxy)biphenyl-4-ol (62). Following the general procedure 
6.1.1.8, azide 62 was obtained from mesylate 97 (41 mg, 0.10 mmol) in 77% yield (26 
mg). Chromatography: hexane to hexane/EtOAc, 9:1. Rf: 0.14 (hexane/EtOAc, 9:1). 
 
IR (ATR, ): 3388 (OH), 2098 (N3), 1640 (CH=CH2), 1607, 1493, 1398 (Ar), 1268, 1235 
(COC); 1H-NMR (CDCl3, ): 1.95 (qt, J=6.3, 2H, CH2), 3.371 (d, J=6.6, 2H, CH2C5’), 3.373 (t, 
J=6.6, 2H, CH2N3), 3.46 (d, J=6.3, 2H, CH2C3), 4.00 (t, J=5.8, 2H, CH2O), 5.04-5.13 (m, 2H, 
CH2=CHCH2C5’) 5.15-5.23 (m, 2H, CH2=CHCH2C3), 5.98 (ddt, J=16.9, 10.1, 6.8, 1H, 
CHCH2C5’), 6.06 (ddt, J=16.9, 10.3, 6.5, 1H, CHCH2C3), 6.85 (d, J=8.3, 1H, H5), 6.89 (d, 
J=8.3, 1H, H3’), 7.08 (dd, J=8.3, 2.2, 1H, H4’), 7.13 (d, J=2.2, 1H, H6’), 7.25-7.28 (m, 2H, H2, 
H6); 
13C-NMR (CDCl3, ): 28.9 (CH2), 35.3 (CH2C3), 39.6 (CH2C5’), 48.4 (CH2N3), 65.3 (CH2O), 
113.0 (C3’), 115.4 (C5), 115.7 (CH2=CHCH2C5’), 116.6 (CH2=CHCH2C3), 124.8 (C3), 128.1 
(C4’), 129.0 (C6), 130.9 (C1/C1’), 131.1 (C6’), 131.2 (C1/C1’), 131.7 (C2), 132.9 (C5’), 136.6 
(CHCH2C3), 137.9 (CHCH2C5’), 153.4 (C4), 154.0 (C2’); HRMS (ESI, m/z): calcd for [M-H]
- 
C21H22N3O2: 348.17175; found: 348.17175; HPLC-MS (ESI, m/z): 348.1 [M-H]
-; tR (method 
A): 12.53 min. 
 Synthesis of alkyne 63 
3-Bromo-4-ethoxybenzaldehyde (98). Following the general procedure 6.1.1.2, 
bromoderivative 98 was obtained from 3-bromo-4-hydroxybenzaldehyde (600 mg, 3.0 
mmol) and bromoethane (0.3 mL, 3.6 mmol) in 89% yield (612 mg). Chromatography: 
hexane to hexane/EtOAc, 9:1. Mp: 69-72 ºC (lit.156 64.5 ºC). Rf: 0.30 (hexane/EtOAc, 8:2). 
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IR (ATR, ): 2835, 2729, 1693 (CHO), 1593, 1567, 1494 (Ar), 1271 (COC); 1H-NMR 
(CDCl3, ): 1.52 (t, J=7.0, 3H, CH3), 4.21 (q, J=7.0, 2H, CH2), 6.98 (d, J=8.5, 1H, H5), 7.80 
(dd, J=8.5, 2.0, 1H, H6), 8.09 (d, J=2.0, 1H, H2), 9.84 (s, 1H, CHO); 
13C-NMR (CDCl3, ): 14.6 
(CH3), 65.4 (CH2), 112.4 (C5), 113.0 (C3), 130.6 (C1), 131.2 (C6), 134.8 (C2), 160.3 (C4), 189.8 
(CHO); MS (ESI, m/z): 250.8 [M(79Br)+Na]+, 252.9 [M(81Br)+Na]+. 
6-Ethoxy-4'-hydroxy-1,1'-biphenyl-3-carbaldehyde (99). Following the general 
procedure 6.1.1.3, biphenyl derivative 99 was obtained from bromoderivative 98 (750 
mg, 3.3 mmol) and 4-hydroxyphenylboronic acid (677 mg, 4.9 mmol) in 68% yield (544 
mg). Chromatography: DCM to DCM/EtOAc, 9:1. Mp: 122-125 ºC. Rf: 0.18 
(hexane/EtOAc, 7:3). 
 
IR (ATR, ): 3344 (OH), 2853, 1670 (CHO), 1592, 1515, 1496 (Ar), 1262 (COC); 1H-
NMR (CDCl3, ): 1.41 (t, J=7.0, 3H, CH3), 4.16 (q, J=7.0, 2H, CH2), 5.36 (br s, 1H, OH), 6.90 
(d, J=8.6, 2H, H3’, H5’), 7.05 (d, J=8.4, 1H, H5), 7.46 (d, J=8.6, 2H, H2’, H6’), 7.81 (dd, J=8.4, 
2.1, 1H, H4), 7.84 (d, J=2.0, 1H, H2), 9.91 (s, 1H, CHO); 
13C-NMR (CDCl3, ): 14.7 (CH3), 64.5 
(CH2), 112.0 (C5), 115.2 (C3’, C5’), 129.7 (C1’), 129.8 (C3), 130.9 (C2’, C6’), 131.1 (C1), 131.2 
(C4), 132.3 (C2), 155.3 (C4’), 161.1 (C6), 191.4 (CHO); MS (ESI, m/z): 241.1 [M-H]
-. 
4'-(Allyloxy)-6-ethoxy-1,1'-biphenyl-3-carbaldehyde (100). Following the general 
procedure 6.1.1.2, allyl ether 100 was obtained from phenol 99 (134 mg, 0.55 mmol) 
and allyl bromide (72 µL, 0.83 mmol) in 96% yield (149 mg). Chromatography: hexane to 
hexane/EtOAc, 8:2. Mp: 60.5-61.2 ºC. Rf: 0.35 (hexane/EtOAc, 8:2). 
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IR (ATR, ): 2729, 1690 (CHO), 1597, 1513, 1496, 1471 (Ar), 1263, 1244 (COC); 1H-
NMR (CDCl3, ): 1.42 (t, J=7.0, 3H, CH3), 4.16 (q, J=7.0, 2H, CH2CH3), 4.59 (dt, J=5.3, 1.5, 
2H, CH2CH=), 5.32 (dq, J=10.5, 1.4, 1H, ½CH2=), 5.45 (dq, J=17.3, 1.6, 1H, ½CH2=), 6.10 
(ddt, J=17.2, 10.5, 5.3, 1H, CH=), 6.98 (d, J=8.9, 2H, H3’, H5’), 7.05 (d, J=8.4, 1H, H5), 7.50 
(d, J=8.8, 2H, H2’, H6’), 7.81 (dd, J=8.4, 2.1, 1H, H4), 7.85 (d, J=2.1, 1H, H2), 9.92 (s, 1H, 
CHO); 13C-NMR (CDCl3, ): 14.7 (CH3), 64.5 (CH2CH3), 69.0 (CH2CH=), 112.0 (C5), 114.5 (C3’, 
C5’), 117.9 (CH2=), 129.8 (C1’), 129.9 (C3), 130.7 (C2’, C6’), 131.0 (C4), 131.1 (C1), 132.3 (C2), 
133.4 (CH=), 158.2 (C4’), 161.0 (C6), 191.2 (CHO); MS (ESI, m/z): 283.1 [M+H]
+. 
1-[4'-(Allyloxy)-6-ethoxy-1,1'-biphenyl-3-yl]propargyl-1-ol (101). To a solution of 
aldehyde 100 (390 mg, 1.4 mmol) in anhydrous THF (1 mL) at 0 ºC and under an argon 
atmosphere, ethynylmagnesium bromide (8.3 mL, 0.5 M in THF) was added dropwise 
and the mixture was stirred at rt for 2.5 h. The reaction was quenched with saturated 
NH4Cl (aq) at 0 ºC, followed by Et2O and 1 M HCl (aq). The organic phase was separated 
and the aqueous phase was extracted with Et2O. The combined organic extracts were 
washed with water and brine, dried (Na2SO4), filtered and evaporated under reduced 
pressure to yield pure 101 (412 mg, 97%), which was used in the next step without 
further purification. Rf: 0.26 (hexane/EtOAc, 7:3). 
 
IR (ATR, ): 3407, 3286 (OH), 2117 (C≡C), 1607, 1513, 1493 (Ar); 1H-NMR (CDCl3, ): 
1.36 (t, J=7.0, 3H, CH3), 2.25 (br s, 1H, OH), 2.66 (d, J=2.2, 1H, CH≡), 4.05 (q, J=7.0, 2H, 
CH2CH3), 4.58 (dt, J=5.3, 1.5, 2H, CH2CH=), 5.31 (dq, J=10.5, 1.4, 1H, ½CH2=), 5.45 (dq, 
J=17.2, 1.6, 1H, ½CH2=), 5.46 (d, J=1.9, 1H, CHOH), 6.10 (ddt, J=17.2, 10.5, 5.3, 1H, CH=), 
6.96 (d, J=8.2, 1H, H5), 6.97 (d, J=8.9, 2H, H3’, H5’), 7.45 (dd, J=8.4, 2.4, 1H, H4), 7.50 (d, 
J=2.4, 1H, H2), 7.51 (d, J=8.9, 2H, H2’, H6’); 
13C-NMR (CDCl3, ): 14.9 (CH3), 64.29 (CHOH), 
64.30 (CH2CH3), 69.0 (CH2CH=), 74.8 (CH≡), 83.8 (C≡), 112.7 (C5), 114.3 (C3’, C5’), 117.8 
(CH2=), 126.6 (C4), 129.4 (C2), 130.7 (C2’, C6’), 130.8, 130.9 (C1, C1’), 132.5 (C3), 133.5 
(CH=), 156.2 (C6), 157.9 (C4’); MS (ESI, m/z): 331.1 [M+Na]
+. 
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2-Ethoxy-4'-(allyloxy)-5-(propargyl)biphenyl (102). To a solution of alcohol 101 (50 
mg, 0.16 mmol) in dry DCM (0.4 mL) at 0 ºC and under an argon atmosphere, 
triethylsilane (TES, 39 µL, 0.24 mmol) and TFA (50 µL, 0.65 mmol) were added and the 
mixture was stirred at that temperature for 10 min. The reaction was quenched with 
saturated NaHCO3 (aq), extracted with DCM, dried (Na2SO4), filtered, and evaporated 
under reduced pressure. The crude was purified by chromatography (glass column, 
hexane/EtOAc 8:2 to hexane/EtOAc 7:3) to afford 102 (16 mg, 33%). Rf: 0.17 
(hexane/DCM, 7:3). 
 
IR (ATR, ): 1646 (C=C), 1608, 1574, 1515, 1495 (Ar), 1268, 1242 (COC); 1H-NMR 
(CDCl3, ): 1.34 (t, J=7.0, 3H, CH3), 2.18 (t, J=2.7, 1H, CH≡), 3.58 (d, J=2.7, 2H, CH2C≡), 4.02 
(q, J=7.0, 2H, CH2CH3), 4.58 (dt, J=5.3, 1.5, 2H, CH2CH=), 5.31 (dq, J=10.5, 1.4, 1H, 
½CH2=), 5.45 (dq, J=17.3, 1.6, 1H, ½CH2=), 6.10 (ddt, J=17.2, 10.5, 5.3, 1H, CH=), 6.92 (d, 
J=8.4, 1H, H3), 6.96 (d, J=8.9, 2H, H3’, H5’), 7.24 (dd, J=8.3, 2.4, 1H, H4), 7.28 (d, J=2.3, 1H, 
H6), 7.50 (d, J=8.9, 2H, H2’, H6’); 
13C-NMR (CDCl3, ): 15.0 (CH3), 24.2 (CH2C≡), 64.4 
(CH2CH3), 69.0 (CH2CH=), 70.4 (CH≡), 82.6 (C≡), 113.1 (C3), 114.3 (C3’, C5’), 117.8 (CH2=), 
127.4 (C4), 128.1 (C5), 130.3 (C6), 130.7 (C2’, C6’, C1), 131.1 (C1’), 133.6 (CH=), 154.8 (C2), 
157.8 (C4’); MS (ESI, m/z): 293.2 [M+H]
+. 
2'-Ethoxy-3-(allyl)-5'-(propargyl)biphenyl-4-ol (63). Following the general procedure 
6.1.1.9, phenol 63 was obtained from allyl ether 102 (63 mg, 0.22 mmol) in 51% yield (33 
mg). Chromatography: glass column, hexane/EtOAc, 9:1. Rf: 0.23 (hexane/EtOAc, 8:2). 
 
IR (ATR, ): 3307, 3291 (OH), 2253 (C≡C), 1511, 1493, 1475, 1438 (Ar), 1270, 1237 
(COC); 1H-NMR (500 MHz, CDCl3, ): 1.34 (t, J=7.0, 3H, CH3), 2.17 (t, J=2.7, 1H, CH≡), 3.46 
(d, J=6.4, 2H, CH2C=), 3.58 (d, J=2.7, 2H, CH2C≡), 4.00 (q, J=7.0, 2H, CH2O), 4.94 (br s, 1H, 
OH), 5.17 (dq, J=10.1, 1.5, 1H, ½CH2=), 5.21 (dq, J=17.2, 1.7, 1H, ½CH2=), 6.06 (ddt, 
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J=16.9, 10.2, 6.5, 1H, CH=), 6.84 (d, J=8.9, 1H, H5), 6.90 (d, J=8.3, 1H, H3’), 7.23 (dd, J=8.3, 
2.3, 1H, H4’), 7.27 (d, J=2.3, 1H, H6’), 7.34 (dd, J=6.9, 2.0, 1H, H6), 7.35 (m, 1H, H2); 
13C-
NMR (125 MHz, CDCl3, ): 15.0 (CH3), 24.2 (CH2C≡), 35.4 (CH2C3), 64.4 (CH2O), 70.4 (CH≡), 
82.6 (C≡), 113.1 (C3’), 115.5 (C5), 116.7 (CH2=), 124.8 (C3), 127.4 (C4’), 128.4 (C5’), 129.1 
(C6), 130.3 (C6’), 130.8 (C1’), 131.2 (C1), 131.8 (C2), 136.6 (CH=), 153.3 (C4), 154.8 (C2’); 
HPLC-MS (ESI, m/z): 291.1 [M-H]-; tR (method A): 10.60 min. 
 Synthesis of probes 56-59 
(+)-N-[4-(4-Aminobenzoyl)phenylbiotinamide (103). A suspension of biotin (293 mg, 
1.2 mmol), HOBt (163 mg, 1.2 mmol), and activated 4 Å molecular sieves in anhydrous 
DMF (10 mL) under an argon atmosphere, was heated at 77 ºC for 50 min until 
dissolution of biotin. After cooling to rt, a solution of DCC (272 mg, 1.3 mmol) in dry 
DCM (2 mL) was added dropwise. The mixture was stirred at rt for 3 h before a solution 
of 4,4’-diaminobenzophenone (500 mg, 2.4 mmol) and DMAP (15 mg, 0.12 mmol) in 
anhydrous DMF (2 mL) was added. The resulting mixture was heated at 60 ºC for 4 h and 
allowed to stir at rt for 16 h. The mixture was filtered, washed with DCM/MeOH 1:1, and 
evaporated under reduced pressure. The crude was purified by chromatography (glass 
column, DCM to DCM/MeOH 7:3) to afford amine 103 (500 mg, 97%). Mp: 272-275 ºC 
(lit.157 269-270 ºC). []D
20= +41.0 (c=0.9, DMSO). The spectroscopic data correspond with 
those previously reported.157 
 
1H-NMR ((CD3)2SO, ): 1.32-1.67 (m, 6H, (CH2)3), 2.36 (t, J=7.3, 2H, CH2CO), 2.58 (d, 
J=12.4, 1H, ½CH2S), 2.83 (dd, J=12.4, 5.1, 1H, ½CH2S), 3.10-3.16 (m, 1H, CHS), 4.12-4.16 
(m, 1H, CHN), 4.29-4.33 (m, 1H, CHN), 6.09 (br s, 2H, NH2), 6.37 (br s, 1H, NH), 6.45 (br s, 
1H, NH), 6.59 (d, J=8.7, 2H, 2CHArCNH2), 7.50 (d, J=8.7, 2H, 2CHArCCO), 7.59 (d, J=8.7, 2H, 
2CHArCCO), 7.71 (d, J=8.7, 2H, 2CHArCNH), 10.20 (br s, 1H, NHCAr). 
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6-Azidohexanoic acid (104). Compound 104 was obtained following a previously 
described procedure, and the spectroscopic data correspond with those reported.129 
A solution of 6-bromohexanoic acid (500 mg, 2.6 mmol) and NaN3 (500 mg, 7.7 
mmol) in anhydrous DMF (2.5 mL) was heated at 50 ºC for 3 h. The solvent was 
evaporated under reduced pressure and the residue was treated with EtOAc and 10% 
HCl (aq) and the organic phase was separated, washed with brine, dried (Na2SO4), 
filtered and evaporated under reduced pressure to yield 104 (308 mg, 76%), which was 
used in the next step without further purification. 
 
1H-NMR (CDCl3, ): 1.38-1.49 (m, 2H, CH2), 1.65 (sept, J=7.3, 4H, CH2CH2CO, 
CH2CH2N), 2.38 (t, J =7.4, 2H, CH2COO), 3.28 (t, J=6.8, 2H, CH2N3). 
General procedure for the synthesis of amides 105 and 106. To a solution of the 
corresponding carboxylic acid (1 equiv) and HOBt (1.1 equiv) in dry DCM (28 mL/mmol 
of acid) under an argon atmosphere, EDC (1.1 equiv) was added and the mixture was 
stirred at rt for 40 min. Then, a solution of the corresponding amine (1.5 equiv) in DMF 
(4.5 mL/mmol) was added, and the mixture was stirred at rt for 48 h. The reaction was 
diluted with EtOAc, washed with saturated NaHCO3 (aq), dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The crude was purified by chromatography (DCM 
to DCM/MeOH, 8:2) to afford the corresponding amide. 
(+)-N-{4-[4-(Biotinylamino)benzoyl]phenyl}hex-5-ynamide (105). Obtained from 5-
hexynoic acid (0.25 mL, 2.1 mmol) and amine 103 (578 mg, 1.1 mmol) in 36% yield (211 
mg). Mp: 149-152 ºC. [α]D
20:+25.7 (c=0.53, DMSO). Rf: 0.30 (DCM/MeOH, 9:1). 
 
IR (ATR, ): 3424, 3299 (NH), 1689, 1641 (CO, CON), 1593, 1526, 1457 (Ar); 1H-NMR 
((CD3)2SO, ): 1.27-1.69 (m, 6H, (CH2)3CHS), 1.77 (qt, J=7.2, 2H, CH2CH2C≡), 2.23 (td, 
J=6.9, 2.4, 2H, CH2C≡), 2.37 (t, J=7.1, 2H, CH2CO), 2.48 (t, J=7.5, 2H, CH2CO), 2.58 (d, 
J=12.5, 1H, ½CH2S), 2.79-2.85 (m, 2H, ½CH2S, CH≡), 3.09-3.15 (m, 1H, CHS), 4.12-4.16 (m, 
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1H, CHN), 4.29-4.33 (m, 1H, CHN), 6.40 (br s, 1H, NH), 6.48 (br s, 1H, NH), 7.69 (d, J=8.7, 
4H, 4CHArCCO), 7.76 (d, J=8.6, 4H, 4CHArCN), 10.26 (br s, 1H, NHCAr), 10.31 (br s, 1H, 
NHCAr); 
13C-NMR ((CD3)2SO, ): 17.4 (CH2C≡), 23.8 (CH2CH2C≡), 25.1, 28.2, 28.3 
((CH2)3CHS), 35.3, 36.4 (2CH2CO), 39.9 (CH2S), 55.5 (CHS), 59.3, 61.1 (2CHN), 71.8 (CH≡), 
84.0 (C≡), 118.2, 118.3 (4CHArCN), 131.0 (4CHArCCO), 131.7, 131.8 (2CArN), 143.1, 143.2 
(2CArCO), 162.9 (NCON), 171.3, 171.9 (2CON), 193.4 (CO); MS (ESI, m/z): 530.9 [M-H]
-. 
6-Azido-N-{[(4-biotinylamino)benzoyl]phenyl}hexanamide  (106). Obtained from 
acid 104 (181 mg, 1.2 mmol) and amine 103 (420 mg, 0.96 mmol) in 14% yield (78 mg). 
Mp: 169-172 ºC. Rf: 0.23 (DCM/MeOH, 95:5). 
 
IR (ATR, ): 3311 (NH), 2096 (N3), 1691, 1593 (CO), 1527, 1458, 1407 (Ar); 
1H-NMR 
(700 MHz, (CD3)2SO, ): 1.35-1.41 (m, 4H, CH2CH2CHS, CH2(CH2)2CHS), 1.48-1.67 (m, 8H, 
CH2CHS, (CH2)3CH2N3), 2.37 (t, J=7.3, 4H, 2CH2CO), 2.58 (d, J=12.4, 1H, ½CH2S), 2.82 (dd, 
J=12.4, 5.1, 1H, ½CH2S), 3.13 (ddd, J=8.4, 5.9, 4.4, 1H, CHS), 3.34 (t, J=6.9, 2H, CH2N3), 
4.13-4.15 (m, 1H, CHN), 4.31 (dd, J=7.3, 5.5, 1H, CHN), 6.37 (s, 1H, NH), 6.45 (s, 1H, NH), 
7.70 (d, J=8.6, 4H, 4CHArCCO), 7.76 (d, J=8.7, 4H, 4CHArCN), 10.25 (br s, 2H, 2NHCAr); 
13C-
NMR (175 MHz, (CD3)2SO, ): 24.5, 25.0, 25.8, 28.0 (CH2(CH2)2CHS, (CH2)3CH2N3), 28.1, 
28.2 ((CH2)2CHS), 36.4 (2CH2CO), 39.9 (CH2S), 50.5 (CH2N3), 55.4 (CHS), 59.2, 61.0 (2CHN), 
118.2 (4CHArCN), 130.9 (4CHArCCO), 131.7 (2CArN), 143.1 (2CArCO), 162.7 (NCON), 171.7, 
171.8 (2CON), 193.4 (CO); MS (ESI, m/z): 576.2 [M-H]-. 
General procedure for the synthesis of probes 56-59 To a mixture of the 
corresponding biotinylated alkyne or azide 105 or 106 (1 equiv), CuSO4·5H2O (1.1 equiv) 
and sodium ascorbate (1.1 equiv) in water (11 mL/mmol), a solution of the 
corresponding honokiol-based azide or alkyne 60-63 (1 equiv) in DMF (9 mL/mmmol) 
was added, and the mixture was stirred at rt for 16 h. Then, EtOAc and water were 
added and the organic phase was separated, washed with brine, dried (Na2SO4), filtered 
and evaporated under reduced pressure. The resulting solid was triturated and washed 
with Et2O to afford the corresponding pure 1,2,3-triazol. 
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(+)-N-(4-{4-[(4-{1-[3-(5'-Allyl-2'-ethoxy-4-hydroxybiphenyl-3-yl)propyl]-1H-1,2,3-
triazol-4-yl}butanoyl)amino]benzoyl}phenyl)biotinamide (56). Obtained from alkyne 
105 (24 mg, 45 mol) and azide 60 (15 mg, 45 mol) in 64% yield (25 mg). Mp: 198.6-
199.3 ºC. []D
20:+25.6 (c=0.18, DMSO). Rf: 0.15 (DCM/MeOH, 9:1). 
 
IR (ATR, ): 3300 (OH, NH), 1676 (CO), 1592, 1524, 1474, 1456 (Ar), 1255 (COC); 1H-
NMR (700 MHz, (CD3)2SO, ): 1.22 (t, J=6.9, 3H, CH3), 1.34-1.43 (m, 2H, CH2CH2CHS), 
1.48-1.54 (m, 1H, ½CH2CHS), 1.60-1.68 (m, 3H, ½CH2CHS, CH2(CH2)2CHS), 1.93 (qt, J=7.5, 
2H, CH2CH2C=), 2.09 (qt, J=7.3, 2H, CH2CH2C3), 2.37 (td, J=7.4, 2.6, 2H, CH2CO), 2.42 (t, 
J=7.5, 2H, CH2CO), 2.55 (app t, J=7.5, 2H, CH2C3), 2.58 (d, J=12.6, 1H, ½CH2S), 2.67 (t, 
J=7.5, 2H, CH2C=), 2.83 (dd, J=12.5, 5.1, 1H, ½CH2S), 3.11-3.14 (m, 1H, CHS), 3.31 (d, 
J=6.7, 2H, CH2C5’), 3.96 (q, J=6.9, 2H, CH2O), 4.14-4.15 (m, 1H, CHN), 4.31 (dd, J=7.2, 5.5, 
1H, CHN), 4.34 (t, J=7.1, 2H, CH2N), 5.00-5.02 (m, 1H, ½CH2=), 5.06 (ddd, J=17.0, 3.2, 1.4, 
1H, ½CH2=), 5.95 (ddt, J=17.0, 10.1, 6.9, 1H, CH=), 6.37 (br s, 1H, NH), 6.45 (br s, 1H, NH), 
6.81 (d, J=8.2, 1H, H5), 6.95 (d, J=8.4, 1H, H3’), 7.03 (dd, J=8.2, 2.0, 1H, H4’), 7.05 (d, J=2.0, 
1H, H6’), 7.15 (dd, J=8.2, 2.1, 1H, H6), 7.23 (d, J=2.0, 1H, H2), 7.69 (dd, J=8.7, 2.0, 4H, 
4CHArCCO), 7.75 (dd, J=8.6, 2.8, 4H, 4CHArCN), 7.92 (s, 1H, NCH=), 9.41 (br s, 1H, OH), 
10.25 (br s, 1H, NHCAr), 10.26 (br s, 1H, NHCAr); 
13C-NMR (175 MHz, (CD3)2SO, ): 14.7 
(CH3), 24.6 (CH2C=), 24.8 (CH2CH2C=), 25.0 (CH2(CH2)2CHS), 26.8 (CH2C3), 28.1, 28.2 
((CH2)2CHS), 30.0 (CH2CH2C3), 35.9, 36.4 (2CH2CO), 38.7 (CH2C5’), 39.9 (CH2S), 49.1 
(CH2N), 55.4 (CHS), 59.2, 61.1 (2CHN), 63.6 (CH2O), 112.9 (C3’), 114.5 (C5), 115.5 (CH2=), 
118.2 (4CHArCN), 121.8 (NCH=), 126.2 (C3), 127.6 (C4’), 127.9 (C6), 128.9 (C1), 129.9 (C1’), 
130.2 (C6’), 130.88 (C2), 130.91 (4CHArCCO), 131.7 (2CArN), 131.8 (C5’), 138.2 (CH=), 143.1 
(2CArCO), 146.3 (NC=), 153.7 (C2’), 154.1 (C4), 162.7 (NCON), 171.6, 171.8 (2CON), 193.4 
(CO); HRMS (MALDI, m/z): calcd for [M+H]+ C49H56N7O6S: 870.4013; found: 870.4024; 
HPLC-MS (ESI, m/z): 868.4 [M-H]-; tR (method B): 12.04 min. 
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(+)-N-(4-{4-[(4-{1-[3-(3'-Allyl-6-ethoxy-4'-hydroxybiphenyl-3-yl)propyl]-1H-1,2,3-
triazol-4-yl}butanoyl)amino]benzoyl}phenyl)biotinamide (57). Obtained from alkyne 
105 (79 mg, 0.15 mmol) and azide 61 (50 mg, 0.15 mmol) in 25% yield (33 mg). Mp: 
180.9-181.7 ºC. []D
20:+11.8 (c=0.39, DMSO). Rf: 0.17 (DCM/MeOH, 9:1). 
 
IR (ATR, ): 3334 (OH, NH), 1685 (CO), 1596, 1456 (Ar), 1262 (COC); 1H-NMR (700 
MHz, (CD3)2SO, ): 1.24 (t, J=6.9, 3H, CH3), 1.24-1.41 (m, 2H, CH2CH2CHS), 1.48-1.54 (m, 
1H, ½CH2CHS), 1.60-1.68 (m, 3H, ½CH2CHS, CH2(CH2)2CHS), 1.93 (qt, J=7.4, 2H, 
CH2CH2C=), 2.10 (qt, J=7.3, 2H, CH2CH2C3), 2.37 (td, J=7.3, 2.6, 2H, CH2CO), 2.42 (t, J=7.4, 
2H, CH2CO), 2.50-2.53 (m, 2H, CH2C3), 2.58 (d, J=12.6, 1H, ½CH2S), 2.67 (t, J=7.4, 2H, 
CH2C=), 2.83 (dd, J=12.4, 5.1, 1H, ½CH2S), 3.11-3.14 (m, 1H, CHS), 3.30 (d, J=6.7, 2H, 
CH2C3’), 3.95 (q, J=6.9, 2H, CH2O), 4.13-4.15 (m, 1H, CHN), 4.30 (t, J=7.0, 2H, CH2N), 4.29-
4.31 (m, 1H, CHN), 4.99-5.01 (m, 1H, ½CH2=), 5.06 (ddd, J=17.1, 3.2, 1.5, 1H, ½CH2=), 
5.97 (ddt, J=16.9, 10.1, 6.7, 1H, CH=), 6.37 (br s, 1H, NH), 6.45 (br s, 1H, NH), 6.80 (d, 
J=8.2, 1H, H5’), 6.93 (d, J=8.1, 1H, H5), 7.04-7.06 (m, 2H, H2, H4), 7.16 (dd, J=8.2, 2.0, 1H, 
H6’), 7.24 (d, J=1.6, 1H, H2’), 7.69 (dd, J=8.6, 1.7, 4H, 4CHArCCO), 7.75 (dd, J=8.6, 3.0, 4H, 
4CHArCN), 7.92 (s, 1H, NCH=), 9.37 (br s, 1H, OH), 10.25 (br s, 1H, NHCAr), 10.26 (br s, 1H, 
NHCAr); 
13C-NMR (175 MHz, (CD3)2SO, ): 14.7 (CH3), 24.6 (CH2C=), 24.8 (CH2CH2C=), 25.0 
(CH2(CH2)2CHS), 28.1, 28.2 ((CH2)2CHS), 31.1 (CH2C3), 31.6 (CH2CH2C3), 33.8 (CH2C3’), 35.8, 
36.4 (2CH2CO), 39.9 (CH2S), 48.7 (CH2N), 55.4 (CHS), 59.2, 61.0 (2CHN), 63.5 (CH2O), 
112.9 (C5), 114.4 (C5’), 115.3 (CH2=), 118.2 (4CHArCN), 121.9 (NCH=), 125.2 (C3’), 127.5 
(C4), 127.8 (C6’), 128.8 (C1’), 129.9 (C1), 130.0 (C2), 130.8 (C2’), 130.9 (4CHArCCO), 131.7 
(2CArN), 132.8 (C3), 137.2 (CH=), 143.1 (2CArCO), 146.4 (NC=), 153.6 (C6), 153.9 (C4’), 162.7 
(NCON), 171.6, 171.8 (2CON), 193.4 (CO); HRMS (MALDI, m/z): calcd for [M+H]+ 
C49H56N7O6S: 870.4013; found: 870.3966; HPLC-MS (ESI, m/z): 868.3 [M-H]
-; tR (method 
B): 11.89 min. 
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N-[4-(4-{[4-(1-{3-[(3',5-Diallyl-4'-hydroxybiphenyl-2-yl)oxy]propyl}-1H-1,2,3-triazol-
4-yl)butanoyl]amino}benzoyl)phenyl]biotinamide (58). Obtained from alkyne 105 (20 
mg, 37 mol) and azide 62 (13 mg, 37 mol) in 25% yield (8 mg). Rf: 0.13 (DCM/MeOH, 
9:1). 
 
IR (ATR, ): 3333 (OH, NH), 1682 (CO), 1591, 1530, 1460 (Ar), 1265 (COC); 1H-NMR 
(700 MHz, (CD3)2SO, ): 1.35-1.42 (m, 2H, CH2CH2CHS), 1.49-1.53 (m, 1H, ½CH2CHS), 
1.60-1.67 (m, 3H, ½CH2CHS, CH2(CH2)2CHS), 1.91 (qt, J=7.5, 2H, CH2CH2C=), 2.16 (qt, 
J=6.3, 2H, CH2CH2O), 2.37 (td, J=7.3, 2.8, 2H, CH2CO), 2.41 (t, J=7.6, 2H, CH2CO), 2.58 (d, 
J=12.7, 1H, ½CH2S), 2.65 (t, J=7.5, 2H, CH2C=), 2.83 (dd, J=12.4, 5.1, 1H, ½CH2S), 3.11-
3.14 (m, 1H, CHS), 3.31-3.33 (m, 4H, CH2C5, CH2C3’), 3.87 (t, J=5.9, 2H, CH2O), 4.13-4.15 
(m, 1H, CHN), 4.31 (dd, J=7.5, 5.5, 1H, CHN) 4.38 (t, J=7.0, 2H, CH2N), 4.94-4.95 (m, 1H, 
½CH2=CHCH2C3’), 5.00-5.04 (m, 2H, ½CH2=CHCH2C5, ½CH2=CHCH2C3’), 5.06 (ddd, J=16.9, 
2.8, 1.5, 1H, ½CH2=CHCH2C5), 5.92-5.98 (m, 2H, 2CH=), 6.37 (br s, 1H, NH), 6.45 (br s, 1H, 
NH), 6.84 (d, J=8.3, 1H, H5’), 6.94 (d, J=8.2, 1H, H3), 7.03 (dd, J=8.3, 2.2, 1H, H4), 7.04 (d, 
J=2.1, 1H, H6), 7.17 (dd, J=8.2, 2.1, 1H, H6’), 7.25 (d, J=1.9, 1H, H2’), 7.69 (d, J=8.6, 4H, 
4CHArCCO), 7.76 (d, J=9.7, 4H, 4CHArCN), 7.77 (s, 1H, NCH=), 9.42 (br s, 1H, OH), 10.25 (br 
s, 1H, NHCAr), 10.26 (br s, 1H, NHCAr); 
13C-NMR (175 MHz, (CD3)2SO, ): 24.6 (CH2C=), 24.8 
(CH2CH2C=), 25.0 (CH2(CH2)2CHS), 28.1, 28.2 ((CH2)2CHS), 29.6 (CH2CH2O), 33.8 (CH2C3’), 
35.9, 36.4 (2CH2CO), 38.7 (CH2C5), 39.9 (CH2S), 46.3 (CH2N), 55.4 (CHS), 59.2, 61.0 
(2CHN), 64.7 (CH2O), 112.9 (C3), 114.5 (C5’), 115.3, 115.5 (2CH2=), 118.2 (4CHArCN), 121.9 
(NCH=), 125.4 (C3’), 127.7 (C4), 127.9 (C6’), 128.8 (C1’), 130.1 (C1), 130.2 (C6), 130.7 (C2), 
130.9 (4CHArCCO), 131.7 (2CArN, C5), 137.2 (CHCH2C3’), 138.1 (CHCH2C5), 143.1 (2CArCO), 
146.4 (NC=), 153.4 (C2), 154.0 (C4’), 162.7 (NCON), 171.5, 171.8 (2CON), 193.4 (CO); 
HPLC-MS (ESI, m/z): 880.4 [M-H]-; tR (method B): 12.54 min. 
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(+)-6-(4-{[6-Ethoxy-4'-hydroxy-3'-(allyl)biphenyl-3-yl]methyl}-1H-1,2,3-triazol-1-yl)-
N-biotinylamino)benzoyl]phenyl}hexanamide (59). Obtained from azide 106 (26 mg, 44 
mol) and alkyne 63 (13 mg, 44 mol) in 49% yield (19 mg). Mp: 143-146 ºC. []D
20:+27.8 
(c=0.23, DMSO). Rf: 0.12 (DCM/MeOH, 9:1) 
 
IR (ATR, ): 3305 (OH, NH), 1688, 1593 (CO), 1525, 1459, 1405 (Ar), 1259 (COC); 1H-
NMR (700 MHz, (CD3)2SO, ): 1.23 (t, J=6.9, 3H, CH3), 1.25-1.28 (m, 2H, CH2(CH2)2N), 
1.35-1.46 (m, 2H, CH2CH2CHS), 1.48-1.53 (m, 1H, ½CH2CHS), 1.59-1.68 (m, 5H, ½CH2CHS, 
CH2(CH2)2CHS, CH2(CH2)3N), 1.81 (qt, J=7.3, 2H, CH2CH2N), 2.33 (t, J=7.4, 2H, CH2CO), 
2.35-2.38 (m, 2H, CH2CO), 2.58 (d, J=12.5, 1H, ½CH2S), 2.82 (dd, J=12.4, 5.1, 1H, ½CH2S), 
3.11-3.14 (m, 1H, CHS), 3.30 (d, J=6.6, 2H, CH2C3’), 3.91 (s, 2H, CH2C3) 3.94 (q, J=7.0, 2H, 
CH2O), 4.13-4.15 (m, 1H, CHN), 4.28-4.32 (m, 3H, CHN, CH2N), 5.00 (br d, J=9.9, 1H, 
½CH2=), 5.07 (dd, J=17.1, 1.3, 1H, ½CH2=), 5.96 (ddt, J=17.0, 10.1, 6.8, 1H, CH=), 6.37 (br 
s, 1H, NH), 6.45 (br s, 1H, NH), 6.80 (d, J=8.2, 1H, H5’), 6.93 (d, J=8.4, 1H, H5), 7.06 (dd, 
J=8.40, 2.0, 1H, H4), 7.10 (d, J=1.9, 1H, H2), 7.12 (dd, J=8.3, 2.0, 1H, H6’), 7.20 (d, J=1.6, 
1H, H2’), 7.69 (d, J=8.6, 4H, 4CHArCCO), 7.74 (d, J=8.0, 2H, 2CHArCN), 7.76 (d, J=8.4, 2H, 
2CHArCN), 7.83 (m, 1H, NCH=), 9.39 (br s, 1H, OH), 10.23 (br s, 1H, NHCAr), 10.25 (br s, 
1H, NHCAr); 
13C-NMR (175 MHz, (CD3)2SO, ): 14.7 (CH3), 24.4, 25.0, 25.5 (CH2(CH2)2CHS, 
(CH2)2CH2CO), 28.1, 28.2 ((CH2)2CHS), 29.6 (CH2CH2N), 30.5 (CH2C3), 33.8 (CH2C3’), 36.3, 
36.4 (2CH2CO), 40.0 (CH2S), 49.0 (CH2N), 55.4 (CHS), 59.2, 61.0 (2CHN), 63.5 (CH2O), 
112.9 (C5), 114.4 (C5’), 115.4 (CH2=), 118.2 (4CHArCN), 122.2 (NCH=), 125.2 (C3’), 127.7 
(C4), 127.8 (C6’), 128.8 (C1’), 129.9 (C1), 130.2 (C2), 130.7 (C2’), 130.9 (4CHArCCO), 131.7 
(2CArN), 131.8 (C3), 137.1 (CH=), 143.1 (2CArCO), 146.4 (NC=), 153.7 (C6), 153.9 (C4’), 162.7 
(NCON), 171.7, 171.8 (2CON), 193.4 (CO); HRMS (MALDI, m/z): calcd for [M+H]+ 
C49H56N7O6S: 870.4013; found: 870.4027; HPLC-MS (ESI, m/z): 868.4 [M-H]
-; tR (method 
B): 11.21 min. 
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6.1.6. Synthesis of clickable probes 64 and 65 
Pent-4-ynal (107). Derivative 107 was obtained following the experimental 
procedure previously described by Janza et al.,158 and the spectroscopic data correspond 
with those reported.159 
To a solution of oxalyl chloride (56 mL, 0.66 mol) in DCM (1 L) at -78 ºC, a solution of 
DMSO (93 mL, 1.3 mol) in DCM (80 mL) was added dropwise and the mixture was stirred 
at that temperature for 30 min, before a solution of 4-pentynol (50 g, 0.60 mol) in DCM 
(80 mL) was slowly added. The resulting mixture was stirred at -78 ºC for 1 h and then, a 
solution of triethylamine (330 mL, 2.4 mol) in DCM (80 mL) was slowly added. The 
mixture was stirred at -78 ºC for an additional 1 h and then allowed to warm to rt over 
12 h. The mixture was diluted with DCM, washed with 2 M HCl (aq), saturated NaHCO3 
(aq) and brine, dried (Na2SO4), filtered, and evaporated under reduced pressure to 
obtain aldehyde 107 (42 g, 85%), which was used in the next step without further 
purification. 
 
1H-NMR (500 MHz, CDCl3, ): 1.99 (t, J=2.7, 1H, CH≡), 2.47 (td, J=7.1, 2.7, 2H, CH2C≡), 
2.67 (t, J=6.9, 2H, CH2CHO), 9.75 (s, 1H, CHO). 
Ethyl 4-oxooct-7-ynoate (108). A solution of aldehyde 107 (17.20 g, 210 mmol) and 
ethyl acrylate (46 mL, 420 mmol) in 1,4-dioxane (250 mL) was added dropwise over a 
period of 4 h to a suspension of 3-benzyl-5-(2-hydroxyethyl)-4-methyl-1,3-thiazolium 
chloride (7.88 g, 29 mmol) and triethylamine (20 mL, 147 mmol) in 1,4-dioxane (300 mL) 
at 80 ºC and under a nitrogen atmosphere. The mixture was stirred at this temperature 
for 54 h and then the solvents were removed under reduced pressure. The residue was 
resuspended in DCM (600 mL), washed with aqueous 10% H2SO4 (150 mL), saturated 
NaHCO3 (aq) (250 mL) and brine (250 mL), dried (Na2SO4), filtered, and evaporated 
under reduced pressure. The crude was purified by chromatography (glass column, 
hexane to hexane/EtOAc, 8:2) to obtain 108 (10.70 g, 28%). 
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1H-NMR (CDCl3, ): 1.33 (t, J=7.2, 3H, CH3), 2.04 (t, J=2.7, 1H, CH≡), 2.54 (td, J=7.3, 
2.6, 2H, CH2C≡), 2.68 (t, J=6.5, 2H, CH2), 2.76-2.86 (m, 4H, 2CH2), 4.20 (q, J=7.1, 2H, 
CH2O); MS(ESI, m/z): 183.1 [M+H]
+. 
4-Oxooct-7-ynoic acid (109). To a solution of ester 108 (9.46 g, 52 mmol) in MeOH 
(400 mL) at rt and under a nitrogen atmosphere, LiOH (6.23 g, 260 mmol) and water (4.8 
mL, 267 mmol) were added and the resulting solution was stirred at rt for 15 h. The 
solution was carefully acidified (pH=3) with 6 M HCl (aq). The resulting solution was 
extracted with DCM (2x) and the combined organic layers were dried (Na2SO4), filtered, 
and evaporated under reduced pressure to yield acid 109 (7.60 g, 95%), which was used 
in the next step without further purification. 
 
1H-NMR (CDCl3, δ): 1.98 (t, J=2.5, 1H, CH≡), 2.48 (td, J=7.3, 2.5, 2H, CH2C≡), 2.57-2.90 
(m, 6H, 2CH2CO, CH2COO); MS(ESI, m/z): 153.0 [M+H]
+. 
3-[3-(But-3-yn-1-yl)-3H-diazirin-3-yl]propanoic acid (110). A dried round bottom 
flask containing 109 (3.10 g, 20 mmol) at 0 ºC and under a nitrogen atmosphere was 
charged with ammonia (195 mL, 7 M in MeOH) and the resulting solution was stirred at 
0 ºC for 3 h. Then, a solution of hydroxylamine-O-sulfonic acid (3.20 g, 28 mmol) in 
anhydrous MeOH (25 mL) was added dropwise at 0 ºC and the mixture was stirred at 
this temperature for an additional 1 h and then allowed to warm to rt over 14 h. The 
suspension was evaporated to dryness and resuspended in MeOH (30 mL). The insoluble 
solid was filtered off and washed several times with MeOH. The solvent was evaporated 
under reduced pressure, and the residue was suspended in anhydrous MeOH (180 mL) 
and cooled to 0 ºC (protected from light). Diisopropylethylamine (DIPEA, 7.8 mL) was 
then added, followed by iodine (portion-wise), until a dark brown color persisted for 
more than 30 min, indicating total oxidation of the diaziridine group. The solution was 
then diluted with EtOAc, washed with 1 M HCl (aq), saturated Na2S2O3 (aq, 3x) and brine. 
The combined aqueous phases were washed once with EtOAc and all organic layers 
were combined, dried (Na2SO4), filtered, and evaporated under reduced pressure. The 
residue was purified by chromatography (glass column, hexane to hexane/EtOAc, 8:2) to 
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obtain diazirine 110 (889 mg, 28%). The spectroscopic data correspond with those 
previously reported.160 
 
1H-NMR (CDCl3, δ): 1.66 (t, J=7.4, 2H, CH2CH2C≡), 1.81 (t, J=7.7, 2H, CH2CH2CO), 1.98-
2.06 (m, 3H, CH≡, CH2C≡), 2.18 (t, J=7.7, 2H, CH2CO). 
General procedure for the synthesis of amines 111 and 112. To a solution of the 
corresponding azide 60 or 61 (1 equiv) in anhydrous THF (7.8 mL/mmol) under a 
nitrogen atmosphere, PPh3 (3 equiv) was added followed by water (10 equiv) and the 
resulting solution was heated under reflux for 3 h. The solvents were evaporated under 
reduced pressure and the residue was purified by chromatography (glass column, DCM 
to DCM/MeOH 8:2) to yield the corresponding amine. 
5'-Allyl-3-(3-aminopropyl)-2'-ethoxybiphenyl-4-ol (111). Obtained from azide 60 (22 
mg, 64 mol) in 76% yield (15 mg). Rf: 0.16 (DCM/MeOH, 9:1). 
 
IR (ATR, ): 2976 (OH, NH), 1560, 1508 (Ar), 1270, 1238 (COC); 1H-NMR (CD3OD, ): 
1.31 (t, J=6.9, 3H, CH3), 1.90 (br s, 2H, NH2), 1.99 (qt, J=7.5, 2H, CH2), 2.75 (t, J=7.2, 2H, 
CH2C3), 2.94 (app t, J=7.6, 2H, CH2N), 3.34 (d, J=7.3, 2H, CH2C5’), 3.98 (q, J=7.0, 2H, CH2O), 
5.00-5.09 (m, 2H, CH2=), 5.97 (ddt, J=16.9, 10.1, 6.7, 1H, CH=), 6.80 (d, J=8.3, 1H, H5), 
6.93 (d, J=8.9, 1H, H3’), 7.03-7.06 (m, 2H, H4’, H6’), 7.21 (dd, J=8.3, 2.2, 1H, H6), 7.26 (d, 
J=2.0, 1H, H2); 
13C-NMR (CD3OD, ): 15.3 (CH3), 28.0 (CH2C3), 29.3 (CH2), 40.3, 40.4 (CH2N, 
CH2C5’), 65.3 (CH2O), 114.2 (C3’), 115.4 (C5), 115.6 (CH2=), 127.2 (C3), 128.9 (C4’), 129.8 
(C6), 131.6 (C6’, C1’), 132.5 (C2, C1), 133.7 (C5’), 139.4 (CH=), 155.4 (C4), 155.5 (C2’); HRMS 
(ESI, m/z): calcd for [M+H]+ C20H26NO2: 312.1964; found: 312.1958; HPLC-MS (ESI, m/z): 
310.1 [M-H]-; tR (method A): 8.90 min. 
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3-Allyl-5'-(3-aminopropyl)-2'-ethoxybiphenyl-4-ol (112). Obtained from azide 61 (40 
mg, 0.12 mmol) in 49% yield (18 mg). Rf: 0.19 (DCM/MeOH/NH3, 9:1:0.1). 
 
IR (ATR, ): 2977 (NH, OH), 1559, 1496 (Ar), 1271, 1238 (COC); 1H-NMR (CD3OD, ): 
1.30 (t, J=7.0, 3H, CH3), 1.90 (br s, 2H, NH2), 1.94 (qt, J=7.7, 2H, CH2), 2.68 (t, J=7.6, 2H, 
CH2C5’), 2.91 (app t, J=7.8, 2H, CH2N), 3.37 (d, J=6.5, 2H, CH2C3), 3.97 (q, J=7.0, 2H, CH2O), 
4.98-5.09 (m, 2H, CH2=), 6.02 (ddt, J=16.9, 10.2, 6.6, 1H, CH=), 6.78 (d, J=8.2, 1H, H5), 
6.94 (d, J=8.2, 1H, H3’), 7.08 (dd, J=8.3, 2.2, 1H, H4’), 7.11 (d, J=2.1, 1H, H6’), 7.18 (dd, 
J=8.3, 2.2, 1H, H6), 7.24 (d, J=2.1, 1H, H2); 
13C-NMR (CD3OD, ): 15.2 (CH3), 30.9 (CH2), 
32.8 (CH2C5’), 35.3 (CH2C3), 40.3 (CH2N), 65.4 (CH2O), 114.4 (C3’), 115.4 (C5), 115.4 (CH2=), 
127.0 (C3), 128.6 (C4’), 129.2 (C6), 131.2 (C1/C1’), 131.4 (C6’), 132.3 (C2), 132.6 (C1/C1’), 
134.0 (C5’), 138.6 (CH=), 155.2 (C4), 155.8 (C2’); HRMS (ESI, m/z): calcd for [M+H]
+ 
C20H26NO2: 312.1964; found: 312.1958; HPLC-MS (ESI, m/z): 310.1 [M-H]
-; tR (method A): 
10.2 min. 
General procedure for the synthesis of final compounds 64 and 65. To a solution of 
acid 110 (1 equiv) in dry DCM (6.7 mL/mmol of acid), HOBt (1.2 equiv) was added under 
a nitrogen atmosphere and the mixture was stirred at rt for 10 min. Then, a solution of 
EDC (1.2 equiv) in dry DCM (6.7 mL/mmol of acid) was added and the reaction was 
stirred at rt for 30 min before a solution of the corresponding amine 111 or 112 (1 
equiv) in dry DCM (6.7 mL/mmol of amine) was added, followed by DIPEA (2.2 equiv). 
The resulting mixture was stirred at rt for 16 h, diluted with EtOAc, washed with 
saturated NaHCO3 (aq, 2x) and brine. The organic layer was dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The residue was purified by chromatography using 
the appropriate eluent to afford the corresponding amide. 
 
 
 
Experimental section 
 
181 
 
N-[3-(5'-Allyl-2'-ethoxy-4-hydroxybiphenyl-3-yl)propyl]-3-(3-but-3-yn-1-yl-3H-
diaziren-3-yl)propanamide (64). Obtained from from acid 110 (5 mg, 30 mol) and 
amine 111 (9 mg, 30 mol) in 45% yield (6 mg). Chromatography: glass column, DCM to 
DCM/EtOAc, 95:5. Rf: 0.07 (DCM/EtOAc, 95:5). 
 
IR (ATR, ): 3305, 3367 (NH, OH), 1644 (CO), 1550, 1509, 1491, 1469 (Ar), 1271, 1237 
(COC); 1H-NMR (700 MHz, CD3OD, ): 1.30 (t, J=7.0, 3H, CH3), 1.60 (t, J=7.5, 2H, 
CH2CH2C≡), 1.73 (t, J=7.1, 1H, CH2CH2CO), 1.83 (qt, J=7.4, 2H, CH2CH2C3), 1.998 (td, J=7.5, 
2.7, 2H, CH2C≡), 2.002 (t, J=7.7, 2H, CH2CO), 2.21 (t, J=2.7, 1H, CH≡), 2.67 (t, J=7.5, 2H, 
CH2C3), 3.22 (t, J=7.1, 2H, CH2N), 3.34 (d, J=6.7, 2H, CH2C5’), 3.97 (q, J=7.0, 2H, CH2O), 
5.01-5.03 (m, 1H, ½CH2=), 5.06 (ddd, J=17.0, 3.6, 1.7, 1H, ½CH2=), 5.97 (ddt, J=17.0, 10.1, 
6.8, 1H, CH=), 6.76 (d, J=8.3, 1H, H5), 6.91 (d, J=8.3, 1H, H3’), 7.03 (dd, J=8.2, 2.2, 1H, H4’), 
7.06 (d, J=2.2, 1H, H6’), 7.16 (dd, J=8.2, 2.3, 1H, H6), 7.25 (d, J=2.2, 1H, H2); 
13C-NMR (175 
MHz, CD3OD, ): 13.8 (CH2C≡), 15.3 (CH3), 28.7 (CH2CH2CO), 28.8 (CN2), 29.9 (CH2CO), 
30.6 (CH2CH2C3), 31.1 (CH2CH2C≡), 33.3 (CH2C3), 40.3, 40.4 (CH2N, CH2C5’), 65.4 (CH2O), 
70.2 (CH≡), 83.5 (C≡), 114.3 (C3’), 115.3 (C5), 115.6 (CH2=), 128.4 (C3), 128.7 (C4’), 129.1 
(C6), 131.3 (C1), 131.6 (C6’), 132.3 (C1’), 132.4 (C2), 133.6 (C5’), 139.3 (CH=), 155.2 (C4), 
155.4 (C2’), 174.2 (CON); HRMS (ESI, m/z): calcd for [M+Na]
+ C28H33N3NaO3: 482.2420; 
found: 482.2414; HPLC-MS (ESI, m/z): 458.0 [M-H]-; tR (method A): 11.14 min. 
N-[3-(3'-Allyl-6-ethoxy-4'-hydroxybiphenyl-3-yl)propyl]-3-(3-but-3-yn-1-yl-3H-
diaziren-3-yl)propanamide (65). Obtained from acid 110 (5 mg, 30 mol) and amine 112 
(9 mg, 30 mol) in 62% yield (9 mg). Chromatography: glass column, DCM to 
DCM/MeOH 95:5. Rf: 0.10 (DCM/EtOAc, 95:5). 
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IR (ATR, ): 3293, 3078 (NH, OH), 1640 (CO), 1607, 1472, 1439 (Ar), 1269, 1235 
(COC); 1H-NMR (700 MHz, CD3OD, ): 1.29 (t, J=7.0, 3H, CH3), 1.59 (t, J=7.5, 2H, 
CH2CH2C≡), 1.72 (t, J=7.2, 2H, CH2CH2CO), 1.81 (qt, J=7.3, 2H, CH2CH2C3), 1.98-2.01 (m, 
4H, CH2C≡, CH2CO), 2.22 (t, J=2.6, 1H, CH≡), 2.61 (t, J=7.6, 2H, CH2C3), 3.18 (t, J=7.0, 2H, 
CH2N), 3.38 (d, J=6.6, 2H, CH2C3’), 3.95 (q, J=7.0, 2H, CH2O), 4.99-5.01 (m, 1H, ½CH2=), 
5.06 (ddd, J=17.1, 3.5, 1.6, 1H, ½CH2=), 6.02 (ddt, J=16.9, 10.2, 6.7, 1H, CH=), 6.78 (d, 
J=8.2, 1H, H5’), 6.89 (d, J=8.3, 1H, H5), 7.04 (dd, J=8.3, 2.2, 1H, H4), 7.08 (d, J=2.2, 1H, H2), 
7.18 (dd, J=8.2, 2.2, 1H, H6’), 7.25 (d, J=2.1, 1H, H2’); 
13C-NMR (175 MHz, CD3OD, ): 13.8 
(CH2C≡), 15.3 (CH3), 28.8 (CN2), 29.8 (CH2CH2CO), 31.0 (CH2CO), 32.3 (CH2CH2C3), 33.3 
(CH2CH2C≡), 33.4 (CH2C3), 35.2 (CH2C3’), 40.1 (CH2N), 65.4 (CH2O), 70.2 (CH≡), 83.5 (C≡), 
114.3 (C5), 115.3 (C5’), 115.4 (CH2=), 126.9 (C3’), 128.5 (C4), 129.2 (C6’), 131.3 (C1’), 131.4 
(C2), 132.3 (C2’, C1), 135.3 (C3), 138.5 (CH=), 155.0 (C4’), 155.3 (C6), 174.2 (CON); HRMS 
(ESI, m/z): calcd for [M+Na]+ C28H33N3NaO3: 482.2420; found: 482.2401; HPLC-MS (ESI, 
m/z): 458.1 [M-H]-; tR (method A): 10.71 min. 
6.1.7. Synthesis of 2-O-ethylhonokiol 
5-Allyl-4'-(allyloxy)-2-ethoxybiphenyl (113). Following the general procedure 
6.1.1.2, allyl ether 113 was obtained from phenol 87 (30 mg, 0.12 mmol) and allyl 
bromide (13 µL, 0.14 mmol) in 92% yield (32 mg), and was used in the next step without 
further purification. Rf: 0.60 (hexane/EtOAc, 9:1). 
 
1H-NMR (CDCl3, ): 1.33 (t, J=6.9, 3H, CH3), 3.36 (d, J=6.7, 2H, CH2C5), 4.00 (q, J=7.0, 
2H, CH2O), 4.58 (d, J=5.3, 2H, CH2OC4’), 5.03-5.12 (m, 2H, CH2=CHCH2C5), 5.28-5.32 (m, 
1H, ½CH2=CHCH2O), 5.41-5.47 (m, 1H, ½CH2=CHCH2O), 5.98 (ddt, J=16.9, 10.0, 6.7, 1H, 
CHCH2C5), 6.02 (ddt, J=17.1, 10.7, 5.4, 1H, CHCH2O), 6.89 (d, J=8.3, 1H, H3), 6.95 (d, J=9.0, 
2H, H3’, H5’), 7.07 (dd, J=8.3, 2.2, 1H, H4), 7.13 (d, J=2.2, 1H, H6), 7.49 (d, J=8.9, 2H, H2’, 
H6’). 
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3,5'-Diallyl-2'-ethoxybiphenyl-4-ol (2-O-ethylhonokiol). Following the general 
procedure 6.1.1.9, 2-O-ethylhonokiol was obtained from allyl ether 113 (25 mg, 80 
mol) in 97% yield (24 mg). Chromatography: hexane to hexane/EtOAc, 9:1. Rf: 0.24 
(hexane/EtOAc, 9:1). The spectroscopic data correspond with those reported.126 
 
1H-NMR (CDCl3, ): 1.33 (t, J=7.0, 3H, CH3), 3.36 (d, J=6.8, 2H, CH2C5’), 3.45 (d, J=6.3, 
2H, CH2C3), 4.00 (q, J=6.9, 2H, CH2O), 5.09-5.12 (m, 2H, CH2=), 5.15-5.24 (m, 2H, CH2=), 
5.98 (ddt, J=17.1, 10.2, 6.8, 1H, CHCH2C5’), 6.06 (ddt, J=17.0, 10.2, 6.6, 1H, CHCH2C3), 
6.84 (d, J=8.8, 1H, H5), 6.88 (d, J=8.2, 1H, H3’), 7.06 (dd, J=8.4, 2.0, 1H, H4’), 7.12 (d, J=2.1, 
1H, H6’), 7.32-7.35 (m, 2H, H2, H6); HRMS (ESI): calcd for [M+Na]
+ C20H22NaO2: 317.1518; 
found: 317.1512; HPLC-MS (ESI, m/z): 293.1 [M-H]-; tR (method A): 11.38 min. 
6.2. Biological assays 
6.2.1. Binding assays 
Membranes from HEK-293-EBNA cells expressing the hCB1 or hCB2 receptors were 
purchased from PerkinElmer and conserved at -80 ºC in packaging buffer for subsequent 
use. Competitive inhibition assays were performed according to standard procedures, 
briefly detailed below.  
Cell membranes (8 mg/mL for CB1 and 4 mg/mL for CB2) were homogenized at 0 ºC 
using a glass dounce homogenizer in assay buffer (50 mM Tris·HCl, 2.5 mM 
ethylenediaminetetraacetic acid (EDTA), 5 mM MgCl 2 and 0.5 mg/mL bovine serum 
albumin (BSA), pH=7.4 for CB1; or 50 mM Tris·HCl, 2.5 mM ethyleneglycoltetraacetic acid 
(EGTA), 5 mM MgCl2 and 1 mg/mL fatty acid free BSA, pH=7.4 for CB2) at 1:500 dilution. 
Fractions of 500 μL of the membrane suspension were incubated in 96-multiwell plates 
(Optiplate), which had been previously silanized with Sigmacote (Sigma) to prevent 
adsorption of the compounds, at 30 ºC for 90 min with [3H]-CP55940 at a concentration 
of 0.4 nM for CB1 and 0.53 nM for CB2, respectively (144 Ci/mmol, PerkinElmer), in the 
absence or presence of different concentrations of the compound under study (ranging 
from 10-5 to 10-11 M), in a final volume of 550 μL. Nonspecific binding was determined by 
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radioligand binding in the presence of a saturating concentration of 10 μM (R)-(+)-
WIN552122 (Tocris), and represented less than 15% of total binding. 
For all binding assays, competing drug and nonspecific, total, and radioligand 
bindings were defined in triplicate. Incubation was terminated by rapid vacuum filtration 
through Wallac Filtermat A filters (PerkinElmer), presoaked in polyethylenimine (0.05%), 
using a FilterMate Unifilter 96-Harvester (PerkinElmer). The filters were then washed 9 
times with 500 μL of ice-cold assay buffer and air-dried. Then, a MeltiLex solid 
scintillator sheet (PerkinElmer) was immediately melted onto the filter and the 
radioactivity bound to the filter was quantified by scintillation spectrometry, using a 
Microbeta TopCount instrument (PerkinElmer). The data were analyzed by an iterative 
curve-fitting procedure using GraphPad Prism program and Ki values were calculated 
from the IC50 values using the Cheng-Prusoff equation
87 and are expressed as the 
average and standard error obtained from two to four independent experiments carried 
out in triplicate. 
6.2.2. Visualization of CB1R in tonsil TMCs, pDCs and mDCs  
TMCs and tonsil dendritic cell subsets (pDCs and mDCs) were purified following the 
protocol previously described by Palomares et al.91 
For labelling experiments, TMCs or purified pDCs and mDCs from tonsils of atopic 
donors were suspended in phosphate buffered saline (PBS), centrifuged onto glass slides 
(cytospin, 200 rpm, 2 min), and fixed in 4% paraformaldehyde for 7 min. Then, cells were 
washed twice with PBS and treated with the endogenous biotin-blocking kit (Invitrogen) 
following the manufacturer’s recommendations. After rinsing  with PBS, cells were 
incubated with probe 1 at 0.5 M and HU308 100 M (for the visualization of CB1 
receptor) or HU210 0.5 M (for the nonspecific fluorescence) in PBS for 60 min. Then, 
samples were rinsed twice with PBS and incubated with Streptavidin-Alexa Fluor 488 
(1:1000, Invitrogen) in PBS for 1 h. After washing, cells were incubated with the 
corresponding primary anti-human antibody (CD3 [IgG1 mouse, produced in-house], 
CD20 [IgG rabbit, Epitomics], CD123 [IgG1 mouse, eBioscience], or HLA-DR-Alexa647 
[IgG2b mouse, Biolegend]) or the proper isotype controls in PBS containing 4% normal 
goat serum for 45 min. Next, after washing, CD3-, CD20-, and CD123-binding antibodies 
were detected by using Alexa Fluor 546-conjugated goat anti-mouse, anti-rabbit, and 
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anti-mouse, respectively. Finally, cells were washed and treated with 1% 
paraformaldehyde and mounted with ProLong Gold antifade reagent with 4’-6-
diamidino-2-phenylindole dihydrochloride (DAPI, Invitrogen) for nuclei staining. Images 
were acquired and analyzed by using the confocal microscope Leica DMI 4000B and the 
Leica TSC SPE system (Leica Microsystems GmBh). All assay and control  samples were 
imaged under the same microscope conditions, and the images shown are 
representative of 2 independent experiments. There was no significant background in 
any of the assayed control conditions. 
6.2.3. Flow cytometry analysis of PBMCs 
PBMCs were isolated by Ficoll density gradient centrifugation from buffy coats of 
healthy donors as previously described.91 Then, PBMCs (500000 cells/tube) were 
incubated with 1 μM of compound 22, Alexa Fluor 488 alkyne (Life Technologies) or 
DMSO (vehicle) in PBS (200 L) at rt for 30 min in the dark. Then, 1 mL of PBS was added 
and cells were isolated by centrifugation (3000 rpm, 3.5 min), resuspended in 0.01 
mg/mL of propidium iodide in PBS (200 L) and analyzed by flow cytometry. Flow 
cytometric analysis was performed on a Gallios flow cytometer (Beckman Coulter) and 
the data were analyzed by a Weasel v2.5 software. 
6.2.4. Mass spectrometry profiling of ligand-binding proteins in cell membranes 
 Incubation and photocrosslinking of samples 
Membrane homogenates of HEK-293-EBNA (500 L of 1.07 mg/mL for CB2R) were 
incubated in the absence or presence of probe 39 (25 μM) in a final volume of 600 μL of 
incubation buffer in a 24-well polystyrene plate. After incubation at 37 ºC for 30 min, 
samples were irradiated at 360 nm using an UV lamp on ice for 1 h. Then, samples were 
transferred to microtubes (eppendorf) and 100 μL of a solution of 7% Triton X-100 in 
PBS were added to solubilize proteins and shaken at rt for 1 h, before 50 μL of a solution 
of 4% SDS in water and 50 μL of PBS were added. The samples were incubated with 100 
μL of streptavidin-agarose beads (Pierce) for 12 h at 4 ºC, transferred to conical tubes 
and rinsed consecutively with 0.2% SDS in PBS (1x5 mL), PBS (3x5 mL), and water (3x5 
mL). The beads were settled down by centrifugation (2500 rpm, 2 min) after each wash. 
The washed beads were suspended in 500 μL of 6 M urea in PBS and 25 μL of a 250 mM 
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solution of tris(2-carboxyethyl)phosphine (TCEP) in water were added and shaken at rt 
for 30 min. Then, 25 μL of a 400 mM iodoacetamide solution in water were added and 
allowed to react at rt for 30 min protected from light. Following reduction and 
alkylation, the beads were diluted in 800 μL of PBS, pelleted by centrifugation (4000 
rpm, 3 min) and washed with PBS (3x1 mL). 
 Mass spectrometry analysis 
Proteins from pull-down samples were loaded onto SDS-PAGE and run in a unique 
band that concentrated all the proteins in the sample, stained with Coomassie Brilliant 
Blue G-250 and excised in 1 mm3 small pieces, which were washed in ultrapure water. 
Samples were subjected to reduction and alkylation, and digested in-gel for 16 h at 37 ºC 
by adding modified porcine trypsin (Promega) at a final ratio of 1:20 (trypsin:protein). 
After digestion, peptides were vacuum-dried and finally dissolved in 0.1% formic acid for 
LC-MS/MS analysis. The tryptic peptide mixtures were subjected to nano-LC-MS for 
protein identification. Peptides were injected onto a C-18 reversed phase (RP) nano-
column (100 mm I.D. and 12 cm, Mediterranea sea, Teknokroma) and analyzed in a 
continuous acetonitrile gradient consisting of 0-50% B in 90 min, 50-90% B in 1 min 
(B=95% acetonitrile, 0.5% acetic acid). A flow rate of 300 nL/min was used to elute 
peptides from the RP nano-column to an emitter nanospray needle for real time 
ionization and peptide fragmentation on an LTQ Orbitrap XL mass spectrometer 
(Thermo Fisher). An enhanced Fourier transform (FT)-resolution spectrum 
(resolution=30000) followed by the MS/MS spectra from most intense three parent ions 
(dissociated using CID activation) was analyzed along the chromatographic run (130 
min). Dynamic exclusion was set at 1 min.  
A second set of samples were processed as before, but the tryptic peptide mixtures 
were dissolved in 0.1% formic acid (gradient buffer A), injected onto a C-18 RP 
precolumn (Acclaim PepMap100 nanoViper Column, C18, 3 μm, 75 μm I.D. x 2 cm) and 
analyzed in a continuous acetonitrile gradient consisting of 8-31% B in 120 min, 31-90% 
B in 1 min (B=90% acetonitrile, 0.1% formic acid) using an Acclaim PepMap100, C18, 3 
μm, 100Å, 75 μm i.d. x 25 cm nanocolumn. A flow rate of 200 nL/min was used to elute 
peptides from the RP nano-column to an emitter nanospray needle for real time 
ionization and peptide fragmentation on an Orbitrap Elite mass spectrometer (Thermo 
Fisher). 
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 Database searching 
Tandem mass spectra were extracted by Proteome Discoverer v1.3 (for Orbi XL data) 
or Proteome Discoverer v1.4 (for Elite data) (Thermo Fisher). Charge state 
deconvolution and deisotoping were not performed. For protein identification, 
fragmentation spectra were searched against a curated subset of a human database 
(human_ref.fasta; 2003, April; 39414 entries) using Sequest (Thermo Fisher Scientific 
version 1.0.43.2) and X-Tandem S54 (The GPM, thegpm.org; version 2007.01.01.1) 
engines. Sequest and X-Tandem were searched allowing two missed trypsin cleavages, 
and a tolerance of 15 ppm or 0.8 Da was set for full MS or MS/MS spectra searches, 
respectively. Iodoacetamide alkylation of cysteine residues was selected as fixed 
modification and oxidation of methionine was allowed as variable modification. Finally, 
Scaffold v.3.00.02 software (Proteome Software Inc) was used to validate MS/MS based 
peptide and protein identifications. 
6.2.5. Cell culture 
MDA-MB-231 cells were grown in Dulbecco’s modified Eagle medium (DMEM), while 
SKOV3 and OVCAR3 cells were grown in RPMI-1640 medium, both supplemented with 
10% fetal bovine serum (FBS), 1% non-essential aminoacids, 1% sodium pyruvate, 100 
U/mL penicillin, and 100 g/mL streptomycin in a 5% CO2 humidified atmosphere at 37 
ºC. For passage, cells were rinsed with PBS and incubated with 0.125% trypsin (0.02% 
EDTA solution) at 37 ºC for 2 min. Detached cells were resuspended in growth medium, 
counted if necessary, and splitted onto fresh dishes. 
6.2.6. Cytotoxicity assay 
Cell viability was assessed by a colorimetric assay based on the metabolic reduction 
of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to formazan by 
the mitochondrial enzyme succinate dehydrogenase. MDA-MB-231, SKOV3, or OVCAR3 
cells were plated in a 96-well plate (7500 cells/well) and treated with 50 M of 
compounds 56-59, 64, and 65, or with DMSO (vehicle-treated cells) in growth media 
(100 L), in a 5% CO2 humidified atmosphere at 37 ºC for 48 h. Then, after removing the 
culture media, 100 μL of a premixed 2:3 solution of MTT/growth media (5 mg/mL of 
MTT in PBS) were added to each well, and cells were incubated at 37 ºC for 4 h 
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protected from light. The medium was carefully removed and the precipitates of 
formazan were dissolved in 100 μL of DMSO and shaken mechanically for 5 min. The 
absorbance values were measured at a wavelength of 570 nm on a multi -well plate 
reader (Model Anthos Labtec 2010 1.7). Percentages of cell viability were relative to the 
DMSO controls.  
6.2.7. In-gel analysis 
For in situ labelling, cells were plated in 6 cm dishes and grown to 100% confluency, 
washed with PBS, and treated with the corresponding concentration of probe 64 or 65 
(0.2-20 M) in 1 mL of serum-free media. For the competition experiments, 10 μM of 
probe 64 or 65 and 100 μM of honokiol or 2-O-ethylhonokiol were used. After 30 min at 
37 ºC, media was aspirated off and cells were irradiated (365 nm, 4 ºC, 10 min) using a 
Stratagene UV Stratalinker 1800 and scrapped in 1 mL of cold PBS (pH 7.4). Cell pellets 
were isolated by centrifugation (3000 rpm, 3 min), rinsed with PBS and centrifuged 
(3000 rpm, 3 min, 2x), lysed by probe sonication, and centrifuged (100000g, 45 min) to 
provide the soluble (supernatant) and membrane (pellet) fractions. Protein 
concentrations were determined using the bicinchoninic acid (BCA) protein assay (Bio-
Rad) following the manufacturer’s instructions, and adjusted to 1 mg/mL. Then, 50 μg of 
lysate were conjugated to rhodamine azide (Rh-N3)
138 by treating with 6 μL of a pre-
mixed solution containing 3 μL of 1.7 mM tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA) in 4:1 DMSO:t-BuOH, 1 μL of 50 mM CuSO4 in water, 1 μL of 50 
mM TCEP in water (freshly prepared), and 1 μL of 1.25 mM Rh-N3 in DMSO. After 1 h at 
rt in the dark, samples were mixed with Laemmli loading buffer and 30 L of the click 
reaction mixture (20 g of protein) were loaded into each gel lane and resolved using 
SDS-PAGE. Images were acquired using a Hitachi FMBIO-II flatbed fluorescence scanner. 
Fluorescent images are shown in gray scale. 
6.2.8. Sample processing for SILAC quantitative mass spectrometry 
MDA-MB-231 cells, cultured as described above, were plated in 10 cm dishes and 
grown to 100% confluency and washed with PBS. “Light” cells were treated with probe 
65 (10 μM) and honokiol (100 μM), and “heavy” cells only with probe 65 (10 μM) in 2 mL 
of serum-free media. Cells were incubated with compound(s) at 37 ºC for 30 min, 
irradiated (365 nm, 4 ºC, 10 min), harvested, and lysed as described above. Heavy and 
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light proteomes were combined in equal amounts (0.75 mg of proteome each) and 
diluted with PBS to a final volume of 1.0 mL. The sample was treated with 110 μL of a 
pre-mixed solution containing 60 μL of 1.7 mM TBTA in 4:1 DMSO:t-BuOH, 20 μL of 50 
mM CuSO4 in water, 20 μL of 50 mM TCEP in water (freshly prepared) and 10 μL of 10 
mM biotin-PEG3-azide (ChemPepInc). After mixing for 1 h at rt, MeOH (2.0 mL), 
chloroform (0.5 mL), and PBS (1.0 mL) were added to the reaction mixture and the 
cloudy mixture was centrifuged at 5000 rpm for 15 min yielding a precipitated protein 
disc between the aqueous and organic layers. The top and bottom liquid phases were 
aspirated, and the protein disc was then washed with MeOH:chloroform (1:1 vol, 3x2 
mL). MeOH (2 mL) was then added and the solution was sonicated to yield a cloudy 
mixture. Chloroform (0.5 mL) was added and the solution was centrifuged (5000 rpm, 10 
min), aspirated, and the pellet was solubilized in urea (500 μL, 6 M in PBS). The solution 
was treated with 1:1 vol of TCEP:K2CO3 (50 L, 200 mM:600 mM in PBS). The pellet was 
resuspended by sonication, and the resulting solution was incubated at 37 °C for 30 min. 
Then, iodoacetamide (70 L, 400 mM in PBS) was added and the solution was incubated 
at rt for 30 min in the dark. 10% SDS in PBS was then added to each sample, followed by 
5.5 mL of PBS to achieve a final concentration of 0.2% SDS. Streptavidin beads (Thermo 
Fisher) [100 μL slurry previously washed with PBS (3x)] were added and the mixture was 
rotated at rt for 2 h. Beads were washed with 0.2% SDS in PBS (5 mL), PBS (2x5 mL), and 
water (2x5 mL) before transferring to low-bind eppendorf tubes and centrifuged (1000 
rpm, 2 min) into a pellet. Following aspiration of the supernatant, the beads were 
resuspended in 200 L of urea (2 M in PBS) supplemented with CaCl 2 (1.0 mM final 
concentration) and sequencing grade porcine trypsin (Promega). Following overnight 
digestion at 37 ºC, the tryptic digest solution (supernatant) was removed from the beads 
following centrifugation (1000 rpm, 2 min) and acidified with 5% formic acid. The tryptic 
digests were stored at -20 ºC until analyzed by LC-MS/MS.  
 Mass spectrometry and data analysis 
Mass spectrometry was performed using a Thermo Orbitrap Velos mass 
spectrometer, as previously described.141 Peptides were eluted using a five-step 
multidimensional LC-MS (MudPIT161) protocol (using 0%, 25%, 50%, 80% and 100% salt 
bumps of 500 mM aqueous NH4OAc, followed by an increasing gradient of aqueous 
acetonitrile and 0.1% formic acid in each step), and data were collected in data-
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dependent acquisition mode ‒two MS1 microscans (400–1800 mass to charge ratio 
[m/z]) and 30 data dependent fragmentation (MS2) scans‒ with dynamic exclusion 
enabled (repeat count of 1, exclusion duration of 20 s) with monoisotopic precursor 
selection enabled. All other parameters were left at default values. Prolucid searches 
allowed for variable oxidation of methionine (+15.9949 m/z), static modification of 
cysteine residues (+57.0215 m/z; iodoacetamide alkylation) and accepted only half or 
fully tryptic peptides. Each data set was independently searched with light and heavy 
parameter files; for the light search, all other amino acids were left at default masses; 
for the heavy search, static modifications on lysine (+8.0142 m/z) and arginine (+10.0082 
m/z) were specified. The precursor-ion mass tolerance was set to 50 ppm and the 
fragment-ion mass tolerance was the default assignment of 0. The data were searched 
using the human reverse-concatenated nonredundant (gene-centric) FASTA database 
that assembled from the Uniprot database (www.uniprot.org). The resulting matched 
MS2 spectra were assembled into protein identifications, then filtered using DTASelect 
(version 2.0.47), and only half-tryptic or fully tryptic peptides were accepted for 
identification, and only fully-tryptic peptides were considered for quantification. 
Peptides were restricted to a specified false positive rate of 1%. Redundant peptide 
identifications common between multiple proteins were allowed, but the database was 
restricted to a single consensus splice variant. SILAC ratios were quantified using in-
house software as described (CIMAGE162). Briefly, extracted MS1 ion chromatograms 
(±10 ppm) from both “light” and “heavy” targeted peptide masses (m/z) were generated 
using a retention time window (±10 min) centered on the time when the peptide ion 
was selected for MS/MS fragmentation, and subsequently identified. Next, the ratio of 
the peak areas under the light and heavy signals (signal-to-noise ratio>2.5) are 
calculated. Computational filters used to ensure that the correct peak-pair is used for 
quantification include a co-elution correlation score filter (R2≥0.8), removing target 
peptides with bad co-elution profile, and an “envelope correlation score” filter (R2>0.8) 
that eliminates target peptides whose predicted pattern of the isotopic envelope 
distribution does not match the experimentally observed high-resolution MS1 spectrum. 
Also peptides detected as singletons, where only the heavy or light isotopically labelled 
peptide was detected and sequenced ‒but which passed all other filtering parameters‒ 
were given the maximum standard SILAC ratio of 20. 
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8. SUPPLEMENTARY INFORMATION 
8.1. Coomassie brilliant blue stained gels 
In order to confirm that the amount of protein is the same in all comparable lanes, 
the gels shown in the results and discussion section of this work were stained with 
coomassie brilliant blue (0.1% in water/MeOH/AcOH, 4:5:1 vol) at rt for 16 h, and 
destained with the corresponding destaining solution (water/MeOH/AcOH, 5:4:1 vol) at 
rt for 2 h. Imaging was achieved using a B446-LI-COR Odyssey Infrared Imaging System. 
Staining is shown in red scale. 
 
Figure S1. Coomassie staining of gel in Figure 26. 
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Figure S2. Coomassie staining of gel in Figure 27. 
 
Figure S3. Coomassie staining of gel in Figure 28. 
 
